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Abstract 
The Aboriginal population of Central Australia use endemic Nicotiana spp. to make a 
smokeless tobacco product known as pituri that they chew/suck for nicotine absorption. This 
thesis describes the relative abundance of nicotine alkaloids amongst Australian Nicotiana 
spp., with special focus on the molecular characteristics of nicotine to nornicotine conversion. 
The most popular chewed species, N. gossei, is investigated for nicotine release and 
cytotoxicity in comparison to similar products to gain insight into potential hazards to pituri 
users. 
To analyse the alkaloids of Nicotiana leaves, a HPLC-UV method was developed to separate 
and quantify six closely related alkaloids (nicotine, nornicotine, anatabine, anabasine, 
myosmine, cotinine). A C18 column with a mobile phase of ammonium formate buffer (pH 
10.5) separated the six alkaloids within 13 min with detection at 260 nm. Linearity, precision 
and reproducibility were satisfactory. The limit of quantification was 2.8 and 4.8 µg/mL for 
nornicotine and nicotine, respectively, and below 2 µg/mL for other alkaloids. This method 
quantifies more alkaloids and in less time than previously reported methods. 
Tobacco alkaloids are responsible in formation of carcinogenic tobacco specific nitrosamines 
such as N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK). To quantify NNN and NNK, a fast LC-MS/MS method was developed using a HILIC 
column with a triple quadrupole tandem mass spectrometry. The linearity, accuracy, recovery 
and repeatability for this method were satisfactory, with quantification limit of 2.6 and 4.3 
ng/mL for NNN and NNK, respectively.  
From 73 donated seedlots, plant growth under controlled environment conditions was 
successful for 24 of the 26 recognised Australian Nicotiana taxa. The quantification of 
alkaloids in leaves indicated nicotine as the abundant alkaloid in 15 taxa but nornicotine in 9. 
Nornicotine results from demethylation of nicotine, and is associated with negative effects on 
health. A group of cytochrome P450 genes that are mainly expressed during senescence or 
drying is involved in this conversion. The conversion loci were amplified in all studied 24 taxa, 
and sequenced in 6 selected species that contrast in conversion phenotype. Transcript 
accumulation of the responsible loci in fresh versus dried leaves of low or nonconverter N. 
gossei, N. excelsior and N. benthamiana maintained a steady level or a slight increase, but 
increased by 3 fold in cured leaves of the high converter N. goodspeedii, N. velutina and N. 
cavicola. This indicates the presence of functional loci that are triggered by curing only in high 
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converter species and poses a potential risk for chewers of these species due to their greater 
potential for nornicotine production. 
The release of nicotine from the leaves of N. gossei was compared to that from a Swedish snus, 
the CORESTA reference smokeless tobacco (CRP2), and Nicabate chewing gum. A model 
buccal cavity system was developed and three different chewing conditions, performed 
manually were tested over 120 minutes: no chewing action, initial chewing and chewing at 15-
minute intervals. To simulate the effect of alkaline wood ash, the effect of alkaline pH on the 
release of nicotine from N. gossei dry leaves was also evaluated. Samples of the dissolution 
media were analysed for alkaloids, and the media resulting from chewing every 15 minutes 
was quantified for NNN and NNK. The maximum cumulative nicotine release was produced 
by pressing every 15 minutes. Nicotine release from N. gossei dry leaves was not increased 
under alkaline condition. Nicotine release from smokeless tobacco products is faster and less 
dependent on chewing than that from Nicabate gum. N. gossei leaves showed similar release 
profile to snus, but contained higher nicotine and also released more nornicotine, anatabine, 
anabasine, and NNN and NNK into the media which can indicate potential health risks. 
The in vitro toxicity of the aqueous extract from N. gossei leaves on human lung epithelium 
cell survival was compared with CRP2 and pure nicotine in an MTS assay. Results indicated 
remarkably lower survival of cells treated with extracts from N. gossei leaves and CRP2 than 
cells treated with nicotine at similar concentrations as present in the extracts. Nicotine in N. 
gossei leaves and CRP2 was not responsible for their cytotoxicity. Extracts contained other 
compounds, including NNN and NNK, which might be responsible for the higher toxicity. 
In conclusion, Australian Nicotiana species used in pituri vary in their alkaloid compositions, 
with genetics driving some to contain higher nornicotine. These high-nornicotine species are 
more hazardous for chewing as pituri, especially when cured (dried). The nicotine release rate 
from N. gossei dry leaves, which is the main species used in pituri, is similar to Swedish snus 
and isn’t increased by chewing. The extract from N. gossei dry leaves results in higher toxicity 
to human lung epithelium cells compared to nicotine at similar concentrations. Altogether, 
these results indicate the need for further investigation of pituri, its chemicals, and effects on 
health, as pituri remains a popular smokeless tobacco product within some Australian 
Aboriginal communities. 
  
iii 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my 
thesis is the result of work I have carried out since the commencement of my research higher 
degree candidature and does not include a substantial part of work that has been submitted to 
qualify for the award of any other degree or diploma in any university or other tertiary 
institution. I have clearly stated which parts of my thesis, if any, have been submitted to qualify 
for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library 
and, subject to the policy and procedures of The University of Queensland, the thesis be made 
available for research and study in accordance with the Copyright Act 1968 unless a period of 
embargo has been approved by the Dean of the Graduate School.  
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
iv 
 
Publications during candidature 
Peer reviewed papers 
Moghbel N, Ryu B, Cabot PJ, Ratsch A, Steadman KJ. In vitro cytotoxicity of Nicotiana gossei 
leaves, used in the Australian Aboriginal smokeless tobacco known as pituri or mingkulpa. 
Toxicology Letters 2016, 254:45-51. 
Moghbel N, Ryu B, Steadman KJ. A reversed-phase HPLC-UV method developed and 
validated for simultaneous quantification of six alkaloids from Nicotiana spp. Journal of 
Chromatography B 2015, 997:142-5. 
Conference abstracts - oral 
Moghbel N, Ryu B, Steadman K.J. The in vitro cytotoxicity induced by the extract of the 
aboriginal Australian’s smokeless tobacco product “Pituri” compared to nicotine, 69th Tobacco 
Science Research Conference (TSRC), 20-23 September 2015, Naples, Florida. 
Moghbel N, Ryu B, Steadman K.J. Chemical and molecular characterization of nicotine to 
nornicotine conversion phenotype in Australian Nicotiana species used as chewing tobacco. 
31st Conference for the International Society of Chemical Ecology (ISCE 2015), 29th June - 
3rd July 2015, Stockholm, Sweden. 
Moghbel N, Ryu B, Steadman K.J. In vitro evaluation of nicotine release from pituri, a 
smokeless tobacco used by Australian aboriginals. Australian Pharmaceutical Sciences 
Association 2014, Conference, 5-6 December, 2014 Brisbane, Australia. 
Conference abstracts - poster 
Moghbel N, Ryu B, Steadman K.J. In vitro cytotoxicity induced by Pituri, the Aboriginal 
Australian smokeless tobacco, APSA-ASCEPT Joint Scientific Meeting, 29 November - 2 
December 2015, Hobart, Australia. 
Siah M. L, Moghbel N, Steadman KJ. In vitro evaluation of nicotine release from nicotine gum, 
Swedish snus and Pituri. APSA-ASCEPT Joint Scientific Meeting, 29 November - 2 December 
2015, Hobart, Australia. 
v 
 
Moghbel N, Ryu B, Steadman K.J. Chemical and molecular characterization of nicotine to 
nornicotine conversion phenotype in Australian Nicotiana species used as chewing tobacco. 
Combined ASBMB, ASPS, ANZSCDB, NZSBMB and NZSPB Annual Meeting (Combio 
2015), 27 September - 1 October 2015, Melbourne, Australia. 
Moghbel N, Ryu B, Steadman K.J. Nicotine to nornicotine conversion chemotype in Australian 
Nicotiana species used as smokeless tobacco by Aboriginal people. BBOCS 2014 (Brisbane 
Biological and Organic Chemistry Symposium), 1 December 2014, Brisbane, Australia. 
Moghbel N, Ryu B, Steadman K.J. The alkaloid composition of Nicotiana gossei and Duboisia 
hopwoodii used in the production of pituri by Australian aboriginal people. Australian 5th 
Pharmaceutical Sciences World Congress, 13-16 April 2014, Melbourne, Australia.  
Publications included in this thesis 
Moghbel N, Ryu B, Steadman KJ. A reversed-phase HPLC-UV method developed and 
validated for simultaneous quantification of six alkaloids from Nicotiana spp. J Chromatogr B 
2015;997:142-5. 
Incorporated as part of Chapter 2 
Contributor Statement of contribution 
Nahid Moghbel Designed experiments (80%) 
Conducted experiments (95%) 
Wrote the paper (90%) 
BoMi Ryu Member of PhD advisory team  
Designed experiments (10%) 
Conducted experiments (5%) 
Kathryn J Steadman Member of PhD advisory team  
Designed experiments (10%) 
Wrote and edited the paper (10%) 
 
 
vi 
 
Moghbel N, Ryu B, Cabot PJ, Ratsch A, Steadman KJ. In vitro cytotoxicity of Nicotiana gossei 
leaves, used in the Australian Aboriginal smokeless tobacco known as pituri or mingkulpa. 
Toxicol Lett. 2016;254:45-51. 
Incorporated as Chapter 4 
Contributor Statement of contribution 
Nahid Moghbel Designed experiments (70%) 
Conducted experiments (90%) 
Wrote and edited the paper (75%) 
BoMi Ryu Member of PhD advisory team  
Designed experiments (10%) 
Conducted experiments (10%) 
Wrote and edited the paper (5%) 
Peter J Cabot Designed experiments (10%) 
Wrote and edited the paper (5%) 
Angela Ratsch Obtained the plant material (100%) 
Wrote and edited the paper (5%) 
Kathryn J Steadman Member of PhD advisory team.  
Designed experiments (10%) 
Wrote and edited the paper (10%) 
vii 
 
Contributions by others to the thesis 
Ms Angela Ratsch (UQ School of Nursing, Midwifery and Social Work) provided important 
contextual information, advised on aspects of pituri preparation and use that were essential to 
the project, and obtained the dry leaf material analysed in Chapters 4 and 5 of the project. 
A/Prof Peter J Cabot (UQ School of Pharmacy) contributed to the design and data analysis of 
Chapter 5 and A/Prof Jiahua Xie (North Carolina Central University) contributed in 
experimental design of Chapter 3. 
Dr Neville Walsh (Royal Botanic Gardens Victoria) identified some of the Nicotiana species 
using voucher specimens that I prepared. 
The dry pituri leaf material used in Chapters 4 and 5 was donated by Peter Latz (Northern 
Territory Herbarium, Alice Springs, NT), via Ms Angela Ratsch. The human lung epithelial 
cells used in Chapter 5 were contributed by Professor Tom Gonda (UQ School of Pharmacy). 
The seeds used in this project were contributed by: Mr Philip Cameron (Brisbane Botanic 
Gardens, Qld), Mr Gary Dinham (Alice Springs Desert Park, Parks and Wildlife Commission, 
NT), Mr Daniel Duval (South Australian Seed Conservation Centre, Botanic Gardens of South 
Australia, SA), Mr Graeme Errington (Australian PlantBank, Australian Botanic Gardens, 
Mount Annan, NSW), Ms Megan Hirst (Royal Botanic Gardens Victoria), Ms Brenda Leighton 
(Australian Tropical Grains Germplasm Centre, Department of Agriculture and Fisheries, Qld), 
Associate Professor Ed Newbigin (School of BioSciences, The University of Melbourne, Vic), 
Dr Shane Turner (Botanic Gardens and Parks Authority, WA) and Dr Steve Wylie (WA State 
Agricultural Biotechnology Centre, Murdoch University, WA). 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
None 
  
viii 
 
Acknowledgements 
My journey at the University of Queensland would not have become fruitful without the advice 
and assistance of some special persons. I am really indebted to Associate Professor Kathryn 
Steadman for providing me an opportunity to pursue my doctoral research in her lab and for 
her constant support for helping me to have a grasp of conducting research and to develop the 
ability to think independently. I am grateful to Dr BoMi Ryu for her untiring support as a 
supervisor and her massive expertise and troubleshooting skills in the lab. I am so thankful to 
Associate Professor Peter Cabot and Dr Amitha Hewavitharana for their great insights, when I 
was in need. Special thanks to Mr Stuart Baldwin from Agilent technologies for his outstanding 
technical knowledge and support with the instruments used for obtaining data throughout my 
research. I also would like to express my gratitude to Associate Professor Jiahua Xie and his 
lab staff who hosted my visit at the Pharmaceutical Sciences Department at North Carolina 
Central University and his helpful advice and suggestion for further improvement of the 
project. 
I would like to acknowledge the UQ School of Pharmacy for the travel grant to attend the 
overseas conferences and administrative, research and academic staff for their support and 
advice. Special thanks to Dr Iman Azimi for his expert advice and friendship. I had the most 
amazing experience with lab members and friends within UQ School of Pharmacy, Juliana, 
Karnaker, Thao, Utpal, Fabio other friends and co-workers, thank you all for your support and 
friendship. 
Finally my deep gratitude and appreciation go to my husband, Mehdi for his unconditional 
love, immense patience, great support and faith in me and my intellect through this uneasy ride 
and my family for their encouragement, love and support. 
  
ix 
 
Keywords 
Nicotiana, smokeless tobacco, pituri, mingkulpa, nicotine release, cytotoxicity, alkaloid, 
tobacco specific nitrosamines 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code 111504 Pharmaceutical Sciences, 80% 
ANZSRC code: 111506 Toxicology (incl. Clinical Toxicology), 10% 
ANZSRC code: 060702 Plant Cell and Molecular Biology, 10% 
Fields of Research (FoR) Classification 
FoR code: 1115 Pharmacology and Pharmaceutical Sciences, 80% 
FoR code: 0607 Plant Biology, 20% 
  
x 
 
Table of Contents 
 
Abstract ...................................................................................................................................... i 
Declaration by author ............................................................................................................ iii 
Publications during candidature ........................................................................................... iv 
Publications included in this thesis ......................................................................................... v 
Contributions by others to the thesis ................................................................................... vii 
Statement of parts of the thesis submitted to qualify for the award of another degree .. vii 
Acknowledgements .............................................................................................................. viii 
Keywords ................................................................................................................................. ix 
Australian and New Zealand Standard Research Classifications (ANZSRC) .................. ix 
Fields of Research (FoR) Classification ................................................................................ ix 
Table of Contents ..................................................................................................................... x 
List of Figures ........................................................................................................................ xiv 
List of Tables ......................................................................................................................... xvi 
List of Abbreviations used in the thesis ........................................................................... xviii 
 Literature review ........................................................................................... 20 
1.1 Tobacco and health issues ........................................................................................ 21 
1.2 Smokeless tobacco products .................................................................................... 22 
1.2.1 Postharvest processing of tobacco ....................................................................... 22 
1.2.2 Varieties of smokeless tobacco products used around the world ........................ 23 
1.2.2.1 Pituri as a smokeless tobacco form used by Australian Aboriginals ........... 25 
1.2.2.2 Pituri chewing process ................................................................................. 25 
1.2.2.3 Psychoactive alkaloids source in pituri: Nicotiana spp. or Duboisia 
hopwoodii? ................................................................................................................... 26 
1.3 Nicotiana spp. .......................................................................................................... 27 
1.3.1 Australian Nicotiana species used as “Pituri” for chewing by Aboriginals ........ 29 
1.4 Chemistry of Nicotiana spp. .................................................................................... 31 
1.4.1 Alkaloids in Nicotiana spp................................................................................... 31 
1.4.2 Biochemistry and biosynthesis of alkaloids in Nicotiana spp. ............................ 32 
1.4.2.1 Nicotine to nornicotine conversion .............................................................. 35 
xi 
 
1.4.2.1.1 Biochemical and molecular characterization of N'-demethylation of 
nicotine 35 
1.4.2.1.2 Cytochrome P450s in alkaloid biosynthesis ............................................ 36 
1.4.2.2 Conversion phenotype in Nicotiana species ................................................ 37 
1.4.2.3 Spatio-temporal distribution of nicotine to nornicotine conversion ............ 38 
1.4.3 Alkaloid levels and composition in different species .......................................... 39 
1.4.4 Alkaloid distribution and translocation in Nicotiana spp. ................................... 40 
1.5 Chemical composition of smokeless tobacco products ........................................... 41 
1.5.1 Tobacco specific N-nitrosamines (TSNAs) ......................................................... 42 
1.6 Nicotine delivery in smokeless tobacco products .................................................... 44 
1.6.1 Nicotine release from smokeless tobacco products ............................................. 45 
1.7 Toxicity of smokeless tobacco products .................................................................. 46 
1.8 Rationale .................................................................................................................. 47 
1.9 Aims and hypotheses to be tested ............................................................................ 48 
 HPLC-UV and LC-MS/MS method development and validation for 
quantification of six alkaloids and two nitrosamines in tobacco plants and products .... 50 
2.1 Introduction .............................................................................................................. 51 
2.2 Experimental ............................................................................................................ 53 
2.2.1 Chemicals ............................................................................................................. 53 
2.2.2 Instrumentation and chromatographic conditions ................................................ 54 
2.2.2.1 HPLC-UV .................................................................................................... 54 
2.2.2.2 LC-MS/MS .................................................................................................. 54 
2.2.3 Sample preparation .............................................................................................. 55 
2.2.3.1 HPLC-UV .................................................................................................... 55 
2.2.3.2 LC-MS/MS .................................................................................................. 55 
2.2.4 Method validation ................................................................................................ 55 
2.2.4.1 HPLC-UV .................................................................................................... 55 
2.2.4.2 LC-MS/MS .................................................................................................. 56 
2.3 Results and discussion ............................................................................................. 57 
2.3.1 Method development ........................................................................................... 57 
2.3.1.1 HPLC-UV .................................................................................................... 57 
2.3.1.2 LC-MS/MS .................................................................................................. 58 
2.3.2 Method validation ................................................................................................ 59 
2.3.2.1 HPLC-UV .................................................................................................... 59 
2.3.2.2 LC-MS/MS .................................................................................................. 61 
2.4 Conclusion ............................................................................................................... 62 
 Chemical and molecular characterization of nicotine to nornicotine 
conversion in Australian Nicotiana species used as chewing tobacco ............................... 63 
3.1 Introduction .............................................................................................................. 64 
xii 
 
3.2 Materials and methods ............................................................................................. 66 
3.2.1 Plant Material ....................................................................................................... 66 
3.2.2 Chemical analysis ................................................................................................ 67 
3.2.2.1 Chemicals and reagents................................................................................ 67 
3.2.2.2 Alkaloid analysis .......................................................................................... 67 
3.2.3 Molecular analysis ............................................................................................... 68 
3.2.3.1 PCR amplification of CYP82E related genes .............................................. 68 
3.2.3.2 Sequencing the amplified CYP82E regions for selected species ................. 68 
3.2.3.3 Agarose gel electrophoretic analysis of CYP82E related genes transcript 
levels in fresh versus cured leaves of selected species ................................................ 69 
3.2.4 Statistical analysis ................................................................................................ 69 
3.3 Results ...................................................................................................................... 69 
3.3.1 Plant growth ......................................................................................................... 69 
3.3.2 Alkaloid profile .................................................................................................... 71 
3.3.3 CYP82E genes in Australian Nicotiana spp. ....................................................... 73 
3.3.3.1 Agarose gel electrophoretic analysis of CYP82E related genes transcript 
levels in fresh versus cured leaves of the selected high converter versus low or 
nonconverter species .................................................................................................... 74 
3.4 Discussion ................................................................................................................ 75 
 In vitro evaluation of nicotine release from dry leaves of Nicotiana gossei 
used in pituri, the Australian Aboriginal smokeless tobacco ............................................. 80 
4.1 Introduction .............................................................................................................. 81 
4.2 Materials and methods ............................................................................................. 84 
4.2.1 Materials .............................................................................................................. 84 
4.2.2 Simulation of a model buccal cavity .................................................................... 85 
4.2.3 Chemical analysis ................................................................................................ 85 
4.2.3.1 Nicotine and other alkaloids analysis with HPLC-UV ................................ 85 
4.2.3.2 TSNAs analysis with LC-MS/MS ............................................................... 85 
4.2.4 Statistical analysis ................................................................................................ 86 
4.3 Results ...................................................................................................................... 86 
4.4 Discussion ................................................................................................................ 89 
4.5 Conclusion ............................................................................................................... 92 
 The alkaloids chemistry and in vitro cytotoxicity of the Nicotiana gossei 
leaves used in Australian Aboriginal smokeless tobacco, ‘pituri’ compared to nicotine 93 
5.1 Introduction .............................................................................................................. 94 
5.2 Materials and methods ............................................................................................. 96 
5.2.1 Chemicals and reagents........................................................................................ 96 
5.2.2 Preparation of extracts ......................................................................................... 97 
5.2.3 Quantification of nicotine and other alkaloids ..................................................... 97 
xiii 
 
5.2.4 Quantification of NNN and NNK ........................................................................ 97 
5.2.5 Cell culture, treatment and viability assay ........................................................... 98 
5.2.6 Data analysis ........................................................................................................ 99 
5.3 Results ...................................................................................................................... 99 
5.3.1 Chemical analysis of the extracts ......................................................................... 99 
5.3.2 Effect of nicotine and smokeless tobacco extracts on cell viability .................. 100 
5.4 Discussion .............................................................................................................. 103 
5.5 Conclusion ............................................................................................................. 105 
 Summary, conclusions and future research .............................................. 106 
6.1 Summary and conclusions ..................................................................................... 107 
6.2 Future direction ...................................................................................................... 112 
References ............................................................................................................................. 116 
Appendix ............................................................................................................................... 130 
 
 
  
xiv 
 
List of Figures 
Figure 1-1 Pituri is prepared by mixing native tobacco leaves (A), with wood ash (B). 
An aboriginal woman chewing pituri (C) in Ernabella, South Australia. Photographs 
(A) and (B) taken by author. Photograph (C) published with consent from (National 
Library of Australia, 2016). ................................................................................................... 26 
Figure 1-2 Pituri bag on display at the Queensland museum. Photograph taken by the 
author. .................................................................................................................................... 27 
Figure 1-3 Nicotine alkaloid structures.................................................................................. 32 
Figure 1-4 Biosynthesis of nicotine and related alkaloids (Hakkinen et al., 2007) PMT, 
putrescine N-methyltransferase; MPO, N-methylputrescine oxidase; QPRTase, 
quinolinate phosphoribosyltransferase; LDC, lysine decarboxylase; CYP82E, 
Cytochrome P450s belonging to the 82E subfamily.............................................................. 34 
Figure 1-5 Tobacco alkaloids, and the nitrosamines that can be formed from them. 
With the exception of NNA, all of these compounds are present in tobacco and tobacco 
smoke (Hoffmann et al., 1995). ............................................................................................. 43 
Figure 2-1 Structure, molecular weight (MW, g/mol) and pKa values of A) the 
common tobacco alkaloids shown in order of HPLC elution and B) the two major 
carcinogenic TSNAs, NNN and NNK ................................................................................... 52 
Figure 2-2 Chromatograms depicting separation of alkaloids on a 150 × 3 mm, 3.5 µm 
particle size Zorbax Extend C-18 column and detection at 260 nm. The mobile phase 
(flow rate 0.8 mL/min) consisted of a gradient of acetonitrile and 15 mM ammonium 
formate in water (pH adjusted to 10.5 with triethylamine); the gradient elution was 9 
to 10% acetonitrile from 0-5 min and then 10 to 13% acetonitrile from 5 to 13 min. 
(A) Standard solution of alkaloids and IS, (B) Extraction from Nicotiana benthamiana 
fresh leaves. 1. Cotinine; 2. Caffeine (IS); 3. Nornicotine; 4. Anatabine; 5. Myosmine; 
6. Anabasine; 7. Nicotine. ...................................................................................................... 58 
Figure 3-1 Agarose gel electrophoretic photo of the CYP82E related fragment 
produced by 35 cycles of PCR amplification of DNA isolated from 1. N. forsteri, 2. N. 
benthamiana, 3. N. excelsior, 4. N. gossei, 5. N. suaveolens (exigua), 6. N. 
goodspeedii, 7. N. simulans, 8. N. velutina, 9. N. cavicola, 10. N. amplexicaulis, 11. 
N. megalosiphon subsp. megalosiphon, 12. N. megalosiphon subsp. sessifolia, 13. N. 
truncate, 14. N. maritima, 15. N. occidentalis subsp. obliqua, 16. N. occidentalis 
subsp. Occidentalis, 17. N. occidentalis subsp. hesperis, 18. N. sp. 'Corunna', 19. N. 
xv 
 
heterantha, 20. N. rosulata subsp. rosulata, 21. N. rosulata var. ingulba, 22. N. 
rotundifolia, 23. N. burbidgae, 24. N. monoschizocarpa. ..................................................... 74 
Figure 3-2 Agarose gel electrophoretic analysis and normalised band densitometry 
values of the CYP82E related fragment produced by 35 cycles of PCR amplification 
of cDNA isolated from A) fresh leaves B) Cured leaves (at 35° C for 6 hours) of 1. N. 
gossei 2. N. excelsior 3. N. benthamiana, 4. N. cavicola, 5. N. goodspeedii, 6. N. 
velutina. A 562 bp GAPDH fragment obtained by 35 cycles of PCR amplification of 
the cDNA for each sample is shown as an internal gene and for normalising the 
densitometric values that all were quantified using ImageJ software. The data points 
in graphs show mean ± std error of 3 independent experiments *: p<0.05 ........................... 75 
Figure 4-1 Percent cumulative release of nicotine from (A) CRP2 (B) Snus (C) N. 
gossei dry leaves (D) N. gossei dry leaves in alkaline media adjusted to pH 9 (E) and 
Nicabate gum in 3 conditions of without pressing, initial pressing for 30 seconds and 
pressing for 30 seconds at every 15 minutes. The data points show mean ± std error of 
3 independent experiments. ................................................................................................... 88 
Figure 5-1 MTS assay results showing the effects of A) aqueous extract of N. gossei 
leaves used in pituri and B) aqueous extract of CRP2 on cell viability of human lung 
epithelial cells (A549). Applied concentrations of both extracts were 2, 10, 20, 50 
mg/ml that were equivalent to approximately 0.05, 0.2, 0.5, 1-1.5 mg/ml of nicotine 
respectively. The data show the mean ± SEM of the 3 replicate experiments. ................... 101 
Figure 5-2 MTS assay results showing the effects of a concentration range of nicotine 
standard on cell viability of human lung epithelial cells (A549). Concentrations of 0.05 
to 1.5 mg/ml covers the concentration range found in the 2-50 mg/ml of the pituri leaf 
and CRP2 extracts. Higher concentrations of 5 and 10 mg/ml were applied for 
calculation of IC50. The data show the mean ± SEM of the 3 replicate experiments. . ...... 102 
Figure 5-3 Nicotine equivalent concentrations of extracts from pituri leaves and CRP2, 
and concentration of nicotine standard that resulted in 50% inhibition of growth in 
human lung epithelial cells (A549). The data show the mean ± SEM of the 3 replicate 
experiments. * P < 0.05, ** P < 0.01, *** P < 0.001........................................................... 102 
 
  
xvi 
 
List of Tables 
Table 1-1 Smokeless tobacco products based on their mode of use with WHO regions 
in which they are used; AFRO: African region, AMRO: American region, SEARO: 
South-East Asian region, EURO: European region, EMRO: Eastern Mediterranean 
region, WPRO: Western Pacific region (International Agency for Research on Cancer, 
2007) ...................................................................................................................................... 24 
Table 1-2 Sections classification of the Nicotiana genus, with species listed for the 
mainly Australian section, Suaveolentes (Knapp et al., 2004, Clarkson et al., 2004, 
Marks et al., 2011) ................................................................................................................. 29 
Table 1-3 Australian species of Nicotiana that have any report in relation to use as 
smokeless tobacco products (Latz et al., 1995, Symon, 2005, Peterson, 1979). ................... 29 
Table 1-4 Allele frequencies of CYP 82E genes among F2 plants (Pakdeechanuan et 
al., 2012) ................................................................................................................................ 37 
Table 1-5 Subdivision of Australian species of Nicotiana in terms of total alkaloid, 
major alkaloid type and geographic distribution (Sisson and Severson, 1990) ..................... 40 
Table 1-6 Carcinogens in smokeless tobacco products, and the types of cancer they 
may cause (Hoffmann et al., 2001, International Agency for Research on Cancer, 2004, 
Hecht, 2003) ........................................................................................................................... 42 
Table 2-1 Mass spectrometry parameters used in MRM mode for two TSNAs ................... 55 
Table 2-2 System suitability data obtained for validation of the developed method with 
mobile phase pH 10.5. The values are the average or relative standard deviation (RSD) 
of six consecutive injections of a mixture of alkaloids and IS (caffeine) all at a 
concentration of 5 µg/mL using the developed method. ....................................................... 59 
Table 2-3 Regression statistics, limit of detection (LOD) and limit of quantification 
(LOQ) for alkaloid standards. ................................................................................................ 60 
Table 2-4 Method accuracy results obtained by calculating the relative standard 
deviation (RSD) value for the retention time (Rt) and average peak area ratio (Pa) of 
alkaloids to internal standard from six replicate injections within intra and inter-day 
runs in a mixture of alkaloids and IS (caffeine) all at a concentration of 5 µg/mL. .............. 60 
Table 2-5 Within-laboratory reproducibility results. Relative standard deviation (RSD) 
for the retention time (Rt) and peak area ratio (Pa) of six replicate injections of a 
mixture of alkaloids and IS at a concentration of 5 µg/mL for each, obtained from 
performing the developed method on two different HPLC systems within the lab............... 61 
xvii 
 
Table 2-6 The LC-MS/MS validation parameters for the two major TSNAs, NNN and 
NNK. ...................................................................................................................................... 61 
Table 3-1 Sequences of the primers used for PCR amplification of CYP82E related 
genes designed from N. tabacum CYP82E4 mRNA (Accession: KC120817.1) and 
internal gene GAPDH designed from N. benthamiana glyderaldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA (Accession: JQ256517.1). ............................................... 68 
Table 3-2 Sources of seeds used for growing the Nicotiana species for this study, with 
their corresponding herbarium voucher number, collection date, tetrazolium (V) and 
germination (G) results. ......................................................................................................... 70 
Table 3-3 Alkaloid content (mean ± se for 3 replicates) in freeze-dried fresh leaves of 
Australian Nicotiana spp. grown in a plant growth incubator under 16 h photoperiod 
provided with cool white fluorescent lamps, 23°C day and 21ºC night temperature, 
constant 70–90% relative humidity. Plants were watered daily as needed. Conversion 
rate was defined using the formula: [nornicotine content / (nornicotine content + 
nicotine content)] x 100. Species with less than 10% conversion rate are regarded to 
be low or nonconverters while those with 10-50% and more than 50% conversion rate 
are assigned as medium and high converters, respectively. ................................................... 72 
Table 3-4 Alkaloids (mean ± se for 3 replicates) of fresh versus cured (35°C for 6 
hours in the dark) leaves for selected species of Australian Nicotiana spp. Significant 
differences (p<0.05) between fresh and cured leaves are indicated (*). ................................ 73 
Table 4-1 Concentration (mg/g; mean ± se for 3 independent replicates) of nicotine 
and related alkaloids in smokeless tobacco products (fresh weight basis). For each 
alkaloid, mean values with the same superscript letter are not significantly different 
(p<0.05). ................................................................................................................................. 86 
Table 4-2 Concentration of nicotine alkaloids and TSNAs (mean ± se of 3 replicates) 
released into 50 ml of simulated saliva in vessels with chewing at 15 minute intervals 
from smokeless tobacco products and Nicabate gum at 120 min. ......................................... 89 
Table 5-1 Alkaloid and TSNA composition (mean ± se for 3 independent replicates) 
of the Coresta reference smokeless tobacco product (CRP2 Moist Snuff) and dry 
leaves of Nicotiana gossei, along with freeze-dried aqueous extracts of CRP2 and dry 
leaves of N. gossei. ND: not detected. ................................................................................... 99 
  
xviii 
 
List of Abbreviations used in the thesis 
ANOVA Analysis of Variance 
BP British Pharmacopoeia 
cDNA Complementary DNA 
CORESTA Cooperation Centre for Scientific Research Relative for Tobacco 
CRP2 CORESTA reference smokeless tobacco product 
DMEM Dulbecco’s Modified Eagle Medium 
EDTA Ethylenediaminetetraacetic Acid 
FBS Fetal Bovine Serum 
FDA Food and Drug Administration 
HCl Hydrochloric Acid 
HPLC-UV High Performance Liquid Chromatography- Ultra Violet Detector 
IARC International Agency for Research on Cancer 
IS Internal Standard 
LC-MS/MS Liquid Chromatography- Tandem Mass Spectrometry 
LOD  Limit of Detection 
LOQ Limit of Quantification 
MRM Multiple Reaction Monitoring 
NAB N′ Nitrosoanabasine 
NAT N′-Nitrosoanatabine 
NCBI National Centre for Biotechnology Information 
NNK 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone 
NNN N′-Nitrosonornicotine 
NRT Nicotine Replacement Therapy 
NSW New South Wales 
NT Northern Territories 
PA Peak Area 
xix 
 
PAH Polycyclic Aromatic Hydrocarbon 
PCR Polymerase Chain Reaction 
PREP Potential Reduced Exposure Products 
QLD Queensland 
RSD Relative Standard Deviation 
RT Retention Time 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
SA South Australia 
SLT Smokeless Tobacco Product 
TEA Triethylamine 
TF Tailing Factor 
TSNA Tobacco Specific Nitrosamine 
USP United States Pharmacopoeia 
VIC Victoria 
WA Western Australia 
 
 
CHAPTER 1
 
20 
 
 
 
 
 
 
 
 Literature review 
 
CHAPTER 1
 
21 
 
1.1 Tobacco and health issues 
Worldwide use of tobacco products is responsible for nearly 6 million deaths each year and, if 
this trend continues, it is expected to reach to 8 million by 2030 (World Health Organization, 
2011). In developing countries, smoking is responsible for 30% of all cancer related deaths and 
this figure is 13% in developed countries, and 5.2% for Australia (Begg et al., 2007). Lung 
cancer is the most dominant cancer resulting from smoking (Hecht, 1999). Cigarette smoking 
is also associated with various other types of cancer including liver, pancreas, stomach, urinary 
bladder, and oesophagus (Sasco et al., 2004). Sixty-two compounds that are carcinogenic to 
laboratory animals have been shown to be present in cigarette smoke and 15 of them were 
proven to be carcinogenic to humans (International Agency for Research on Cancer, 2004). 
Other tobacco products such as smokeless tobacco have been gaining greater interest as a 
substitute for cigarette smoking (Christen, 1980). Smokeless tobacco products have different 
health effects and not all of them have been studied for the health outcomes and diseases they 
may cause (Ebbert et al., 2004, Scientific Advisory Committee on Tobacco Products 
Regulation, 2010, Winstanley, 2012). 
Short-term increase of blood pressure and heart rate is one of the health effects attributed to 
smokeless tobacco products use and users are probably more prone to the risk of dying from 
stroke and heart disease (International Agency for Research on Cancer, 2007, Paolo and Kurt, 
2009). Also, significant effects on the soft and hard tissues of the mouth caused by smokeless 
tobacco products can lead to oral disease like bad breath, tooth decay, receding gums, lesions 
in the mouth (Carr and Ebbert, 2006, Christen, 1980, International Agency for Research on 
Cancer, 2007); hence, dentists are urging health professionals to warn people of the hazards of 
using smokeless tobacco products (Christen, 1980). 
So far 28 carcinogenic compounds have been reported to be present in smokeless tobacco 
products (International Agency for Research on Cancer, 2007). Mouth cancer is the most 
prevalent cancer caused by using smokeless tobacco (Ebbert et al., 2004, Scientific Advisory 
Committee on Tobacco Products Regulation, 2010) and the risk of mouth cancer is reported to 
be the highest by using tobacco-betel, tobacco-lime and other mixtures of tobacco in India, 
Pakistan and South Asia and Toombak from the Sudan (Critchley and Unal, 2003, International 
Agency for Research on Cancer, 2007). Also, pancreas and oesophagus cancer have been 
reported to be caused by smokeless tobacco products (Secretan et al., 2009). 
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In pregnant women using smokeless tobacco products, there is a high risk of low birth weight, 
premature birth and preeclampsia (Ebbert et al., 2004, International Agency for Research on 
Cancer, 2007, Scientific Advisory Committee on Tobacco Products Regulation, 2010). In male 
users of smokeless tobacco products, there is an increase in number of abnormal sperm, while 
sperm count and semen volume decrease (International Agency for Research on Cancer, 2007, 
Paolo and Kurt, 2009). 
In Australia, tobacco is a widely used legal drug and in 2003, 15,511 deaths have been reported 
as attributable to tobacco (Begg et al., 2007). It is a major risk factor for the development of 
diseases like coronary heart disease, stroke, peripheral vascular disease, several cancers, 
respiratory disorders and other diseases and condition. It has been reported that between 2003 
and 2007, there have been nine deaths of Indigenous Australians, and 301 deaths of non-
Indigenous Australians with direct cause of death related to tobacco use. Also 327 deaths of 
Indigenous Australians, and 7,582 deaths of non-Indigenous Australians in this period were 
indirectly linked to tobacco use in New South Wales, Queensland, Western Australia, South 
Australia and the Northern Territory (Australian Institute of Health and Welfare, 2011, 
Australian Institute of Health and Welfare, 2012). 
1.2 Smokeless tobacco products  
Smokeless tobacco products are used without burning and consumed orally (chewed, sucked) 
or nasally (inhaled) (International Agency for Research on Cancer, 2007, Winstanley, 2012). 
Depending on their composition and process of production, each smokeless tobacco product 
has different ingredients, and most of them have not been fully studied for the extent of their 
ingredients (Ebbert et al., 2004, Scientific Advisory Committee on Tobacco Products 
Regulation, 2010, Winstanley, 2012). 
1.2.1 Postharvest processing of tobacco  
Tobacco plants used in smokeless tobacco products are from the genus Nicotiana, mainly N. 
tabacum and sometimes N. rustica, which are harvested and then cured (International Agency 
for Research on Cancer, 2007). Curing refers to treating harvested fresh Nicotiana leaves with 
regulated conditions of temperature and humidity to remove moisture from the leaves without 
sacrificing quality and to produce a stable product of suitable physical and chemical 
composition with desired colour and aroma (Abubakar et al., 2000, Touton, 1961). Curing 
should be done in a way that biological activities in the leaf continues, so moisture should be 
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removed slowly at the beginning and then this rate should increase to arrest the chemical 
reactions and complete curing (Abubakar et al., 2000). 
For the commercial production of tobacco, after harvest the plants are immediately transferred 
to tobacco barns (kilns) to be cured. There are different designs of barns depending to the 
method of curing and type of tobacco: 
 In air-curing, leaves are hung and dried over a period of four to eight weeks in well-
ventilated barns. The smoke from this type of tobacco is light and sweet in flavour, and the 
level of sugar is low while there is high nicotine content. Examples are the tobacco used in 
cigar and burley tobacco used primarily for cigarette production (Bacon et al., 1952, Alfred, 
1920). 
 For fire-curing, which takes between three days to ten weeks, plants are hung in large barns 
and exposed to fires of hardwoods. Sugar is low in fire cured tobacco and nicotine is high. 
Fire curing is used for pipe tobacco, chewing tobacco, and snuff (Alfred, 1920). 
 Flue-curing involves conveying flues of external fire to the curing barns that slowly raises 
the temperature and heat-cures the tobacco without exposing it to smoke. The process lasts 
for about a week. Cigarette tobacco is produced by this method and it is high in sugar and 
has medium to high levels of nicotine (Bacon et al., 1952, Alfred, 1920). 
 In sun-curing, the plants are laid uncovered in the sun in order to dry. Both sugar and 
nicotine level is reported to be low and the sun-cured tobacco is mainly used in cigarettes 
(Alfred, 1920). 
1.2.2 Varieties of smokeless tobacco products used around the world 
The two main types of smokeless tobacco products are snuff and chewing tobacco (Ebbert et 
al., 2004) and there are a wide range of commercially available or native smokeless tobacco 
products used around the world (Table 1-1). Snuff is a cured and ground tobacco that can be 
held in the mouth and sucked or inhaled (in its dry form). Chewing tobacco consists of 
Nicotiana leaves chewed in combination with substances such as lime, betel leaf, areca nut 
(Winstanley, 2012). 
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Table 1-1 Smokeless tobacco products based on their mode of use with WHO regions in which they are used; 
AFRO: African region, AMRO: American region, SEARO: South-East Asian region, EURO: European region, 
EMRO: Eastern Mediterranean region, WPRO: Western Pacific region (International Agency for Research on 
Cancer, 2007) 
Name and composition WHO region 
Oral use 
Betel quid (paan or pan): betel leaf, areca nut, slaked lime and tobacco; Chewed. EMRO, SEARO 
WPRO 
Chimó: tobacco, sodium bicarbonate, brown sugar, ashes from the Mamón tree, vanilla 
and anisette flavourings; kept in the mouth for almost 30 min and then spat out. 
AMRO 
Creamy snuff: ground tobacco mixed with aromatic substances like clove oil, glycerine, 
spearmint and camphor, salts, water; etc.; kept in the mouth; used for cleaning teeth. 
SEARO 
 
Dry snuff (bajjar, tapkir/tapkeer, naffa, tenfeha, nufha): powdered fire cured, fermented 
tobacco; Used orally or nasally. 
AFRO, AMRO 
EURO 
Gul: powdered tobacco, molasses, etc.; applied to the teeth/ gums for cleaning  SEARO 
Gudhaku: powdered tobacco mixed with molasses and applied to the teeth and gums. SEARO 
Gutka: roasted, sun-dried, chopped tobacco mixed with areca nut, slaked lime, catechu, 
flavourings and sweeteners; chewed/ sucked; saliva is spat out or swallowed. 
SEARO 
Iq’mik: fire-cured tobacco and punk ash (made from burning a woody fungus that grows 
on the bark of birch trees); mainly chewed. 
AMRO 
Khaini: sun-dried or fermented tobacco mixed with slaked lime paste or areca nut; rubbed 
in the palm of the hand, then held in the mouth and sucked or chewed. 
SEARO 
Khiwam or qimam: tobacco leaves boiled in the water (containing spices like saffron, 
cardamom, aniseed and additives such as musk) to make a paste; chewed. 
SEARO 
Loose-leaf: cigar tobacco sweetened with liquorice; sucked or chewed;  AMRO, EURO 
Maras: sun-dried powdered tobacco mixed with the wood (oak, walnut or grapevine) ash, 
sprinkled with water to humidify; kept in the mouth for 4–5 min or while sleeping. 
EURO 
Mawa: crushed tobacco, sun-cured areca nut and slaked lime; chewed for 10-20 min. SEARO 
Mishri: powdered toasted tobacco leaves; applied to gums/ teeth as dentifrice. SEARO 
Moist snuff: cured tobacco in fine particles (‘fine cut’) or strips (‘long-cut’); contain up 
to 50% moisture; a pinch (dip) or a pouch is sucked; saliva is spat out or swallowed.  
AMRO 
EURO 
Naswar or nass: sun-dried/ partially cured powdered tobacco mixed with ash, oil, 
flavouring and colouring agents or slaked lime; sucked under the tongue.  
AFRO 
SMRO, EURO 
Plug chewing tobacco: cigarette/ cigar tobacco mixed with liquorice / sugar, pressed into 
plug; contains 15% moisture; chewed/ held in the mouth; saliva swallowed or spat out. 
AMRO 
Red tooth powder: tobacco powder mixed with herbs and flavours; red in colour.  SEARO 
Shammah: greenish-yellow mixture of powdered tobacco, lime, ash, black pepper, oils 
and flavours; placed in the mouth and sucked; debris are spat out. 
EMRO 
EURO 
Snus (Swedish moist snuff): ground dry tobacco, aromatic substances, salts like sodium 
carbonate, humidifying agents, water and buffering agents such as sodium carbonate; a 
dip is placed between the gum and upper lip and kept for 11-14 h per day. 
EURO 
Tobacco chewing gum: developed under the brand name ‘Fire’ WPRO 
Tobacco tablets: ground tobacco (1.3 mg nicotine), mint / eucalyptus; melt in the mouth AMRO 
Toombak: dried and fermented tobacco mixed with sodium bicarbonate (4:1 ratio); 10 g 
ball forms (saffa) are held in the mouth; sucked for 10-15 min and then spit. 
AFRO 
Tuibur: tobacco smoke passed through water, the water is used as Tuibur (hidakphu) for 
gargling or sipping. 
SEARO 
Twist/roll chewing tobacco: twist or roll burely tobacco treated with tobacco leaf extract 
and flavours and twisted into rope-like strands that are dried. 
AMRO 
Zarda: tobacco leaves boiled with lime, spices until dry; coloured with vegetable dyes. EMRO, SEARO 
Nasal use 
Dry snuff: fire-cured, fermented tobacco in dry, powdered form; inhaled into the nostrils. AFRO, EMRO 
EURO, SEARO 
 Liquid snuff: used nasally AFRO 
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1.2.2.1 Pituri as a smokeless tobacco form used by Australian Aboriginals 
Pharmacologically active components in plant material have always been the reason for them 
being chewed by indigenous populations of the Americas, Africa, the Indian subcontinent and 
the Asia-Pacific region including Australia (Latz et al., 1995). One example is the betel quid 
(Table 1-1) that has been reported to be used in the western pacific region including Australia 
(International Agency for Research on Cancer, 2007). Nicotine is the major pharmacologically 
active component in Nicotiana and in the Central Australian region a large group of 
Aboriginals chew a range of Nicotiana species for nicotine (Latz et al., 1995). ‘Pituri’ is the 
most common name, but other names such as ‘mingkulpa’ have been mentioned in the literature 
(Ratsch et al., 2010). The extent of pituri use is not well known, but a survey conducted 30 
years ago reported that 25% of Aboriginal people, majority of which were female (38% women 
against 11% men), use chewing tobacco. According to this survey chewing was more popular 
in Central Australia with 41% of people practicing it (Fleming et al., 1991) and in a recent 
research around 30% of Aboriginal women giving birth in the major public hospital in Alice 
Springs  were reported to use pituri either during their pregnancy or during lactation (Ratsch, 
2011). Despite this, pituri was not listed in the WHO reports on smokeless tobacco types used 
around the world (International Agency for Research on Cancer, 2007). 
1.2.2.2 Pituri chewing process 
To prepare pituri, fresh or sun/fire-dried leaves of Nicotiana are broken into pieces often in 
sand ovens (Watson et al., 1983) and then mixed with burnt alkaline wood ash (Fig. 1-1 A-B) 
and chewed together to form into a ‘quid’ (Fig. 1-1 C). In terms of ingredients and preparation, 
pituri is similar to indigenous Alsakan smokeless tobacco iq’mik (International Agency for 
Research on Cancer, 2007, Hearn et al., 2013) and maras which is a smokeless tobacco used in 
Turkey (International Agency for Research on Cancer, 2007). Also, people of the Asian 
subcontinent have a similar practice by combining betel with lime before chewing 
(International Agency for Research on Cancer, 2004, Watson et al., 1983). The ash used in 
pituri is prepared by burning the wood from selected plants such as Acacia spp., Grevillea spp. 
and Eucalyptus spp. (Aiston, 1937, Barr et al., 1988, Peterson, 1979). Among these, Acacia 
salicina has been mentioned in  a report over 100 years ago as being a preferred source for 
producing a very alkaline wood ash (Higgin, 1903). 
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Figure 1-1 Pituri is prepared by mixing native tobacco leaves (A), with wood ash (B). An aboriginal woman 
chewing pituri (C) in Ernabella, South Australia. Photographs (A) and (B) taken by author. Photograph (C) 
published with consent from (National Library of Australia, 2016). 
Pituri users hold the quids for long periods of time in their mouth and suck it rather than 
chewing it. This is to obtain fast absorption of the nicotine content through their mouth mucosa 
(Peterson, 1979, Winstanley, 2012). Chewers might share their quids with family or friends, 
and add more ash to revitalise the nicotine absorption. During breaks from oral use, the quid 
might be left on their skin in areas such as behind the ear, under a breast or accessories such as 
an arm or a head band. These approaches potentially allow nicotine absorption through the skin 
(Ratsch et al., 2010). Sometimes, a quid is kept in the mouth through the night which allows 
longer exposure to nicotine. Counting the number of chewers by simple observation likely 
results in an underestimation as the pituri quid may be held in a number of body locations and 
not easily visible. 
1.2.2.3 Psychoactive alkaloids source in pituri: Nicotiana spp. or Duboisia hopwoodii? 
The Aboriginal referral of the word “pituri” to a variety of plants they use as either the alkaloid 
source or the ash component in preparation of pituri has resulted in a confusion in the literature 
on the true identity of the plants used as the main component and source of psychoactive 
alkaloids in this smokeless tobacco product (Aiston, 1937). While some of the historical 
literature introduced pituri as Duboisia hopwoodii leaves (Keogh, 2011, Langley and 
Dickinson, 1890, Low, 1987, Watson et al., 1983), others attributed it as a species of Australian 
tobacco such a N. gossei or N. excelsior (Johnston and Cleland, 1934). It is most likely that 
both plants were used because both are reported to contain nicotine (Hicks and LeMessurier, 
1935). What is currently used in the practice of chewing pituri by Aboriginals in Central 
Australia is some species of Nicotiana (Ladiges et al., 2011, Marks et al., 2011, Ratsch et al., 
2010, Symon, 2005). 
A B C 
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The knowledge of processing and preparing pituri (either D. hopwoodii or Nicotiana spp.) had 
a sacred ritual significance among Aboriginal peoples and was reported to be restricted to 
specific groups or tribes (Low, 1987, Watson et al., 1983). Pituri was packed and traded in 
specially woven crescent shaped bags (Fig. 1-2) (Watson et al., 1983). 
Figure 1-2 Pituri bag on display at the Queensland museum. Photograph taken by the author. 
1.3 Nicotiana spp. 
The genus Nicotiana, with 86 naturally occurring species, is the sixth largest in the family 
Solanaceae and it is named after a sixteenth century French diplomat Jean Nicot, who 
popularized tobacco in Europe (Ladiges et al., 2011, Häkkinen and Oksman-Caldentey, 2004, 
Clarkson et al., 2004). It has been reported that this genus first originated in South America 
and subsequently spread to other continents (Aoki and Ito, 2000). Nicotiana has a natural 
distribution limited to the southern hemisphere (neotropical) and about 75% of species occur 
in the Americas and 25% of species occur in Australia (Knapp et al., 2004). Exceptions are N. 
africana which is the first (and only) species to be discovered in Africa (Namibia) and N. 
fragrans which is restricted to islands in South Pacific Ocean (Aoki and Ito, 2000, Clarkson et 
al., 2004). 
Goodspeed described the section Suaveolentes in 1945 (Goodspeed, 1945). The origin of this 
group has not been clear and described as enigmatic (Goodspeed et al., 1954) and paradoxical 
(Chase et al., 2003). However, the section is retained in the current sectional classification of 
the genus (Knapp et al., 2004) and considered as monophyletic (Chase et al., 2003, Clarkson 
et al., 2004). Goodspeed et al. (1954) suggested that the progenitor of the Australian species 
came from relatives of the Noctiflorae and Alatae Chase et al. (2003) have supported the Alatae 
as the possible ancestor of this section, and also using chloroplast phylogeny, Clarkson et al. 
(2004) suggested an ancestor of section Noctiflorae as the maternal progenitor.  
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Members of the genus Nicotiana are widely used in traditional medicine in both South America 
and Australia. N. tabacum and N. rustica, known as cultivated tobaccos, are the most widely 
used drug plants in the world (Chase et al., 2003, Knapp et al., 2004). Floral and vegetative 
morphology in species of this genus is wide and there are species that grow to a few centimetres 
while others reach four or more metres (Clarkson et al., 2004). In 1954 using evidence from 
morphology, cytology, biogeography, and crossing experiments, Goodspeed provided a 
detailed history of the taxonomy of the genus. According to Goodspeed the base chromosome 
number of the genus is n=12 and he emphasized the role of doubling and hybridization in the 
evolution of the genus so that the haploid chromosome number variation from n=9 to n=24 is 
observed, but the basic chromosome number is n=12 (Goodspeed et al., 1954). As of 2004, 
there are 13 sections and 86 species recognised within Nicotiana (Table 1-2) (Clarkson et al., 
2004, Knapp et al., 2004). Tobacco (N. tabacum), the species of primary economic importance, 
is an allotetraploid derived from two diploid ancestors, N. tomentosiformis and N. sylvestris 
(Goodspeed et al., 1954). Nicotine is the primary alkaloid accumulated in the cured leaves of 
tobacco, whereas both the ancestral species accumulate nornicotine (Sisson and Severson, 
1990) because they have the conversion locus to convert nicotine to nornicotine. Gene silencing 
occurred after the polyploidization event in the evolution of polyploid species (Chakrabarti et 
al., 2007). 
  
CHAPTER 1
 
29 
 
Table 1-2 Sections classification of the Nicotiana genus, with species listed for the mainly Australian section, 
Suaveolentes (Knapp et al., 2004, Clarkson et al., 2004, Marks et al., 2011) 
Nicotiana section 
Alatae Noctiflorae 
Nicotiana Paniculatae 
Polydicliae Repandae 
Petunioides Tomentosae 
Rusticae Trigonophyllae 
Sylvestres Undulatae 
Suaveolentes  
Species included in Suaveolentes section 
N. africana Merxm. N. monoschizocarpa (P. Horton) Symon & Lepschi 
N. amplexicaulis N.Burb.  N. occidentalis H.Wheeler ssp. hesperis (N.Burb.) 
P.Horton 
N. benthamiana Domin N. occidentalis H.Wheeler ssp. obliqua N. Burb. 
N. burbidgeae Symon;  N. occidentalis H.Wheeler ssp. occidentalis 
N. cavicola N.Burb. N. rosulata (S.Moore) Domin ssp. ingulba (J.Black) 
P. Horton 
N. forsteri Roem. & Schult (syn N. debneyi Domin)  N. rosulata (S.Moore) Domin ssp. rosulata 
N. excelsior (J.Black) J.Black N. rotundifolia Lindley 
N. fatuhivensis F.Br. N. simulans N.Burb. 
N. fragrans Hook.  N. sp.‘Corunna’ Symon 17088 
N. goodspeedii H.Wheeler N. suaveolens Lehm. (syn N. exigua H.Wheeler)  
N. gossei Domin N. truncata Symon 
N. heterantha Symon & Kenneally N. umbratica N.Burb. 
N. maritima H.Wheeler N. velutina H.Wheeler  
N. megalosiphon Van Heurck and Müll. Arg. ssp. 
megalosiphon 
N. wuttkei J.Clarkson & Symon 
N. megalosiphon Van Heurck & Mull. Arg. ssp. 
sessifolia P.Horton 
  
1.3.1 Australian Nicotiana species used as “Pituri” for chewing by Aboriginals  
There are 26 Australian species and subspecies of Nicotiana (Table 1-3) that are contained in 
the section Suaveolentes, along with three other species in the Western Paciﬁc including 
Nicotiana fatuhivensis F.Br. in the Marquesas Islands and Nicotiana forsteri Roem & Schult 
(synonymous with Nicotiana debneyi Domin) and Nicotiana fragrans Hook in New Caledonia 
and nearby islands (Ladiges et al., 2011, Marks et al., 2011). The Australian species are widely 
spread over the continent except for Tasmania. They are less common in the far north and there 
has not been any record of them from the Kimberley, Arnhem Land or Cape York Peninsula. 
Nicotiana does not occur in New Guinea or New Zealand and the main place of speciation has 
been in the warmer arid and semi-arid mainland of Australia (Burbidge, 1960, Symon, 2005). 
Table 1-3 Australian species of Nicotiana that have any report in relation to use as smokeless tobacco products 
(Latz et al., 1995, Symon, 2005, Peterson, 1979). 
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Species Used for chewing Reference 
N. benthamiana Domin Used as a chewing tobacco throughout its range Latz (1995) 
Pintupi people use it  Peterson (1979) 
Alyawara people rank it below N. ingulba. Latz (1974)  
A favoured species  Symon (2005) 
Used in WA (recorded N. suaveolens but as it doesn’t 
grow there it is most likely N. benthamiana) 
Reid and Betts (1977 in 
Symons, 2005) 
N. cavicola N.Burb Used mainly in Western Australia Reid and Betts (1977 in 
Symons, 2005) 
N. excelsior J.Black (J.Black) Important plant for the Pitjantjatjara people.  Latz (1995) 
N. excelsior and N. gossei are the two most popular  Symon, (2005) 
Valued by Aborigines in the Musgrave Ranges area Latz (1974) 
Use recorded in WA 
Reid and Betts (1977 in 
Symons, 2005) 
N. glauca Introduced species, originates from South America, 
reputed to be chewed by Pitjantjatjara. 
Latz (1995) 
N. goodspeedii H.Wheeler Tops and roots used by Aboriginal peoples at the eastern 
end of the Nullarbor Plain and to the south 
Cleland (1957 in Symons, 
2005) 
N. gossei Domin The most important plant in Central Australia  Latz (1995) 
N. excelsior and N. gossei are the two most popular  Symon, (2005) 
N. gossei is preferred as a stronger variety  Peterson (1979) 
The most potent plant, highly prized by Aborigines  Latz (1974) 
N. megalosiphon Van Heurck 
& Mull. Arg. ssp. 
megalosiphon  
Was used by Aborigines, low on the list of preferences. Latz (1974) 
Very rarely used by the Alyawara Peterson (1979) 
Rarely used Latz (1995) 
N. occidentalis H.Wheeler 
ssp. occidentalis 
Rarely used Latz (1974), (1995) 
N. rosulata (S.Moore) Domin 
ssp. ingulba (J.Black) P. 
Horton 
subsp. ingulba: important to Pintupi for availability  Latz (1995) 
N. ingulba is ranked second to N. gossei by the Southern 
Walpiri and Alyawara people. 
Peterson (1979) 
 
N. ingulba is common in Central Australia Latz (1974) 
N. ingulba is in Central Australia and N. rosulata is more 
southern and western. 
Symon (2005) 
N. simulans N.Burb. Rarely used 
Ranked after N. gossei and N. ingulba by the Southern 
Walpiri 
Latz (1974), (1995) 
Peterson (1979) 
 
N. sauveolens Lehm. Used by humans, not clear whether Aboriginal. Lee (1925 in Symon, 2005) 
N. velutina H. Wheeler ‘Shunned by Aborigines’ Latz (1974) 
Rarely if ever used by Aboriginal people Latz (1995) 
Very rarely used by the Alyawara Peterson (1979) 
Australian species of Nicotiana are mostly annuals, or in exceptionally good seasons they may 
survive for a second year. In southern parts there are a few short-lived perennial species (Latz 
et al., 1995, Peterson, 1979). Supply of leaves varies from year to year, for example N. velutina 
may cover sand hills in one year but then not be present in a subsequent year (Symon, 2005). 
The two popular species for chewing, N. excelsior and N. gossei which grow in the Central 
Australian ranges, may have a little more reliable supply, but supply of the species N. ingulba 
from the sand plains is very dependent on irregular rains, especially after bushﬁres (Symon, 
2005). 
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1.4 Chemistry of Nicotiana spp. 
Plant defence and response to environmental stress largely depends on secondary metabolites. 
These are often useful for making natural products, medicines, cosmetics and food additives 
(Häkkinen and Oksman-Caldentey, 2004, Kidd et al., 2006). Nicotiana species (Solanaceae) 
contain a variety of secondary metabolites, the most important groups of which are  alkaloids, 
phenolic compounds, and terpenoids (Keinanen et al., 2001). Among them, alkaloids have been 
long studied for their role in plant defence mechanisms and use as medicines (Häkkinen and 
Oksman-Caldentey, 2004). 
1.4.1 Alkaloids in Nicotiana spp. 
Alkaloids are a diverse group of secondary metabolites in plants and mainly involved in 
defence against herbivores and pathogens. There are more than 12,000 different types of 
alkaloids. The majority of the alkaloids are heterocyclic compounds containing secondary or 
tertiary nitrogen derived from a relatively small group of amino acids in one of the rings (Cane 
et al., 2005, Kidd et al., 2006). 
Alkaloids in Nicotiana have been studied for many years. Production of these metabolites is 
controlled genetically and alkaloid levels can vary dramatically throughout growth in response 
to environmental conditions (Keinanen et al., 2001). Alkaloids have important roles in the life 
and reproductive strategies of their producing plants (Cane et al., 2005, Kidd et al., 2006). 
These secondary metabolites mediate many of the biological interactions between the 
Nicotiana genus with its environment, including a longstanding use by humans (Keinanen et 
al., 2001). Many alkaloids are toxic and protective against herbivores. Plant tissue damage 
induces alkaloid production as a defence against herbivore attack in Nicotiana (Baldwin and 
Schmelz, 1994). 
All species of the genus Nicotiana (L.) have the characteristic feature of producing pyridine 
alkaloids; but the number and abundance of the different alkaloids are highly variable within 
the genus (Sisson and Severson, 1990). While nicotine is considered to be the most abundant 
alkaloid (~95%) in Nicotiana species, it has been reported that there are many other pyridine 
alkaloids in various Nicotiana plants, and in the cured Nicotiana leaves, and all of them are 
structurally related to nicotine. Nornicotine, anabasine, anatabine, myosmine and isonicoteine 
are structurally related alkaloids which are found in several wild Nicotiana species and 
cultivars of commercial tobacco (Nicotiana tabacum) (Fig. 1-3) (Lisko et al., 2013). The four 
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well studied and major alkaloids in Nicotiana species are nicotine, nornicotine, anabasine, and 
anatabine (Siminszky et al., 2005). 
 
Figure 1-3 Nicotine alkaloid structures 
 
1.4.2 Biochemistry and biosynthesis of alkaloids in Nicotiana spp. 
The biosynthesis of all nicotine alkaloids (Fig. 1-4) needs pyrrolidine ring formation that is 
derived from putrescine. For biosynthesis of alkaloids, putrescine, that also serves as the 
precursor of other polyamines (Pegg and McCann, 1982), is converted to N-methylputrescine 
by the action of putrescine N-methyltransferase (PMT). In the alkaloid biosynthetic pathway, 
PMT catalyses the first committed step driving the flux of nitrogen from polyamine 
biosynthesis to alkaloid biosynthesis (Facchini, 2001, Robins et al., 1994). It is the rate-limiting 
enzyme in nicotine synthesis and its transcripts are found only in the roots (Chintapakorn and 
Hamill, 2003). 
The next step is oxidization of N-methyl putrescine to N-methylaminobutanal that is critical 
for alkaloid biosynthesis and is catalysed by methylputrescine oxidase (MPO) (De Luca and St 
Pierre, 2000, Mizusaki et al., 1971, Hakkinen et al., 2007). Then, through a spontaneous 
chemical rearrangement, N-methylaminobutanal is cyclized to form the 1-methyl-D1-
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pyrrolium cation which subsequently condenses with nicotinic acid or its derivative to form 
nicotine. Aspartate and glycerol generate quinolinate, and quinolinate 
phosphoribosyltransferase (QPRTase) catalyses nicotinic acid formation via the quinolinate 
cycle. In the biosynthesis of all the pyridine alkaloids nicotinic acid is considered as a key 
component (Ghosh, 2000, Chintapakorn and Hamill, 2003, Facchini, 2001). 
Nicotine is the precursor for the biosynthesis of some other major alkaloids in Nicotiana 
species. Demethylation of nicotine results in production of nornicotine (Hakkinen et al., 2007) 
and nornicotine can convert to myosmine (Griffith et al., 1960). Anatabine is generated through 
a dimerization reaction of a nicotinic acid metabolite (Hakkinen et al., 2007). 
The oxidation of cadaverine to Δ'–piperideine, which upon condensation with nicotinic acid 
forms anabasine is also catalyzed by MPO. Anabasine formation also competes for MPO with 
nicotine formation and hence, MPO regulates the proportion of nicotine and anabasine in the 
genus Nicotiana (Facchini, 2001, Walton et al., 1988).  
Nicotine, with the chemical name 3-(1-methyl-2-pyrrolidyl) pyridine, is the main and best 
studied alkaloid in cultivated tobacco (N. tabacum L.). It is found in all species of the genus 
Nicotiana and constitutes approximately 0.6–3.0% of leaf dry weight (Keinanen et al., 2001, 
Zhang et al., 2012). It is a colourless to pale oily yellow liquid, which is miscible with water in 
its unionised form and turns brown on exposure to light and air (Lu and Ralapati, 1998). 
Nicotine easily penetrates the skin. It is strongly chromophoric in the UV region and is directly 
detected at about 260 nm (Lu and Ralapati, 1998). Free base nicotine burns at a temperature 
below its boiling point, and its vapours combust at 308 K (35°C; 95°F) in air despite a low 
vapour pressure. Because of this, most of the nicotine is burned when a cigarette is smoked; 
however, enough is inhaled to cause pharmacological effects (Vollhardt and Schore, 2011). 
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Figure 1-4 Biosynthesis of nicotine and related alkaloids (Hakkinen et al., 2007) PMT, putrescine N-
methyltransferase; MPO, N-methylputrescine oxidase; QPRTase, quinolinate phosphoribosyltransferase; LDC, 
lysine decarboxylase; CYP82E, Cytochrome P450s belonging to the 82E subfamily. 
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1.4.2.1 Nicotine to nornicotine conversion 
In tobacco research, nicotine to nornicotine conversion has a vital importance. This is because 
it has been reported that nornicotine affects cigarette smoke quality in a negative way (Roberts, 
1988). It has also some hazardous health outcomes and serves as a precursor for carcinogenic 
nitrosamine N'-nitrosonornicotine (Siminszky et al., 2005, Bush et al., 2001). 
After nicotine, nornicotine is usually the next most abundant alkaloid in Nicotiana plants, 
comprising about 3-5% of the total alkaloid content of fresh leaves (Saitoh et al., 1985). In 
senescing leaves, a large percentage of the nicotine may be metabolized into nornicotine. The 
term “nonconverters” is used for plants that accumulate nicotine as their primary alkaloid in 
both the green and senescing leaves, while Nicotiana species that convert a large portion of 
their nicotine content to nornicotine during senescence and curing are called “converters” 
(Chakrabarti et al., 2007, Gavilano and Siminszky, 2007, Siminszky et al., 2005). 
N'-demethylation of nicotine to nornicotine has been first reported more than half a century 
ago. It is believed that this process depends on some general cellular property, such as 
oxidation-reduction potential, rather than interaction between nicotine and a specific 
dealkylating or alkyl transferring enzymes. Even feeding of different nicotine homologs and 
analogs (e.g., l-nicotine, d, l-nicotine and d, l-N'-ethylnornicotine) to the N. glutinosa leaves 
results in nornicotine production (Dawson, 1951). Nornicotine is a more toxic alkaloid than 
nicotine (Katz et al., 2005). The proven role of nornicotine in age-related macular degeneration 
(AMD) (Brogan et al., 2005, Dickerson and Janda, 2002), one of the major causes of blindness 
in the world, and its causing of periodontal diseases (Katz et al., 2005) makes it a more 
undesirable alkaloid in tobacco plants and products (Brogan et al., 2005). Therefore, efforts 
have been invested in breeding and genetic studies to understand the conversion phenomenon 
because the nicotine-accumulating tobacco is more desirable in terms of smoking quality as 
compared to the nornicotine accumulating tobacco (Mann et al., 1964). 
1.4.2.1.1 Biochemical and molecular characterization of N'-demethylation of nicotine 
Theoretically conversion of nicotine to nornicotine is possible through two different ways: 
transmethylation (though there is not much experimental support for it) or oxidative 
demethylation (Bose et al., 1956, Stepka and Dewey, 1961). Nicotine demethylation is 
associated with increased uptake of oxygen (Il'in and Serebrovskaya, 1958). The methyl group 
of nicotine is oxidised to CO2 in conversion of nicotine to nornicotine, and probably this methyl 
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group is oxidised to the level of formaldehyde, then transferred to a carrier molecule and then 
further oxidized to CO2 (Stepka and Dewey, 1961). NADPH is the preferred reducing element 
and when the concentration of NADPH is subsaturated NADH enhances demethylation 
(Donaldson and Luster, 1991). The molecular identity of the conversion factor in Nicotiana 
has been of great importance. A single dominant locus has been reported to be involved in the 
conversion process in Nicotiana (Yamanaka et al., 2005). A major breakthrough was the 
identification of a group of cytochrome P450 genes, encoding the active nicotine demethylase 
enzymes in Nicotiana (Siminszky et al., 2005). 
1.4.2.1.2 Cytochrome P450s in alkaloid biosynthesis 
Cytochrome P450 names begin with CYP (which stands for cytochrome and pigment), 
followed by a number representing the family (proteins having > 40% sequence similarity 
constitute a family), followed by a letter representing subfamily (proteins with >55% sequence 
identity remain in the same subfamily). The subfamily designation is followed by a number 
representing the individual gene within a subfamily  
In plants, biosynthesis of lots of metabolites involves P450s activity (Kim and Tsukaya, 2002). 
In the pyridine alkaloid synthesis, nornicotine is formed from nicotine by nicotine N-
demethylase involving P450 which belongs to the CYP82E subfamily monooxygenase. 
Nornicotine is accumulated to high levels in some tobacco (Nicotiana tabacum) cultivars and 
many wild Nicotiana species (Chakrabarti et al., 2008, Chelvarajan et al., 1993, Pakdeechanuan 
et al., 2012, Siminszky et al., 2005). 
This group of P450 genes (CYP82E2, CYP82E3 and CYP82E4) was found to be differentially 
regulated between converter and nonconverter Nicotiana (Siminszky et al., 2005). In human 
liver microsomes, nicotine N-demethylation is catalysed by the P450 subfamilies CYP2A and 
CYP2B (Yamanaka et al., 2005). There are at least five CYP82E-related genes in Nicotiana: 
CYP82E4, CYP82E5 and CYP82E10 encode functional nicotine N-demethylases (Siminszky 
et al., 2005, Gavilano and Siminszky, 2007, Lewis et al., 2010) whereas two others CYP82E2 
and CYP82E3 encode inactive enzymes (Chakrabarti et al., 2007, Gavilano and Siminszky, 
2007). 
Inhibition of the nicotine to nornicotine conversion happens as the result of silencing of 
CYP82E gene subfamily. Tetcyclasis, which is an inhibitor of cytochrome P450, and carbon 
monoxide inhibited nicotine demethylation (Chelvarajan et al., 1993, Donaldson and Luster, 
1991); while light of 450 nm reverses this inhibition (Donaldson and Luster, 1991). Therefore 
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these findings suggest a role of CYP82E4 in N-demethylation of nicotine to nornicotine that 
can be used to reduce nornicotine content of tobacco varieties, which is desirable for improving 
smoking quality and harm reduction of tobacco products. 
1.4.2.2 Conversion phenotype in Nicotiana species 
N. tabacum is the result of hybridization of diploid Nicotiana species closely related to modern 
N. sylvestris and N. tomentosiformis (Chakrabarti et al., 2007, Gavilano and Siminszky, 2007). 
In converter N. tabacum conversion happens only in the cured / senesced leaves, whereas N. 
tomentosiformis has both the green and senescing leaf conversion phenotype. That is because 
N. tomentosiformis has both active CYP82E3 and CYP82E4 which control conversion in green 
and senescing leaves, respectively. In contrast in N. tabacum a W330C amino acid substitution 
inactivates CYP82E3 and a CYP82E4 is also transcriptionally silenced (Gavilano et al., 2007). 
Pakdeechanuan and Shoji (2012) examined the relationship between phenotype (nornicotine 
accumulation) and genotype (CYP82E). They studied the nornicotine phenotype in N. alata 
and N. langsdorffii and the molecular mechanisms by which the nicotine N-demethylase 
genes in N. langsdorffii are inactivated. They also provided genetic evidence that nornicotine 
formation in wild Nicotiana species is governed by the expression of functional CYP82E 
genes (Pakdeechanuan et al., 2012). Using gas liquid chromatography, they quantified the 
amount of alkaloids in the roots of 10-week-old plants of N. alata and N. langsdorffii, and 
their F1 hybrid and F2 progeny, and developed a formula to calculate the conversion rate. 
They divided the nornicotine content by the sum of the nicotine and nornicotine content. 
Based on that they classified F2 plants into 3 categories: nonconverters (no nornicotine 
detected), medium converters (<50% conversion) and high converters (conversion rates more 
than 50%). Then they scored allele frequencies of CYP82E genes for each group (Table 1-4). 
Table 1-4 Allele frequencies of CYP 82E genes among F2 plants (Pakdeechanuan et al., 2012) 
Phenotype n NalaE1 NalaE2 NalaE3 NalaE4 NlanE1 NlanE2 
Non-converter 26 0 0 0 0 26 26 
Medium converter 73 71 70 69 24 60 54 
High converter 10 9 10 9 6 0 0 
Total 109 
(100%) 
80 
(73.4%) 
80 
(73.4%) 
78 
(71.6%) 
30 
(27.5%) 
86 
(78.9%) 
80 
(73.4%) 
n: Number of plants containing the indicated CYP82E alleles; NalaE: NalaCYP82E; NlanE: NlanCYP82E 
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According to their results, 26 plants were nonconverters and lacked all four of the N. alata 
CYP82E genes, but instead had both CYP82E genes of N. langsdorffii. In 73 plants which were 
medium converters, two or more N. alata CYP82E genes were always present, and 
NlanCYP82E1 and NlanCYP82E2 were also found in most plants. In 10 plants which were 
high converters two or more N. alata CYP82E genes were present, but no NlanCYP82E1 and 
NlanCYP82E2 were detected. Their genetic data indicates that in these two diploid Nicotiana 
species (N. alata and N. langsdorffii), the clustered CYP82E genes are located at the identical 
locus of the corresponding chromosome (Pakdeechanuan et al., 2012). 
They concluded that whereas the N. alata CYP82E genes act semi-dominantly and individually 
to increase conversion of nicotine to nornicotine, the N. langsdorffii CYP82E genes are both 
non-functional. Also CYP82E genes encoding nicotine N-demethylase are duplicated at 
closely linked chromosomal regions in the two diploid Nicotiana species of the Alatae section, 
and that the two CYP82E genes in N. langsdorffii are rendered non-functional by either 
transcriptional inactivation or premature translational termination, resulting in the absence of 
nornicotine in this species (Pakdeechanuan et al., 2012). 
1.4.2.3 Spatio-temporal distribution of nicotine to nornicotine conversion 
Using grafting techniques in N. tabacum and N. sylvestris, Hall et al. (1965) studied time and 
site of nicotine to nornicotine conversion. They reported nicotine to nornicotine conversion 
happens in converter scions grown on nonconverter stocks, but nonconverter scions grown on 
converter stocks do not display conversion ability, suggesting that nicotine to nornicotine 
conversion happens in the leaf (Hall et al., 1965). 
In another similar study, Wernsman et al. (1968) carried out further experiments and used lines 
that harboured converter genes from N. tabacum, N. sylvestris and N. tomentosiformis, to 
investigate the location and time of conversion. They also employed reciprocal grafting 
experiments. According to their results, the type of the scions used (i.e. whether it is converter 
or nonconverter) determines conversion ability and it doesn’t depend on the type of stock. Also, 
considerable amounts of nornicotine are detected in both green and cured leaves (Wernsman 
and Matzinger, 1968). Hence, all these experiments indicate that conversion of nicotine to 
nornicotine is restricted to the leaves. 
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1.4.3 Alkaloid levels and composition in different species 
Alkaloid levels and composition can vary greatly among the Nicotiana species (Lisko et al., 
2013). Leaf tissues of most wild Nicotiana species contain predominantly either nicotine or its 
derivative nornicotine, with anabasine being a major constituent of the alkaloid fraction in a 
limited number of species (Zhang et al., 2012). In N. glauca for example, the level of nicotine 
is low, while anabasine is high (Lisko et al., 2013). Anatabine is a minor component of the 
alkaloid fraction in most species and is not found at high levels in leaves or roots of any 
Nicotiana species that has been analysed in detail (Chintapakorn and Hamill, 2003). In a study 
that investigated the alkaloid composition of 64 different species of the genus Nicotiana grown 
in greenhouse and field, it has been shown that all tested species contained a measurable 
alkaloid fraction (at least 10 µg. g-1). Both total alkaloid level and the distribution of four major 
alkaloids nicotine, nornicotine, anabasine and anatabine indicated that these measures were 
highly correlated between greenhouse and field grown plants, although total alkaloid levels 
were significantly higher in plants grown in fields (Sisson and Severson, 1990). 
A single alkaloid seems to be prominent in each species (Saitoh et al., 1985, Sisson and 
Severson, 1990). In most of the species, nicotine or nornicotine are the predominant alkaloid 
(Sisson and Severson, 1990), and in a few species including N. noctiflora, N. petunioides, 
(Sisson and Severson, 1990), N. debneyi (syn. N. forsteri) and N. glauca (Saitoh et al., 1985, 
Sisson and Severson, 1990), anabasine has been reported to be the major alkaloid in fresh 
leaves. In addition to the major alkaloid, a secondary alkaloid constitutes the remainder of 
alkaloid composition. Nicotine as major and nornicotine as second abundant alkaloid was the 
most prevalent distribution, followed by nornicotine as the major and nicotine as the second. 
In some species the combination of nicotine and anabasine was observed (Saitoh et al., 1985, 
Sisson and Severson, 1990). 
Total alkaloid level and distribution of alkaloids varies in roots and leaves in Nicotiana species. 
The majority of species contain nicotine as the predominant alkaloid in roots (Saitoh et al., 
1985), and any conversion to nornicotine that occurs is believed to happen in leaves. Anabasine 
and anatabine are more concentrated in roots than in leaves in most of species, except for N. 
glauca, N. tabacum, N. repanda and N. hesperis, in which anabasine is the major alkaloid in 
leaves and N. alata N. corymbosa, N. hesperis in which anatabine is the major leaf alkaloid 
(Saitoh et al., 1985). 
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The composition of alkaloids in air-dried and fresh leaves is different and in some species there 
is an increased proportion of nornicotine at the expense of nicotine, which reflects their 
converter trait (Sisson and Severson, 1990). As mentioned before, all of the species of 
Nicotiana endemic to Australia are from the section Sauveolentes. A wide range of alkaloid 
levels is exhibited and alkaloid composition is also heterogeneous in this section. However, 
there may be an association with the geographic distribution and alkaloid composition and level 
(Table 1-5). It is hypothesised that different alkaloid profiles is related to the adaption of the 
species to the climate in which they grow (Sisson and Severson, 1990). 
Table 1-5 Subdivision of Australian species of Nicotiana in terms of total alkaloid, major alkaloid type and 
geographic distribution (Sisson and Severson, 1990) 
Subdivision 
(included species) 
Major alkaloid Total alkaloid 
level 
Geographic 
distribution 
Subdivision 1 
N. gossei, N. amplexicaulis, N. benthamiana, N. 
excelsior, N. ingulba 
 
Nicotine 
 
Very high 
 
Arid regions of 
central and 
north Australia 
Subdivision 2 
N. suaveolens , N. maritima, N. velutina, N. exigua, 
N. megalosiphon, N. goodspeedii, N. debneyi 
 
 
Nornicotine 
 
 
Medium 
 
South-central 
and east 
Australia 
Subdivision 3 
N. simulans , N. rosulata, N. occidentalis, N. 
hesperis, N. rotundifolia, N. umbratica, N. cavicola 
 
Variable 
Nicotine or 
Nornicotine 
 
Low 
 
Western 
Australia 
1.4.4 Alkaloid distribution and translocation in Nicotiana spp. 
According to optimal defense theory, defense metabolites are distributed within plants but are 
allocated preferentially to tissues with high probability of being attacked and high fitness value 
to the plant so that their fitness benefits are optimized (Baldwin, 1999). Indeed the spatial and 
temporal details of nicotine production in Nicotiana are consistent with optimizing defence 
allocation in plants (Baldwin, 2001b). 
Concentrations in different plant parts varies up to 10-fold, but the whole-plant amount is 
remarkably homeostatic and allometrically corrected constant pools maintained via controlling 
synthesis and biomass accumulation rather than nicotine turnover, regardless of variation in 
nitrogen supply rates, and even externally supplied nicotine. Variation in amounts of nicotine 
in different plant parts results from difference in synthesis and transport profile (Baldwin, 
2001a). 
Nicotine is synthesized exclusively in the roots and then transported to the shoots via xylem.  
This transport requires a signal from the leaves (Kidd et al., 2006). In general, the highest 
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concentration of nicotine is found in young leaves, stems, and reproductive parts, while roots 
and old leaves have the lowest. For example, high concentrations can be found in the trichomes 
of N. attenuata, which cover the calyx of flowers and developing seed capsules. In this case a 
single trichome can contain between 1.3-3.6 µg of nicotine, while in contrast to the calyx, seeds 
contain little nicotine (Baldwin, 1999). It is also likely that during elongation and flowering 
that de novo biosynthesis of nicotine in roots tends to decline; it is redistributed from its 
location in the central vacuole by symplastic transport routes that are not well known (Baldwin, 
2001a). 
1.5 Chemical composition of smokeless tobacco products 
Smokeless tobacco products such as snuff, chewing tobacco and pituri contain fewer 
carcinogens than cigarette smoke because most are formed during combustion, but the level of 
potent carcinogens are still unacceptably high (Hecht, 2003). They mainly contain nicotine and 
some of them can deliver higher doses of nicotine than cigarettes. Nicotine from smokeless 
tobacco products is absorbed through the lining of the mouth or the nose (Winstanley, 2012) 
and the absorption is slower than that from cigarettes, but the level of nicotine in users’ blood 
is similar to its level in smokers (International Agency for Research on Cancer, 2007, Scientific 
Advisory Committee on Tobacco Products Regulation, 2010). There are also significant 
quantities of PAHs (polycyclic aromatic hydrocarbons), nitrosamines, aldehydes (like 
formaldehyde, acetaldehyde and crotonaldehyde) and metals in unburned tobacco which 
contribute to its carcinogenic potential (Table 1-6). Fire-curing of Nicotiana leaves create 
polycyclic aromatic hydrocarbons (PAHs). Polycyclic aromatic hydrocarbons (PAH), N-
nitrosamines and aromatic amines are categorized as strong carcinogens and aldehydes as 
weaker carcinogens (Hecht, 2003). 
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Table 1-6 Carcinogens in smokeless tobacco products, and the types of cancer they may cause (Hoffmann et al., 
2001, International Agency for Research on Cancer, 2004, Hecht, 2003) 
Chemical class Number of 
compounds 
Representative carcinogens and typical amounts in 
processed tobacco (ng g–1) 
Types of cancer they 
cause 
PAH (polycyclic 
aromatic 
hydrocarbons) 
 
 
1 
 
 
BaP (benzo[a]pyrene) 
 
 
0.4-90 
Lung Laryngeal 
Oral cavity 
Cervical 
 
 
 
 
Nitrosamines 
 
 
 
 
6 
 
 
NNK (4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone)  
 
 
 
1,890 
Lung, Nasal, Oral 
cavity, Pancreatic, 
Cervical, Liver 
 
 
NNN (N′-nitrosonornicotine) 
 
 
8,730 
Nasal,  
Oral cavity, 
Oesophageal 
 
Aldehydes 
 
2 
Formaldehyde 1,600-7,400 Nasal, 
 
Lung Acetaldehyde 1,400-7,400 
Inorganic 
compounds 
7 Cadmium 1,300-1,600 Lung 
Total 16    
1.5.1 Tobacco specific N-nitrosamines (TSNAs) 
By far, the most prevalent strong carcinogens in unburned tobacco products like oral snuff, 
chewing tobacco and other smokeless tobacco products, are nitrosamines (Hecht, 2003). 
Tobacco specific nitrosamines (TSNAs) are responsible for increased risk of the upper 
digestive tract and known to cause oral cavity cancer, respiratory tract and pancreatic cancer 
(Brunnemann et al., 1996, Hecht, 2003). Their formation is via nitrosation of tobacco alkaloids 
(Fig. 1-5) (Brunnemann et al., 1996) which mostly happens during curing and there have been 
reports of their presence in smokeless tobacco (Hoffmann et al., 1994). Two of them, 4-
(methylnitrosamino)-1-(3-pyridyl)-1 butanone (NNK) and N′-nitrosonornicotine (NNN) are 
the most potent ones and carcinogenic to laboratory animals (Hecht, 2003). Among the list of 
cancers caused by NNN and NNK are nasal, oral cavity, oesophageal, lung, pancreatic, cervical 
and liver cancer (Hecht, 1998, Hecht, 2003). N′ nitrosoanabasine (NAB) is a weak carcinogen 
and N′-nitrosoanatabine (NAT) apparently lacks activity (Stepanov et al., 2006, Brown et al., 
2003, Hoffmann and Hecht, 1985). Each alkaloid forms one primary nitrosamine by N-
nitrosation; nornicotine is believed to be the main precursor of NNN. Nicotine forms NNN via 
demethylation to nornicotine and then N-nitrosation. 
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Figure 1-5 Tobacco alkaloids, and the nitrosamines that can be formed from them. With the exception of NNA, 
all of these compounds are present in tobacco and tobacco smoke (Hoffmann et al., 1995). 
Concentration ranges of some TSNAs in fresh/dry leaves and in different smokeless tobacco 
products from countries such as India, Canada, US, some European countries, Uzbakistan, 
Sudan, South Africa and Thailand have been compared in the monograph on smokeless tobacco 
products by the International Agency for Research on Cancer (International Agency for 
Research on Cancer, 2007). The levels of TSNA present were up to 0.39 µg/g NNN and up to 
0.42 µg/g NNK in the fresh top leaves of N. tabacum (flue-cured type) grown in the USA. In 
N. tabacum grown in India the levels were up to 0.035 µg/g NNN and 0.0115 µg/g NNK 
(Djordjevic et al., 1989a, Hoffmann et al., 1994). In smokeless tobacco they are mainly 
produced after harvest and during processes like drying, curing, ageing and especially 
fermentation. Storage in elevated temperatures for longer than four weeks results in higher 
amounts of TSNA (Brunnemann et al., 1996). Curing specifically has a huge impact on 
increasing the levels and the concentration ranges of NNN and NNK in cured leaves of 
commercial Nicotiana species (N. tabacum and N. rustica) have been reported to be increased 
by 6 fold compared to concentration in fresh green leaves (Djordjevic et al., 1989b, 
International Agency for Research on Cancer, 2007). Up to 3 mg of NNN and NNK could be 
present in each gram of a smokeless tobacco from Sudan which is called toombak (Idris et al., 
1991). The concentration range in saliva of the users has also been compared in different 
smokeless tobacco products from around the world (International Agency for Research on 
Cancer, 2007) with the highest levels reported for toombak users (Idris et al., 1992). 
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1.6 Nicotine delivery in smokeless tobacco products 
Tobacco dependence results from nicotine, which through binding to nicotinic cholinergic 
receptors, increases their expression in the nervous system and results in releasing 
neurotransmitters and hormones that have effects on mood, cognition, appetite and cause 
dependence (Albuquerque et al., 2009, Henningfield et al., 1995a). Difficulty in quitting 
tobacco and withdrawal symptoms are directly linked to the quantity of nicotine intake 
(Fagerstrom et al., 1990, Hughes and Hatsukami, 1986, Walsh et al., 1994). The rate of 
absorption has also been shown to be an important drug addictive quality (de Wit et al., 1992, 
Henningfield and Keenan, 1993). 
The addictive and toxic effects of nicotine are maximised when it is delivered with a vehicle 
like tobacco (Henningfield et al., 1995a). In smokeless tobacco products use, nicotine is 
extracted from the tobacco and passes through mouth mucosa to enter the blood and finally the 
brain to have the pharmacological effects that result in addiction. In different tobacco products, 
the pH level varies and it affects the quantity of nicotine received by the user (Hoffmann et al., 
1995, Tomar and Henningfield, 1995). The physiological and psychoactive effect of a few mg 
of nicotine delivered rapidly via smokeless tobacco products with high pH will be stronger than 
using 20 mg via nicotine transdermal patch (Henningfield et al., 1995a). 
The fact that pH is the main determinant of nicotine delivery through biological membranes 
has been shown by animal studies (Travell, 1940, Travell, 1960), using a dialysis membrane 
model (Nair et al., 1997), and studies on humans (Beckett et al., 1972, Ivey and Triggs, 1978). 
Based on studies on buccal absorption of alkaloids, no absorption of nicotine was observed at 
pH 5.5, about 10% at pH 7, and more than 30% at pH 9 (Beckett et al., 1972). A similar pattern 
has been reported for nicotine absorption from the stomach; no absorption at pH 1, increased 
absorption at pH 7.4 and even a higher absorption at pH 9.8 (Ivey and Triggs, 1978). In order 
to simulate nicotine absorption through mouth mucosa, the rate of nicotine absorption through 
a dialysis membrane has been studied, also suggesting that increasing pH results in increased 
absorption of nicotine. The difference in transferred amount of nicotine across the membrane 
between high and low pH products was maximum in the first two minutes of applying them 
(Tomar and Henningfield, 1997). The nicotine release rate from smokeless tobacco product 
into saliva has also been reported to be increased by pH of the product (Nasr et al., 1998), 
which in turn can lead to a higher absorption of nicotine. 
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Transferring nicotine through a biological membrane, depends on its concentration in free-base 
form. The pKa (dissociation constant) of nicotine is 8.02 (Haynes et al., 2012), which means 
in an aqueous solution with pH of 8.02, half of it would be in un-ionised and the other half in 
ionised form. When the pH is higher than pKa, nicotine is mainly in its un-ionised and free-
base form; hence its transport through a biological membrane is easier than as the ionised form. 
Therefore the rate of nicotine absorption and its psychoactive and addictive effects will increase 
if pH is raised (Tomar and Henningfield, 1997). Considering this, it has been mentioned in the 
literature that knowing the total amount of nicotine in a smokeless tobacco product without 
knowing its pH is of no value for estimating nicotine absorption rate or quantity (Djordjevic et 
al., 1995, Henningfield et al., 1995b, Connolly, 1995). 
The pH of the oral environment controls nicotine absorption (Henningfield et al., 1990), 
especially in smokeless tobacco products which are left in the mouth for long periods. Naturally 
the tobacco leaf by itself is acidic, but when placed in the mouth due to the buffering action of 
the bicarbonate in saliva, even in the neutral pH of the oral environment a proportion of the 
nicotine will be un-ionised, however this process is very slow. Therefore, buffering tobacco 
products to alkaline levels speeds up this process and improves the rate of release (Tomar and 
Henningfield, 1997). 
Depending on conditions of storage, i.e. temperature, humidity and duration, the pH level of 
smokeless tobacco products may increase (Andersen et al., 1993, Djordjevic et al., 1993). 
Manufacturers can also alter the pH through addition of alkalisers such as sodium carbonate, 
sodium bicarbonate, ammonium carbonate, and calcium carbonate in order to control the dose 
of nicotine (Connolly, 1995). 
1.6.1 Nicotine release from smokeless tobacco products 
The extent of nicotine release from any given smokeless tobacco product and its absorption is 
important in determining its psychoactive and addictive quality (Hatsukami and Severson, 
1999). The commercially available smokeless tobacco products undergo different processes 
such as fermentation and moisture level adjustment and all these processes help in their pH 
adjustments. Sometimes buffering agents are also added to help pH adjustment. The particle 
size of the tobacco fragments and the added chemicals for coating or binding the fragments 
together are very important in determining the nicotine release rate from them. Binding agents 
are added in products such as long cut smokeless tobacco products that have larger fragments 
of tobacco leaves to help packing the products tighter and as a result they tend to show slower 
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nicotine release rates than products with finer tobacco fragments (Connolly, 1995). The in vitro 
release rate has also been shown to be higher in the products with higher pH (Nasr et al., 1998). 
Some products such as snus, come in tea bag like sachets that could be rate limiting for nicotine 
release since they need to be moistened and let the saliva to diffuse inside and release the 
nicotine into the oral environment for absorption through the mucosa (Connolly, 1995). The 
sachets have been shown to control the nicotine release rate in Skoal Bandit Classic, which is 
a commercially manufactured American moist snuff (Nasr et al., 1998). 
1.7 Toxicity of smokeless tobacco products 
Users of smokeless tobacco products are exposed to a spectrum of chemicals with some having 
carcinogenic potential, although it is less than what is reported for smoked tobacco. Recently, 
measures have been put in place by the Food and Drug Administration (FDA) to make sure 
that the manufactured smokeless tobacco products have reduced health risks. Consequently, 
emerging potential reduced exposure products (PREP) need to be evaluated in terms of their 
impact on health. Epidemiologic and clinical trials would be the best approach for risk 
evaluation of these products, however, laboratory models such as in vitro cell assays could also 
be used for the evaluation of their relative toxicity (Johnson et al., 2009). These assays are 
inexpensive and fast, which allows faster screening of toxic levels and helps extrapolation to 
humans. Viability of the cells exposed to the studied matrix is evaluated using these in vitro 
cytotoxicity assays and, since cytotoxicity is an important step in disease development 
mechanisms, it could be used as an indicator for the potential of any given product to cause 
harm. These assays can also help in defining the concentration range and more importantly the 
dose resulting in 50% of cell death (IC50) that is essential in comparing the effects of identical 
compounds delivered in different matrixes or of multiple compounds in one system. Also, the 
basal cytotoxicity tests are the stepping stone for other in vitro assays that determine the 
genotoxicity, mutagenicity and induction of programmed cell death caused by these products 
(Eisenbrand et al., 2002). Different biological endpoints are monitored for determining the 
cytotoxicity. These include the assays that measure plasma membrane permeability, 
mitochondrial function, cell morphology and reproduction changes or a combination of these 
effects (Borenfreund and Puerner, 1985, Eisenbrand et al., 2002, Johnson et al., 2009). 
There are numerous reports on in vitro cytotoxic effects of commercially available smokeless 
tobacco products such as Swedish snus (Coggins et al., 2012, Costea et al., 2010), American 
moist snuff (Misra et al., 2014), commercial chewing tobacco (Coppe et al., 2008) and 
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Kentucky reference smokeless tobacco product (Lombard et al., 2010). There have been reports 
of cytotoxicity caused by Indian manufactured smokeless tobacco such as gutka (Avti et al., 
2010) and khaini (Das et al., 2013). Limited data is available on the toxicity of homemade 
traditional or indigenous smokeless tobacco products used around the world. Generally, the 
manufactured products are monitored to contain less TSNAs. It’s not the case with traditional 
and custom-made products; an example is the Sudanese smokeless tobacco product toombak 
that has been shown to contain at least 100 times higher levels of tobacco specific N-
nitrosamines than the commercially available Swedish and American snuff (Idris et al., 1998). 
Toombak is the only indigenous smokeless tobacco that has been studied for its cytotoxicity 
and the results indicated its higher toxic potential compared to commercially available Swedish 
snuff (Costea et al., 2010). There is very little information available on the extent of toxicity 
caused by indigenous or local smokeless tobacco products similar to pituri. 
1.8 Rationale 
As reviewed in the literature so far, research on the chemistry of tobacco plants and products 
helps us gaining a better understanding of the diversity and levels of psychoactive chemicals 
in them as well as the risks attributed to their consumption. While some scientists suggest 
substitution of smoking with smokeless tobacco as a harm reduction measure, there is little 
support for such claims based on the available evidence. Smokeless tobacco products have 
been reviewed extensively for their ingredients, their chemistry including carcinogenic 
components and the potential toxicity in the International Agency for Research on Cancer’s 
monograph. Other than commercially available smokeless tobacco products, this monograph 
reports on the use of indigenous smokeless tobacco products among some native populations 
around the world. However, pituri, a smokeless tobacco product used by some Aboriginal 
Australians in Central Australia that is prepared from Australian native Nicotiana spp. was not 
included in the monograph and no data on chewing tobacco use is collected by the Australian 
Bureau of Statistics and so official acknowledgement of the existence of pituri is lacking. 
The research proposed here will help to increase knowledge about the chemistry of Australian 
Nicotiana spp., as the tobacco component used in pituri preparation, which will provide some 
insight in terms of potential for harm to users. 
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1.9 Aims and hypotheses to be tested  
The overall aim of this thesis is to investigate the Nicotiana component of pituri in terms of 
pyridine alkaloids and tobacco-specific nitrosamines, their production, release and toxicity. 
Therefore, firstly, this study will establish validated methodologies for routine quantitative 
analysis of important chemicals such as alkaloids and nitrosamines in tobacco plants and 
products. Secondly, it will report on the alkaloid composition of Australian Nicotiana spp. and 
search for the presence of an underlying molecular mechanism in nicotine to nornicotine 
conversion that leads to production of nornicotine. Thirdly, this study will explore the release 
of nicotine and other alkaloids and nitrosamines from the tobacco constituent of pituri and 
compare these with other commercially available products. Finally, the potential toxicity of the 
tobacco constituent of pituri and a reference moist snuff will be compared to that of pure 
nicotine in an in vitro setting. Outcomes of the research described in this dissertation will report 
alkaloid chemistry of Australian Nicotiana species, provide insight into nornicotine production 
and warn about the potential toxicity of the released chemicals to users. 
To help in producing more knowledge and relieve the ambiguity surrounding pituri, which is 
amongst the least studied and acknowledged traditional smokeless tobacco products, this study 
aimed to: 
1. Establish efficient quantification methods for determination of the alkaloids and tobacco 
specific nitrosamines in Nicotiana spp used in pituri. Based on methods described in the 
literature, HPLC-UV and LC-MS/MS techniques are hypothesised to be suitable for 
quantitative analysis of pyridine alkaloids and TSNAs, respectively. Methods will be 
developed and validated to test their efficiency. 
2.  Quantify the alkaloids present in all 26 of the currently recognised Australian Nicotiana 
species. Based on alkaloid measurements published 25-30 years ago (Saitoh et al., 1985, Sisson 
and Severson, 1990) that included 19 of the Australian species, it is hypothesised that 
Australian Nicotiana species vary in terms of abundant alkaloids and are categorised into 
nicotine dominant versus nornicotine dominant species. This will be addressed by germinating 
seeds and growing plants in a single common environment, quantifying the alkaloids present 
in their leaves, and assessing the relative levels of nicotine and nornicotine in order to identify 
those species that are low and high converters. 
Nornicotine production in Nicotiana tabacum is mainly through N-demethylation of nicotine 
and is regulated by a group of cytochrome P450 related subfamily of genes which are triggered 
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by curing and senescence (Chakrabarti et al., 2007, Gavilano and Siminszky, 2007, Siminszky 
et al., 2005). The conversion locus, mainly CYP82E4, has been found to be present in all 
Nicotiana investigated, but its transcription is strongly upregulated by curing and during leaf 
senescence only in high converters (Chakrabarti et al., 2008). Therefore, it was hypothesised 
that the nicotine to nornicotine conversion locus is present in all Australian Nicotiana species 
and is triggered by curing only in high converter species. This will be addressed by assessing 
whether the locus is present in all species, and then further investigating its regulation 
associated with curing for a small number of low and high converter species. 
3. Smokeless tobacco use can be associated with fast release of high levels of nicotine, but 
there is currently no knowledge of nicotine release from pituri. Pituri is sucked rather than 
chewed so it is hypothesised that the release of nicotine from the tobacco constituent of pituri 
is more similar to that of commercial smokeless tobacco products such as Swedish snus than 
from nicotine gum. Additionally, pituri is prepared by mixing alkaline wood ash with Nicotiana 
leaves so it is hypothesised that release is faster at higher pH induced by adding the ash. These 
hypotheses will be addressed by studying nicotine release with and without chewing, and under 
both normal and alkaline pH condition, for comparison with nicotine release from Swedish 
snus and a nicotine replacement therapy product, Nicabate gum. 
4. The major reason for the use of tobacco products is the psychoactive alkaloid nicotine. 
However, based on analyses of other indigenous smokeless tobacco products, pituri users are 
likely to be exposed to a range of other potentially toxic chemicals. Therefore, the aim of this 
section is to investigate the toxicity of the Nicotiana constituents of pituri, with the hypothesis 
that the Nicotiana constituents are associated with higher cytotoxicity than nicotine alone. This 
will be addressed by testing in vitro cytotoxicity of an extract from Nicotiana leaves used in 
pituri on human lung epithelial cells, and comparison to a similar reference product and to 
cytotoxicity caused by only nicotine. 
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 HPLC-UV and LC-MS/MS method 
development and validation for 
quantification of six alkaloids and two 
nitrosamines in tobacco plants and 
products 
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2.1 Introduction 
Nicotiana species (Solanaceae), known as tobacco plants, are the most widely used drug plants 
in the world (Chase et al., 2003, Knapp et al., 2004). Tobacco products are responsible for 
nearly 6 million deaths around the world each year, and it is expected to reach to 8 million by 
2030 (World Health Organization, 2011). All members of the Nicotiana genus produce 
nicotine, which accounts for the widespread human use of tobacco plants and products. They 
also produce many other pharmacologically active pyridine alkaloids, however, these are less 
potent than nicotine (Clark et al., 1965, Keinanen et al., 2001). Structurally related minor 
alkaloids present in several wild Nicotiana species and cultivars of commercial tobacco 
(Nicotiana tabacum) are nornicotine, anabasine, anatabine and myosmine (Huang and Hsieh, 
2007, Lisko et al., 2013 ) (Fig. 2-1 A). Cotinine has been reported to be present at low levels 
(Luanratana and Griffin, 1982) although it is primarily recognised as the major metabolite of 
nicotine in the human body (Benowitz et al., 2009). The number and abundance of the different 
alkaloids are highly variable within the genus (Sisson and Severson, 1990). 
Apart from alkaloids, tobacco specific nitrosamines (TSNAs) are also present in tobacco plants 
and products (Fig. 2-1 B). They are produced through nitrosation of tobacco alkaloids during 
curing and post-harvest processing of tobacco leaves and some of them are strong carcinogens. 
Among the reported TSNAs, N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) are produced from nicotine and nornicotine and have been 
classified as potent carcinogenic compounds to humans. Corresponding TSNA compounds 
derived from anatabine and anabasine are N'- nitrosoanatabine (NAT), which hasn’t reported 
to have carcinogenic activity, and N-nitrosoanabasine (NAB) that is considered to be a weak 
carcinogen (International Agency for Research on Cancer, 2007, Hecht et al., 1983). 
The concomitant presence of multiple alkaloids, which are responsible for the formation of 
carcinogenic TSNAs, drives the need for their quantitation in tobacco plants and products 
(Lisko et al., 2013). It is also of high importance in the tobacco industry for quality control 
purposes (Lu and Ralapati, 1998) and is necessary for the understanding of plant secondary 
and defence metabolism (Gaquerel et al., 2009). 
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A      
  
 
 
 
 
Cotinine Nornicotine  Anatabine  Myosmine Anabasine  Nicotine 
MW=176.22 MW=148.20 MW=160.22 MW=146.19 MW=162.23 MW=162.23 
pKa=4.88 pKa=9.83 pKa=8.76 pKa=6.66 pKa=9.86 pKa=8.02 
      
B      
 
 
N'-nitrosonornicotine 
(NNN) 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) 
MW=177.20314 
pKa=5.25 
MW=207.22912   
pKa=3.79   
Figure 2-1 Structure, molecular weight (MW, g/mol) and pKa values of A) the common tobacco alkaloids 
shown in order of HPLC elution and B) the two major carcinogenic TSNAs, NNN and NNK 
Many reports have focused on the quantitative analysis of nicotine and other minor alkaloids 
in tobacco plants by employing gas chromatography (GC) with a variety of detection methods 
such as flame ionization detection (FID ) (Sheng et al., 2005), nitrogen-phosphorus detection 
(NPD) (Sisson and Severson, 1990, Yang et al., 2002), nitrogen chemiluminescence detection 
(NCD) (Cai et al., 2012b) and mass spectrometry (MS) (Hossain and Salehuddin, 2013 ). Less 
frequently used in tobacco alkaloid analysis are techniques such as micellar electrokinetic 
capillary chromatography with UV detection (MEEC-UV) (Lu and Ralapati, 1998), 
microemulsion electrokinetic chromatography with UV detection (MEEKC-UV) (Huang and 
Hsieh, 2007) and capillary electrophoresis (CE) with UV (Lochmann et al., 2001) or 
electrochemical (ED) detection (Matysik, 1999). High performance liquid chromatographic 
(HPLC) methods for alkaloid determination in tobacco plants mainly involve the use of UV 
detection (Keinanen et al., 2001, Tambwekar et al., 2003, Ciolino et al., 1999a, Sudan et al., 
1984, Švob Troje et al., 1997, Manceau et al., 1992, Saunders and Blume, 1981), and HPLC-
MS has been employed for the determination of only nicotine from tobacco (Vlase et al., 2005). 
HPLC-UV is generally accepted to be a cost effective and convenient method for separation 
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and accurate quantification of chemicals with a chromophore, as is present in alkaloids, but so 
far the methods in the literature are restricted to the quantification of nicotine, as the main 
alkaloid (Tambwekar et al., 2003, Ciolino et al., 1999b), or only two (Sudan et al., 1984, Švob 
Troje et al., 1997) three (Manceau et al., 1992) or maximum of four (Saunders and Blume, 
1981) major alkaloids in tobacco plants and products. 
Similar to alkaloids, there have also been numerous reports of the conventional methods for 
quantification of TSNAs mainly in cigarette smoke and some other tobacco products. Until 
recently the majority of these reports used GC coupled with thermal energy analyser (TEA) 
(Carmella et al., 2000, Stepanov et al., 2002) or mass spectrometry (MS) (Song and Ashley, 
1999, Zhou et al., 2007, Sleiman et al., 2009), or HPLC with various detectors such as UV 
(Hecht et al., 1975), or TEA (Hoffmann et al., 1979). It is now more common to see LC-MS/MS 
being used extensively for quantitative analysis of TSNAs (Kim and Shin, 2013, Wagner et al., 
2005, Wu et al., 2008, Ding et al., 2008, Xiong et al., 2010, Jansson et al., 2003) due to its high 
sensitivity. 
In order to study the alkaloids of wide range of wild Nicotiana species and tobacco products, 
this study aimed to develop and validate two methods. Firstly, a new fast, convenient and 
efficient HPLC-UV method for the simultaneous separation and quantification of six common 
tobacco alkaloids was developed. This method used a reverse-phased column with bidentate 
C18-C18 bonding technology and basic pH mobile phase, and achieved high sensitivity, 
reproducibility, precision and linear response with elution over 13 minutes. Secondly, an LC-
MS/MS method was performed, adapted from methods in the literature (Kim and Shin, 2013), 
to quantify the two main carcinogenic TSNAs, NNN and NNK in some smokeless tobacco 
products. This analysis took less than 2 minutes using a HILIC column with a triple quadrupole 
tandem MS and was validated for linearity, detection limits, accuracy, recovery and 
repeatability. 
2.2 Experimental 
2.2.1 Chemicals 
Acetonitrile and methanol of HPLC grade and hydrochloric acid (HCl) were from Merck 
(Darmstadt, Germany), triethylamine (TEA; pro-analysis) was from Ajax Finechem (Sydney, 
Australia) and ammonium formate (for HPLC, ≥99.0%) was from Sigma-Aldrich (St. Louis, 
MO). The water was from a Milli-Q system (Millipore, Billerica, MA). The analytical 
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standards used for HPLC were nornicotine, myosmine and cotinine from Sigma, nicotine from 
Fluka (Milwaukee, WI), anabasine from Sigma-Aldrich, anatabine from Cayman Chemical 
Company (AnnArbor, MI), and the internal standard used was caffeine from Ajax Finechem 
(Sydney, Australia). The standards used in LC-MS/MS analysis were N’-nitrosonornicotine 
(NNN) and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) from sigma and their 
corresponding internal standards were N’- nitrosonornicotine-d4 (NNN-d4) and 4-
(methylnitrosoamino)-1-(3-pyridyl-d4)-1-butanone (NNK-d4) from Toronto Research 
Chemicals (Ontario, Canada). 
2.2.2 Instrumentation and chromatographic conditions 
2.2.2.1 HPLC-UV 
An Agilent Technologies 1200 series HPLC system (Agilent Technologies, Boeblingen, 
Germany) with a binary pump, degasser, an auto sampler, a thermostat column compartment, 
and a diode array detector was used. ChemStation for LC 3D software version B.04.02 (Agilent 
Technologies, Wilmington, DE) was used for data acquisition and handling. Chromatography 
was performed on a reversed-phase Zorbax Extend C-18 column (Agilent Technologies) of 
150 × 3 mm i.d. dimensions and 3.5 µm particle size. The mobile phase consisted of 15 mM 
ammonium formate in water, pH adjusted to 10.5 with TEA (solvent A) and acetonitrile 
(solvent B). Gradient elution used was: 0-5 min from 9 to 10% solvent B; 5-13 min from 10 to 
13% solvent B; the flow rate was 0.8 mL/min. The column temperature was set at 25ºC and the 
injection volume was 40 µL. Detection was performed at 260 nm. 
2.2.2.2 LC-MS/MS  
The LC-MS/MS analysis was conducted on a 2.1 × 150 mm Poroshell 120 HILIC column with 
2.7 µm particle size (Agilent Technologies). The MS-MS detection was performed in positive 
ion mode on an Agilent 6460 Triple Quadrupole tandem mass spectrometer with a Jet Stream 
source and the workstation operated with MassHunter software (Agilent Technologies). 
Multiple reaction monitoring (MRM) mode was used for detection. Mass spectrometry 
parameters such as the m/z of precursor and product ions, fragment voltage and collision energy 
were as shown in Table 2-1. The nozzle and capillary voltages were 2000 and 5000 V, 
respectively. The mobile phase was composed of 10 mM ammonium formate in methanol 
(70%) and 10 mM ammonium formate in water (30%) with a flow rate of 0.35 mL/min. The 
total run time was 3 min and the injection volume was 1 µL. 
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Table 2-1 Mass spectrometry parameters used in MRM mode for two TSNAs 
Compound Precursor ion (m/z) Product ion (m/z) Fragmentor (V) Collision energy (V) 
NNN 178.1 148.1 60 11 
NNN-d4 182.1 152.1 60 11 
NNK 208.1 122.1 60 11 
NNK-d4 212.1 126.1 60 11 
2.2.3 Sample preparation 
2.2.3.1 HPLC-UV 
For alkaloid extraction, samples of fresh/dried tobacco leaves or smokeless tobacco products 
were freeze dried at -80ºC, and 50 mg were ground to a fine powder. These then were extracted 
by shaking vigorously for 2 h with 1 mL of extraction solution (40% aqueous methanol 
containing 0.1% 1 N hydrochloric acid). After centrifugation the supernatant was removed and 
the remaining pellet subjected to two further extractions with 0.5 mL of extraction solution 
each time and the supernatants combined; no alkaloids were detected in any further extracts 
from the pellet. The extracts then were evaporated to dryness with a vacuum speed evaporative 
concentrator (Savant Speed Vac SC-110 with cooling unit RVT-100, Savant instruments, 
Holbrook, NY) and reconstituted in 10% aqueous acetonitrile. All standards and extracts were 
filtered through a 0.45 µm nylon filter (Grace Davison Discovery Sciences). 
2.2.3.2 LC-MS/MS 
Aqueous extract of smokeless tobacco products (100 µl) were prepared for analysis of NNN 
and NNK by adding 50 ng/ml of both internal standards (NNN-d4 and NNK-d4), evaporating 
to dryness and reconstituting in the mobile phase (10 mM ammonium formate in methanol and 
10 mM ammonium formate in water) before analysis. 
2.2.4 Method validation 
2.2.4.1 HPLC-UV 
To validate the method, system suitability and sensitivity, linearity, precision and 
reproducibility were assessed. System suitability was evaluated by taking data from six 
replicate analyses of a mixture of alkaloid standards at a concentration of 5 µg/mL for all 
alkaloids and IS. Parameters used for monitoring system suitability were tailing factor (Tf), 
plate number (N), peak area (Pa), resolution (Rs) and capacity factor (K′), all calculated using 
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the United States Pharmacopeia (USP) equations (United States Pharmacopoeial Convention, 
2011). System sensitivity was assessed using limits of detection (LOD) and quantification 
(LOQ) (Shabir, 2003, United States Pharmacopoeial Convention, 2011). The linearity of the 
method was assessed by linear regression analysis. Eight concentrations of each alkaloid 
standard, over an expected concentration range of each alkaloid in tobacco plants, were used 
to construct the calibration curves. A fixed concentration of IS was added to all of the 
concentrations and the peak area ratio of each alkaloid to that of IS was used to build the 
calibration plots. To assess the precision of the method, repeatability within intra and inter-day 
runs was checked by calculating the relative standard deviation (RSD) for the retention time 
and peak area ratio of six replicate injections. This was performed for each alkaloid standard 
in a mixture of alkaloids and IS all at a concentration of 5 µg/mL. Method reproducibility was 
evaluated by performing the analytical method on two other HPLC systems within the lab: 
Instrument 2 was an Agilent technologies 1100 series HPLC system with a capillary pump, 
degasser, auto sampler and diode array detector operated with ChemStation for LC 3D software 
version B.04.02, and Instrument 3 was a Shimadzu HPLC system with a dual piston pump, 
degasser, auto sampler, and diode array detector connected by the controller module and 
operated with LabSolutions software (Shimadzu Corporation, Koyoto, Japan). The RSD of six 
replicate injections of the same mixture of alkaloids (5 µg/mL for all alkaloids and IS) for both 
retention time and peak area ratio to IS was calculated for each alkaloid standard. 
2.2.4.2 LC-MS/MS 
For validation of the LC-MS/MS method, sensitivity, linearity, precision and accuracy were 
assessed. Sensitivity was assessed by determining the limit of detection (LOD) and limit of 
quantitation (LOQ). For linearity, regression statistics were calculated from peak area ratios 
for NNN and NNK to their corresponding internal standard (NNN-d4 and NNK-d4) for at least 
eight concentrations in an expected range. Precision of the method was estimated by intra-day 
repeatability in analysing 10 individual aliquots of samples, performed for a mixture of NNN 
and NNK and their corresponding internal standards at a concentration of 10 ng/mL. Accuracy 
was evaluated for recovery of added amounts in six samples at concentrations of 10 ng/ mL for 
NNN and NNK. 
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2.3 Results and discussion 
2.3.1 Method development 
2.3.1.1 HPLC-UV 
HPLC-UV can be difficult due to lack of resolution between the multiple compounds. 
Obtaining acceptable peak parameters for the analytes is essential in quantitative studies. In 
chromatographic analysis, the addition of salts and ion-pairing agents to the mobile phase can 
improve resolution and peak parameters (Mallet et al., 2004). It is also important to consider 
the ionization constants (pKa) for each of the ionisable groups on the analytes when separating 
them by HPLC because the mobile phase pH can play a pivotal role in retention, peak shape, 
resolution, and reproducibility (Claessens, 2001, Kele and Guiochon, 1999, Neue et al., 1999, 
Heyrman, 1999). Most of the common tobacco alkaloids contain a tertiary amine group with a 
pKa value of more than 8 (Fig. 2-1A), so at acidic and neutral pH they are mainly in a ionised 
form with associated shorter retention under reversed-phase HPLC conditions; this can make 
it difficult to quantify them simultaneously using HPLC-UV due to lack of peak separation. 
Increasing the pH ensures the alkaloids are unionised, increasing retention times (Heyrman, 
1999, Chen and Xu, 2011). 
All six alkaloids were fully retained and eluted within less than 13 min with a flow rate of 0.8 
mL/min and pH 10.5 (Fig. 2-2 A); previously it took 24 min to elute and separate just four 
alkaloids using HPLC-UV (Saunders and Blume, 1981). The short run time consumes less 
mobile phase and will prove cost effective for large sample population analysis. The developed 
method was successfully applied to the quantification of alkaloids from fresh leaves of 
Nicotiana benthamiana. No interference with the matrix was observed (Fig. 2-2 B). The 
quantitation shows that the fresh leaves of Nicotiana benthamiana contained 0.2, 0.3, 0.3, and 
2.6 mg/g DW of anatabine, nornicotine, anabasine and nicotine, respectively. 
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Figure 2-2 Chromatograms depicting separation of alkaloids on a 150 × 3 mm, 3.5 µm particle size Zorbax Extend 
C-18 column and detection at 260 nm. The mobile phase (flow rate 0.8 mL/min) consisted of a gradient of 
acetonitrile and 15 mM ammonium formate in water (pH adjusted to 10.5 with triethylamine); the gradient elution 
was 9 to 10% acetonitrile from 0-5 min and then 10 to 13% acetonitrile from 5 to 13 min. (A) Standard solution 
of alkaloids and IS, (B) Extraction from Nicotiana benthamiana fresh leaves. 1. Cotinine; 2. Caffeine (IS); 3. 
Nornicotine; 4. Anatabine; 5. Myosmine; 6. Anabasine; 7. Nicotine. 
2.3.1.2 LC-MS/MS 
A variety of mobile phases were tested for LC-MS/MS analysis of the NNN and NNK (data 
not shown) following the different combinations reported in the literature (Kim and Shin, 
2013). The conditions selected for use, due to excellent sensitivity achieved, were 10 mM 
ammonium formate in methanol and 10 mM ammonium formate in water with a ratio of 70% 
to 30%. This was programmed to be an isocratic 2 minutes long run with flow rate of 0.35 
mL/min. 
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2.3.2 Method validation 
2.3.2.1 HPLC-UV 
The system suitability test is used to verify that resolution and reproducibility are adequate 
(Shabir, 2003). The RSD of peak area and retention time for all alkaloid standards and IS were 
within 2% (Table 2-1), which indicates the suitability of the system. Also the capacity factor 
value (K′), the efficiency of the column as expressed by plate number (N), USP tailing factor 
(Tf) and the baseline separation expressed as resolution (Rs) were all within the acceptable 
range (K′>2.0, N>2000, 0.5≤Tf≤2 and Rs>2) (Shabir, 2003, United States Pharmacopoeial 
Convention, 2011) for all of the six alkaloids and IS, for the six replicate injections (Table 2-
2). 
Table 2-2 System suitability data obtained for validation of the developed method with mobile phase pH 10.5. 
The values are the average or relative standard deviation (RSD) of six consecutive injections of a mixture of 
alkaloids and IS (caffeine) all at a concentration of 5 µg/mL using the developed method. 
 Tobacco alkaloids 
Parameter Cotinine Caffeine Nornicotine Anatabine Myosmine Anabasine Nicotine 
Rt  2.5 3.1 5.4 6.9 7.5 10.8 12.6 
Pa  175.2 391.6 146.4 181.7 345.1 158.7 172.0 
K´ 2.4 3.2 6.5 8.5 9.2 13.7 16.2 
Tf 0.7 0.7 0.5 0.6 0.6 0.6 0.6 
N 11113 14393 5207 15847 16524 22918 43020 
Rs  5.8 11.7 5.8 2.3 12.8 6.8 
RSD (Rt) 0.1 0.2 0.1 0.1 0.1 0.0 0.0 
RSD (Pa) 0.1 0.3 0.3 0.2 0.3 0.7 0.3 
Rt=retention time; Pa=Peak area; K´=capacity factor; Tf=tailing factor; N=plate number; Rs=resolution  
The sensitivity of the method was expressed as limit of detection (LOD) and limit of 
quantification (LOQ) (Table 2-3), using the residual standard deviation of the regression line 
(σ) and slope (S) of the calibration curve for each alkaloid standard with LOD being 3.3 σ/S 
and LOQ 10 σ/S (Shabir, 2003). The method proved to be sensitive for the detection of less 
than 1 µg/mL of all except for nicotine, which had a detection limit of 1.6 µg/mL. The method 
was also capable of quantifying as low as 2 µg/mL of cotinine, anatabine, anabasine and 
myosmine; 3 µg/ml of nornicotine and 5 µg/ml of nicotine in unknown tobacco samples (Table 
2-3). 
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Table 2-3 Regression statistics, limit of detection (LOD) and limit of quantification (LOQ) for alkaloid standards. 
 Tobacco alkaloids 
Parameter Cotinine Nornicotine Anatabine Myosmine Anabasine Nicotine 
Conc. Range, µg/mL 2 to 20 2 to 50 2 to 20 2 to 20 2 to 20 5 to 250 
Regression equation 
y =0.01x-
0.0030 
y =0.010 -
0.012 
y =0.009x 
+0.003 
y =0.019x -
0.002 
y =0.009x 
+0.003 
y =0.010x -
0.012 
R2 0.9991 0.9997 0.9993 0.9997 0.9999 1.0000 
LOD, µg/mL 0.6 0.9 0.6 0.4 0.2 1.6 
LOQ, µg/mL 1.8 2.8 1.7 1.2 0.8 4.8 
       
R2=correlation coefficient; LOD=lower limit of detection; LOQ=lower limit of quantification 
The regression statistics were calculated from the calibration curves constructed for all of the 
studied alkaloids (Table 2-4) and showed satisfactory linearity with the correlation coefficient 
(r2) greater than 0.999 for all. For both intra and inter-day analysis of multiple injections, the 
variation of the RSD for peak area ratio of alkaloids to internal standard and retention time 
(Table 2-4) were within the acceptable range of 2% (Shabir, 2003). 
Table 2-4 Method accuracy results obtained by calculating the relative standard deviation (RSD) value for the 
retention time (Rt) and average peak area ratio (Pa) of alkaloids to internal standard from six replicate injections 
within intra and inter-day runs in a mixture of alkaloids and IS (caffeine) all at a concentration of 5 µg/mL. 
 Tobacco alkaloids 
Parameter Cotinine Caffeine Nornicotine Anatabine Myosmine Anabasine Nicotine 
Precision (RSD)         
Pa        
Day 1 0.107 0.118 0.316 0.002 0.227 0.273 0.211 
Day 2 0.039 0.023 0.504 0.002 0.309 0.119 0.024 
Day 3 0.029 0.045 0.666 0.000 0.113 0.222 0.058 
Rt        
Day1 0.128 0.171 0.073 0.048 0.041 0.017 0.029 
Day2 0.700 0.338 0.193 0.178 0.178 0.014 0.019 
Day 3 0.024 0.070 0.105 0.153 0.153 0.058 0.075 
The obtained values for the RSD (n=6) of the peak area ratio to IS for each alkaloid standard 
and RSD of their retention time in two other HPLC systems in the lab (Table 2-5) were within 
the acceptable criteria of less than 2% (Shabir, 2003) confirming that the method is 
reproducible. 
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Table 2-5 Within-laboratory reproducibility results. Relative standard deviation (RSD) for the retention time 
(Rt) and peak area ratio (Pa) of six replicate injections of a mixture of alkaloids and IS at a concentration of 5 
µg/mL for each, obtained from performing the developed method on two different HPLC systems within the lab. 
 Tobacco alkaloids 
Parameter Cotinine Nornicotine Anatabine Myosmine Anabasine Nicotine 
Reproducibility (RSD)       
Instrument 2 (n=6)       
Pa ratio (n=6) 0.4 0.9 0.9 1.9 0.6 0.5 
Rt (n=6) 0.5 0.6 0.6 0.7 0.6 0.7 
Instrument 3 (n=6)       
Pa ratio (n=6) 0.2 1.0 1.6 0.9 1.1 0.5 
Rt (n=6) 1.6 0.9 0.7 0.6 0.4 0.4 
2.3.2.2 LC-MS/MS 
The LOD and LOQ were calculated as 3.14 and 10 times the standard deviation of peak area 
ratio to internal standard obtained by 6 replicate injections of samples spiked at a concentration 
of 10 ng/ml for each compound, and these were satisfactory for both NNN and NNK. 
Regression statistics calculated from peak area ratio for concentrations (0.1, 0.2, 1, 2, 4, 5, 10, 
20, 100, 500 and 1000 ng/ml) in the range 0.1-1000 ng/ml for NNN and NNK proved sufficient 
linearity with correlation coefficients greater than 0.995 for both compounds (Table 2-6). The 
method was demonstrated to be repeatable with percentage standard deviations of less than 
15% (FOOD AND DRUG ADMINISTRATION, 2007) for both compounds in the studied 
concentration range. Accuracy of the method, expressed as the recovery of the actual amount 
added from six samples with concentration of 10 ng/ml was within the range of 91-109% (Table 
2-6). 
Table 2-6 The LC-MS/MS validation parameters for the two major TSNAs, NNN and NNK. 
 Tobacco Specific Nitrosamines (TSNAs) 
Parameters NNN NNK 
Concentration range (ng/ml) 0.1 to 1000 0.1 to 1000 
Regression equation y = 0.0265x – 0.0386 y = 0.0245x – 0.0299 
Correlation coefficient (R2) 0.9996 0.9989 
Detection limit (ng/ml) 0.83 1.4 
Quantitation limit (ng/ml) 2.6 4.3 
Accuracy (n=6) 91.5 ± 10.4 108.7 ± 2.7 
Repeatability RSD (n=10) 11.30% 2.40% 
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2.4 Conclusion 
The new reversed-phase HPLC-UV method developed and validated herein is simple, does not 
require expensive instrumentation and can therefore be easily applied for simultaneous 
determination and quantification of nicotine, nornicotine, anabasine, anatabine, myosmine and 
cotinine from tobacco plants and products. This approach offers the advantage of using a short 
run time of 13 minutes for separation of six structurally related alkaloids on a Zorbax Extend 
C-18 column with a mobile phase consisting of acetonitrile (gradient 9 to 13%) and 15 mM 
ammonium formate in water adjusted to pH 10.5 with TEA, and detection at a single UV 
wavelength of 260 nm. Results from validation of the method proved satisfactory with respect 
to sensitivity, linearity, accuracy and reproducibility that make it suitable for routine 
quantification of the target alkaloids in tobacco plants and products. The LC-MS/MS method 
developed and validated here for quantification of NNN and NNK is a simple method adapted 
from already published methodologies for fast and efficient quantification of these two 
carcinogenic compounds in smokeless tobacco products. 
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3.1 Introduction 
All species of the genus Nicotiana (L) have the characteristic feature of producing pyridine 
alkaloids; but the number and abundance of the different alkaloids are highly variable within 
the genus (Sisson and Severson, 1990) (Saitoh et al., 1985). While nicotine is considered to be 
the most abundant alkaloid (~95%) in Nicotiana species, there are many other structurally 
related pyridine alkaloids in various Nicotiana plants and their cured leaves, primarily 
nornicotine, anabasine, anatabine, myosmine and cotinine. Nornicotine, the major secondary 
alkaloid in most species, is a demethylated derivative of nicotine. N'-demethylation of nicotine 
to nornicotine mainly occurs in the senescing leaves of Nicotiana plants. Nicotiana species that 
convert a large portion of their nicotine content to nornicotine during senescence and curing 
are called “converters”, whereas the species that mainly accumulate nicotine in their leaves are 
called “nonconverters” (Chakrabarti et al., 2007, Gavilano and Siminszky, 2007, Siminszky et 
al., 2005). 
In tobacco research, nicotine to nornicotine conversion has a vital importance. This is because 
nornicotine affects tobacco quality by causing unwanted flavour and decreasing smoking 
quality (Roberts, 1988). Similar to nicotine, nornicotine accumulates in the brain, evokes 
dopamine release and contributes to the pharmacologic profile of nicotine (Crooks et al., 1997). 
However, nornicotine is believed to be a source of many undesirable health effects. The most 
important health implications attributed to nornicotine are due to its being the main precursor 
of N’-nitrosonornicotine (NNN) which is a tobacco specific nitrosamine (TSNA) with high 
potential in inducing cancer in laboratory animals (Hecht, 1998, Hecht, 2003, Hoffmann et al., 
1994). Nitrosation of nornicotine may also take place in the stomach, which can also lead to 
formation of NNN (Porubin et al., 2007). Other than that, nornicotine induces the aberrant 
glycation of proteins within the cells and alters the pharmacological properties of the 
commonly prescribed steroid medication, prednisone (Dickerson and Janda, 2002). It also 
catalyses retinal isomerization that is responsible for age-related macular degeneration, birth 
defects associated with smoking, and other smoking-associated abnormalities that stem from 
disruption of retinoid metabolism (Brogan et al., 2005). Nornicotine is also believed to be 
responsible for periodontal disease associated with smoking (Katz et al., 2005). Research 
efforts have focussed on understanding the conversion phenomenon, and in breeding low 
nornicotine-producing species (Mann et al., 1964). Nornicotine constitutes about 3-5% of the 
total alkaloid content in major commercial varieties of Nicotiana (mainly N. tabacum), but this 
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could be up to 97% in high converter wild species or varieties of commercial tobacco (Gavilano 
et al., 2006, Pakdeechanuan et al., 2012). 
The molecular identity of the nicotine to nornicotine conversion factor in Nicotiana species has 
been of great importance, since the encoding of nicotine demethylase enzymes is the major 
determinant in formation and accumulation of nornicotine in these species. A group of 
cytochrome P450 genes, belonging to the 82E subfamily have been reported to be involved in 
encoding of these functional N-demethylases in Nicotiana spp. (Siminszky et al., 2005). This 
group of P450 genes are differentially regulated between high converter and low or 
nonconverter Nicotiana (Siminszky et al., 2005). In human liver microsomes, nicotine N-
demethylation is catalysed by the P450 subfamilies CYP2A and CYP2B (Yamanaka et al., 
2005). There are at least five CYP82E related genes in N. tabacum: CYP82E4, CYP82E5 and 
CYP82E10 encode functional nicotine N-demethylases (Siminszky et al., 2005, Gavilano and 
Siminszky, 2007, Lewis et al., 2010) whereas two others CYP82E2 and CYP82E3 encode 
inactive enzymes (Chakrabarti et al., 2007, Gavilano and Siminszky, 2007). Investigations 
conducted on conversion locus analysis in Nicotiana spp. are limited to the varieties of the 
important commercial tobacco, mainly N. tabacum (Cai et al., 2012a, Siminszky et al., 2005, 
Chakrabarti et al., 2008, Gavilano et al., 2006, Gavilano and Siminszky, 2007, Lewis et al., 
2010) and its progenitor species N. tomentosiformis (Mann et al., 1964), and N. sylvestris 
(Chakrabarti et al., 2007). There is also a report of the loci and their functionality in a few 
South American wild species including N. langsdorffii and N. alata (Pakdeechanuan et al., 
2012). 
In Australia, there are 26 wild species and subspecies of Nicotiana, all belonging to 
Suaveolentes section (Ladiges et al., 2011, Marks et al., 2011). Australian species of Nicotiana 
are mostly annuals, or in exceptionally good seasons they may survive for a second year. In 
southern parts there are a few short-lived perennial species (Latz et al., 1995, Peterson, 1979). 
A range of these species have been used for preparing a chewing tobacco products by the 
Aboriginal population of central Australia for hundreds of years (Latz et al., 1995). This 
chewing tobacco product is usually known as ‘pituri’ (Latz et al., 1995, Peterson, 1979, Young, 
2005, Ratsch et al., 2010), though other names may be used, such as ‘mingkulpa’, within some 
Aboriginal communities (Ratsch et al., 2010, Young, 2005). Pituri is a mix of fresh or dry 
leaves of wild Nicotiana with a burnt alkaline wood ash that is chewed to form a ‘quid’ (Latz 
et al., 1995, Ratsch et al., 2010, Watson et al., 1983). A range of species have been reported to 
be used for chewing, depending on their availability in the different geographic locations. The 
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most preferred one is N. gossei (Latz et al., 1995, Peterson, 1979, Symon, 2005), but when not 
available other species such as N. excelsior, N. rosulata subsp. ingulba, N. goodspeedii, N. 
benthamiana and N. cavicola might be used (Latz et al., 1995, Peterson, 1979, Symon, 2005). 
The alkaloid profile of Nicotiana species has been reported previously for 19 out of 26 of the 
recognised Australian taxa (Saitoh et al., 1985, Sisson and Severson, 1990), but so far there is 
no information on nicotine to nornicotine conversion and the molecular characteristics of the 
responsible locus in Australian Nicotiana species. This study aims to quantify the pyridine 
alkaloids in all Australian Nicotiana spp. and investigate the presence and functionality of 
CYP82E related genes. 
3.2 Materials and methods 
3.2.1 Plant Material 
Seeds of Australian Nicotiana species and subspecies were obtained from seedbanks, botanic 
gardens and herbaria across Australia. Seed viability for each seedlot was determined with 
tetrazolium staining. Seeds were imbibed in distilled water for 24 hours and then incubated on 
filter paper soaked with 1% 2,3,5-triphenyltetrazolium chloride (Sigma) solution for 24 hours 
at 35°C in dark. The % viability was determined by scoring the embryos stained red or pink as 
viable. For germination, 10 seeds for each seedlot were incubated in 55 mm plastic Petri dishes 
on a double layer of filter paper (Advantec NO.1 55 mm) soaked with 5 mL distilled water 
containing 200 ppm GA3 (Sigma) at 20°C under 16 hours photoperiod with cool white light. 
After 24 hours seeds were transferred to Petri dishes with filter papers soaked in only distilled 
water. Germination % was monitored: a seed was considered to have germinated once the 
radicle emerged. After 10-14 days, germinated seeds were transferred into seedling trays filled 
with Osmocote seed raising and cutting mix (Scotts, Australia). After 2 weeks seedlings were 
moved to 100×50 mm black tube pots containing Osmocote native potting & planting mix 
(Scotts, Australia). Plants were grown in pots and under controlled environment (Thermoline, 
Climatron 520 & 1100-DL/SL growth cabinet) with 16 h light provided by cool white 
fluorescent lamps, 23°C day and 21ºC night temperature, constant 70–90% relative humidity 
and watered daily as needed. For seedlots with low seed viability, this process was repeated 
until 3 healthy plants were obtained. 
Green leaves were harvested from 8-10 week old non-flowering adult plants. Three plants were 
sampled for each taxon. Fresh leaf material was used for DNA extraction for CYP82E gene 
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analysis. Fresh leaves were freeze-dried and stored at -80ºC for alkaloid analysis. To further 
investigate the conversion locus, fresh leaves of six selected species were cured by incubating 
at 35ºC for 6 hours in the dark and used for RNA extraction and RT-PCR analysis, and cured 
leaves were freeze-dried and stored at -80ºC for alkaloid analysis. 
Herbarium vouchers were prepared and submitted using the laboratory-grown plants unless a 
record for the specific seedlot already existed; the confirmation of identity for six taxa was 
performed by Neville Walsh (Senior Conservation Botanist, Royal Botanic Gardens Victoria). 
3.2.2 Chemical analysis 
3.2.2.1 Chemicals and reagents 
The solvents used for alkaloids extraction and HPLC analysis were methanol and acetonitrile, 
from Merck (Darmstadt, Germany), and a 15 mM ammonium formate buffer prepared using 
ammonium formate from Sigma-Aldrich (St. Louis, MO). The water was deionised and filtered 
using a Milli-Q system (Millipore, Billerica, MA). Hydrochloric acid and sodium hydroxide 
used for adjusting pH were from Merck (Darmstadt, Germany). The analytical standards used 
were nornicotine, myosmine and cotinine from Sigma, nicotine from Fluka (Milwaukee, WI), 
anabasine from Sigma-Aldrich, anatabine from Cayman Chemical Company (AnnArbor, MI), 
and the internal standards used were caffeine from Ajax Finechem (Sydney, Australia). 
3.2.2.2 Alkaloid analysis 
Both fresh and cured freeze-dried leaves (50 mg) were exhaustively extracted for pyridine 
alkaloids using 40% aqueous methanol containing 0.1% 1N hydrochloric acid following our 
previously published method (Moghbel et al., 2015) and were quantified for nicotine, 
nornicotine, anatabine, anabasine, myosmine and cotinine. Quantitative analysis of the extracts 
was carried out on an Agilent 1100 series high performance liquid chromatography (HPLC) 
system equipped with a UV detector and on a Zorbax Extend C18 column (Agilent 
Technologies, Mulgrave, Vic, Australia) with a gradient mobile phase consisting of 15 mM 
ammonium formate buffer and acetonitrile as described in chapter 2 (Moghbel et al., 2015). 
Percent conversion was calculated as [nornicotine content / (nornicotine content + nicotine 
content)] x 100 (Pakdeechanuan et al., 2012). Plants with less than 10% were scored as low or 
nonconverters, plants with 10-50% and 50-100% conversion were assigned as medium and 
high converters, respectively. 
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3.2.3 Molecular analysis 
3.2.3.1 PCR amplification of CYP82E related genes 
Genomic DNA was extracted from fresh leaves using the ZR Plant/Seed DNA MiniPrep™ 
(Zymo Research, CA, USA) following the manufacturer’s instructions. Genomic fragments 
containing CYP82E related genes were obtained by amplifying genomic DNA (around 20 ng) 
with PCR primer set that was designed based on the conserved sequences of the published 
tobacco CYP82E subfamily genes (Table 3-1). Gel electrophoresis was then performed by 
loading 5 µl of the PCR products to investigate the presence of the bands representing the 
amplified targets in studied samples. A 1kb DNA ladder (New England biolabs Inc, MA, 
U.S.A) was used as marker. 
Table 3-1 Sequences of the primers used for PCR amplification of CYP82E related genes designed from N. 
tabacum CYP82E4 mRNA (Accession: KC120817.1) and internal gene GAPDH designed from N. benthamiana 
glyderaldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (Accession: JQ256517.1). 
 Primers Sequence (5'->3') Product length Comment 
82E-F CTGCGGACACAGTTGCTCTT 536 For amplifying CYP82E subfamily 
genes from genomic DNA and 
cDNA CYP82E-R AGTTATGCCTGCACCTTCCT 
GAPDH-F AACCGGTGTCTTCACTGACAAGGA 562 For amplifying internal gene 
GAPDH from cDNA GAPDH-R GCTTGACCTGCTGTCACCAACAAA 
3.2.3.2 Sequencing the amplified CYP82E regions for selected species 
The amplified genomic DNA from three low or nonconverter species (N. benthamiana, N. 
excelsior, N. gossei) and three high converter species (N. cavicola, N. goodspeedii, N. velutina) 
were purified using Rapid PCR Cleanup Enzyme Set (New England biolabs Inc, MA, U.S.A) 
according to the protocol of the manufacturer. Each purified PCR product was sent for BDT 
labelling, purification and sequencing to the Australian Genome Research Facility and 
sequenced following high throughput Sanger sequencing using Applied Biosystems 3730 and 
3730xl capillary sequencers. These automated platforms use ABI Prism BigDye Terminator 
kit (BDT) chemistry version 3.1 (Applied Biosystems) under standardised cycling PCR 
conditions. cDNA sequences of CYP82E subunits were retrieved from GenBank and BLASTn 
was used for confirmation of the identity of CYP82E subunits. 
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3.2.3.3 Agarose gel electrophoretic analysis of CYP82E related genes transcript levels in 
fresh versus cured leaves of selected species 
Total RNA was extracted from fresh and cured leaves of three low or nonconverter species (N. 
benthamiana, N. excelsior, N. gossei) and three high converter species (N. cavicola, N. 
goodspeedii, N. velutina) using the ZR Plant RNA MiniPrep™ (Zymo Research, CA, USA) 
following the instructions provided by the manufacturer. First strand cDNA was then 
synthesized by ProtoScript II First Strand cDNA Synthesis Kit (New England biolabs Inc, MA, 
U.S.A) according to the protocol of the manufacturer. The CYP82E related cDNA fragments 
were amplified by PCR amplification of isolated cDNA from the fresh and cured leaves of the 
studied species. A set of primers was also optimised to amplify 562 bp GAPDH fragments 
from the obtained cDNA to be used as the internal gene (Table 3-1). Optical densitometric 
analysis from the picture of the obtained agarose gel electrophoresis bands was then performed 
using ImageJ software (version 1.48b, https://imagej.nih.gov/ij/) to determine the relative gene 
expression of the CYP82E related genes in fresh versus cured leaves. The optical density of 
the CYP82E bands obtained from loading 5 µl of the PCR product was normalised to that of 
GAPDH bands obtained from loading similar amount of 5 µl of the PCR product used as 
internal gene. 
3.2.4 Statistical analysis 
Statistical analysis was performed using Prism (GraphPad, San Diego, CA) software. One-way 
analysis of variance (ANOVA) was applied with Bonferroni multiple comparisons and P < 
0.05 marked as significant. ImageJ Software version 1.48b (https://imagej.nih.gov/ij/) was used 
for the optical densitometric analysis of expression levels in fresh versus cured leaves. 
3.3 Results 
3.3.1 Plant growth 
Plants were successfully grown for 24 out of the 26 recognised taxa, with two seedlots grown 
for five of the taxa (Table 3-2). In total, 73 seed lots were obtained for the 26 Australian species 
and subspecies (Appendix 1). Not all of the received seed lots were viable and of high enough 
quality to result in successful germination. Germination and growth of N. wuttkei J.R.Clarkson 
& Symon and N. umbratica N.T.Burb. Seeds were not achieved because seeds were either 
inviable or grew into plants that were identified to be other species; N. tabacum for seeds 
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labelled as N. wuttkei, and N. amplexicaulis instead of N. umbratica. Records showing the 
presence of N. wuttkei in a small remote area of northern Queensland are over 20 years old and 
N. umbratica has a limited distribution in northern Western Australia. 
Table 3-2 Sources of seeds used for growing the Nicotiana species for this study, with their corresponding 
herbarium voucher number, collection date, tetrazolium (V) and germination (G) results. 
Taxon Seed Lot Voucher  Collection % V % G 
N. amplexicaulis N.T.Burb NSW4157044 NSW 234670 21/10/1990 60 80 
 TS 298 
(AusTRCF317546) 
MEL 2396301 - 50 50 
N. benthamiana Domin A109412 DNA A0109412 18/07/2001 90 100 
N. burbidgae Symon DJD3167 Voucher confirmed   09/2015 20 20 
N. cavicola N.Burb. NSW877057 NSW 951497 3/08/1995 100 90 
N. excelsior (J.Black) J.Black D194512 AD 246203 21/09/2009 50 30 
N. forsteri Roem. & Schult. BGQLD.0727 BRI AQ0840316 27/05/2010 50 50 
N. goodspeedii H.Wheeler DJD213 AD 192908 22/11/2005 100 100 
N. gossei Domin D204093 DNA D0204093 25/04/2011 100 100 
 NSW4022326 Identity confirmed 09/1997 90 80 
N. heterantha Symon & Kenneally AusTRCF313551 MEL 2396300   - 60 30 
N. maritima H. Wheeler MKJ140 AD 187318 15/11/2005 80 80 
 DJD3341 Voucher confirmed 7/01/2013 50 30 
N. megalosiphon Van Heurck & Mull. 
Arg. ssp. megalosiphon 
NSW870550 NSW 2010147 8/11/2010 100 90 
N. megalosiphon Van Heurck & Mull. 
Arg. ssp. sessifolia P.Horton 
AusTRCF303829 MEL 2396303   - 30 20 
N. monoschizocarpa (P.Horton) Symon 
& Lepschi 
AusTRCF303666 Voucher confirmed  09/1986 50 50 
N. occidentalis H.Wheeler ssp.hesperis 
(N.Burb.) P.Horton 
TS 341 
(AusTRCF303767) 
MEL 2396304  1960 82 70 
N. occidentalis H.Wheeler ssp. obliqua 
N. Burb. 
SL17 (AusTRCF303779) MELU D106540 1/08/1956 70 50 
N. occidentalis H.Wheeler ssp. 
occidentalis 
L 3569 
(AusTRCF303738) 
MELU D106542, 
D106543) 
1959 30 20 
N. rosulata (S.Moore) Domin ssp. 
ingulba (J.Black) P. Horton 
TS 75 
(AusTRCF303907) 
MEL 2396302 -  84 50 
N. rosulata (S.Moore) Domin ssp. 
rosulata 
20070392 PERTH 7821336 20/07/2006 100 100 
N. rotundifolia Lindley  MEL 2396305   08/2015 100 100 
N. simulans N.Burb. RJB70944 AD 206232 12/03/2007 80 70 
 NSW 872310 ASBP 20101508 15/11/2010 40 20 
N. sp. ‘Corunna’ Symon17088 SL23 (MELU D106460, 
D106461, D106462, 
D106463, D106464) 
AD 239243 14/09/2005 50 50 
N. suaveolens H. Wheeler DJD1980 AD 239956 6/10/2010 100 100 
N. truncata Symon TST1056 AD 250303 7/10/2010 50 40 
N. velutina H.Wheeler DJD233  AD 192706 24/11/2005 70 60 
 NSW4139564 NSW 213331 24/01/1989 60 40 
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3.3.2 Alkaloid profile 
Fresh leaves of all 24 taxa contained the major alkaloids nicotine and nornicotine (Table 3-3). 
Anatabine and anabasine were also found in the majority of the taxa but myosmine and cotinine 
were not detected. Nicotine constitutes the major portion of total alkaloids in 15 taxa including 
N. gossei, which tends to be the most important chewed species amongst Aboriginal pituri 
chewers. This was also the case for N. excelsior and N. benthamiana, which are amongst the 
preferred species for pituri chewing (Latz et al., 1995, Symon, 2005). Hence, these three 
species are examples of low or nonconverter phenotypes. In contrast, nornicotine is the 
predominant alkaloid in 9 taxa including N. goodspeedii, N. velutina and N. cavicola and so 
these are classified as high converter species. For four of the five species for which two 
different seed sources were available for comparison (N. amplexicaulis, N. gossei, N. maritima 
and N. velutina) the dominant alkaloid was the same and absolute concentrations were not 
significantly different (Table 3-3). 
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Table 3-3 Alkaloid content (mean ± se for 3 replicates) in freeze-dried fresh leaves of Australian Nicotiana spp. 
grown in a plant growth incubator under 16 h photoperiod provided with cool white fluorescent lamps, 23°C day 
and 21ºC night temperature, constant 70–90% relative humidity. Plants were watered daily as needed. 
Conversion rate was defined using the formula: [nornicotine content / (nornicotine content + nicotine content)] x 
100. Species with less than 10% conversion rate are regarded to be low or nonconverters while those with 10-
50% and more than 50% conversion rate are assigned as medium and high converters, respectively. 
Species Alkaloid Concentrations (mg/g D.W.) 
Conversion 
Status 
  Nicotine Nornicotine Anatabine Myosmine Anabasine Cotinine  
N. amplexicaulis 1.61 ± 0.44 0.23 ± 0.12 0.17 ± 0.15 N.D. 0.28 ± 0.29 N.D. Medium 
 5.09 ± 0.15 0.15 ± 0.05 0.05 ± 0.02 N.D. 0.05 ± 0.02 N.D. Non-Low 
N. benthamiana 2.29 ± 1.61 0.25 ± 0.05 0.14 ± 0.10 N.D. 0.41 ± 0.32 N.D. Non-Low 
N. burbidgae 4.05 ± 1.12 0.20 ± 0.09 0.01 ± 0.00 N.D. 0.66 ± 0.20 N.D. Non-Low 
N. cavicola  0.06 ± 0.02 0.10 ± 0.02 BLQ N.D. 0.01 ± 0.02 N.D. High  
N. excelsior  5.39 ± 1.09 0.17 ± 0.14 0.21 ± 0.05 N.D. 0.17 ± 0.10 N.D. Non-Low 
N. forsteri  1.39 ± 0.35 0.66 ± 0.47 0.24 ± 0.04 N.D. 0.74 ± 0.5 N.D. Medium 
N. goodspeedii 0.24 ± 0.18 1.92 ± 0.08 0.03 ± 0.01 N.D. 0.29 ± 0.11 N.D. High 
N. gossei  5.95 ± 1.33 0.05 ± 0.07 0.07 ± 0.02  N.D. N.D. N.D. Non-Low 
 8.27 ± 3.00 0.05 ± 0.02 0.11 ± 0.06 N.D. 0.10 ± 0.04 N.D. Non-Low 
N. heterantha 0.89 ± 0.12 0.19 ± 0.11 BLQ N.D. 0.48 ± 0.11 N.D. Medium 
N. maritima 3.94 ± 1.39 0.12 ± 0.05 0.05 ± 0.02 N.D. 0.11 ± 0.05 N.D. Non-Low 
 3.17 ± 1.93 0.10 ± 0.06 0.04 ± 0.02 N.D. 0.11 ± 0.07 N.D. Non-Low 
N. megalosiphon subsp. 
megalosiphon  
0.11 ± 0.07 0.63 ± 0.2 0.03 ± 0.01 N.D. 0.23 ± 0.12 N.D. High  
N. megalosiphon subsp. 
sessifolia 
0.14 ± 0.08 0.76 ± 0.30 0.11 ± 0.06 N.D. 0.03 ± 0.01 N.D. High  
N. monoschizocarpa 2.35 ± 0.38 2.82 ± 0.66 0.14 ± 0.12 N.D. 2.67 ± 0.83 N.D. High  
N. occidentalis subsp. 
hesperis 
0.41 ± 0.01 0.14 ± 0.10 0.03 ± 0.01 N.D. 0.17 ± 0.02 N.D. Medium 
N. occidentalis subsp. 
obliqua 
0.65 ± 0.32 0.29 ± 0.04 0.10 ± 0.07 N.D. 0.47 ± 0.45  N.D. Medium 
N. occidentalis subsp. 
occidentalis 
0.15 ± 0.06 0.47 ± 0.12 BLQ N.D. 0.10 ± 0.00 N.D. High 
N. rosulata subsp. 
rosulata  
0.60 ± 0.04 0.10 ± 0.03 0.19 ± 0.11 N.D. 0.13 ± 0.04 N.D. Medium 
N. rosulata var. ingulba 0.81 ± 0.06 0.18 ± 0.08 0.02 ± 0.01 N.D. 0.01 ± 0.02 N.D. Medium 
N. rotundifolia 3.54 ± 1.58 0.15 ± 0.17 0.02 ± 0.03 N.D. 0.24 ± 0.04 N.D. Non-Low 
N. simulans  0.04 ± 0.04 0.44 ± 0.04 0.03 ± 0.00 N.D. 0.10 ± 0.02 N.D. High 
  0.16 ± 0.03 0.22 ± 0.06 BLQ N.D. 0.23 ± 0.03 N.D. High 
N. sp. 'Corunna' 1.61 ± 1.10 0.07 ± 0.03  0.04 ± 0.02 N.D. 0.25 ± 0.12 N.D. Non-Low 
N. suaveolens  0.15 ± 0.21 0.72 ± 0.35 0.01 ± 0.01  N.D. 0.12 ± 0.06 N.D. High 
N. truncata 3.21 ± 0.46 0.11 ± 0.07 0.23 ± 0.12 N.D. 0.11 ± 0.03 N.D. Non-Low 
N. velutina  0.11 ± 0.06 0.92 ± 0.53 0.05 ± 0.06 N.D. 0.31 ± 0.25 N.D. High 
  0.03 ± 0.03 1.18 ± 0.28 BLQ N.D. 0.31 ± 0.03 N.D. High 
N.D.: Not Detected             
BLQ: Below Limit of Quantification       
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The two seedlots of N. simulans, one collected in NSW and the other in SA, differed 
significantly in their absolute levels of nicotine, nornicotine and anabasine. Treatment with 
heat to mimic curing elevated the proportion of nornicotine to nicotine in the leaves of both 
high converter and low or nonconverter species, however this increase did not change the 
dominant alkaloid in either group (Table 3-4). 
Table 3-4 Alkaloids (mean ± se for 3 replicates) of fresh versus cured (35°C for 6 hours in the dark) leaves for 
selected species of Australian Nicotiana spp. Significant differences (p<0.05) between fresh and cured leaves 
are indicated (*). 
  % Nornicotine content / (Nicotine content + Nornicotine content) 
Species Fresh leaves Cured leaves 
N. benthamiana 9.6 ± 2.0 21.4 ± 3.1* 
N. excelsior 2.9 ± 0.9 6.0 ± 2.6 
N. gossei 0.4 ± 0.1 0.7 ± 0.2 
N. goodspeedii 83.2 ± 1.1 90.5 ± 0.8* 
N. cavicola 69.7 ± 1.6 81.4 ± 2.6* 
N. velutina 73.3 ± 3.8 92.6 ± 1.7* 
 
3.3.3 CYP82E genes in Australian Nicotiana spp. 
Since nicotine N-demethylase (NND), the main source for conversion of nicotine to 
nornicotine, is encoded by cytochrome P450 monooxygenase genes of the CYP82E subfamily 
in N. tabacum (Lewis et al., 2010, Siminszky et al., 2005), PCR using CYP82E specific primers 
based on the sequences of the conserved regions of the subfamily in N. tabacum (Table 3-1) 
was optimised to amplify the potential loci in Australian Nicotiana species. Based on the 
agarose gel electrophoresis results, genomic DNA corresponding to the conserved region of 
CYP82E related genes have been amplified in all of the studied Australian Nicotiana species 
(Figure 3-1). To confirm the identity, the amplified regions from three low or nonconverter and 
three high converter species were purified and subjected to Sanger sequencing. The DNA 
sequences of the CYP82E related genes from N. benthamiana, N. gossei, N. goodspeedii, N. 
velutina, N. cavicola and N. excelsior have been deposited in NCBI GenBank with the 
accession numbers KU234094, KU234095, KU234096, KU234097, KU234098 and 
KU504631, respectively. Blasting the obtained sequences in NCBI BLASTN tool 
demonstrated 94-97% resemblance and identity to the published sequences of conversion locus 
CYP82E in other Nicotiana species, confirming their proposed identity (DQ131887.2 and 
EF472002.1). 
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Figure 3-1 Agarose gel electrophoretic photo of the CYP82E related fragment produced by 35 cycles of PCR 
amplification of DNA isolated from 1. N. forsteri, 2. N. benthamiana, 3. N. excelsior, 4. N. gossei, 5. N. suaveolens 
(exigua), 6. N. goodspeedii, 7. N. simulans, 8. N. velutina, 9. N. cavicola, 10. N. amplexicaulis, 11. N. 
megalosiphon subsp. megalosiphon, 12. N. megalosiphon subsp. sessifolia, 13. N. truncate, 14. N. maritima, 15. 
N. occidentalis subsp. obliqua, 16. N. occidentalis subsp. Occidentalis, 17. N. occidentalis subsp. hesperis, 18. N. 
sp. 'Corunna', 19. N. heterantha, 20. N. rosulata subsp. rosulata, 21. N. rosulata var. ingulba, 22. N. rotundifolia, 
23. N. burbidgae, 24. N. monoschizocarpa. 
 
3.3.3.1 Agarose gel electrophoretic analysis of CYP82E related genes transcript levels in 
fresh versus cured leaves of the selected high converter versus low or nonconverter 
species 
The relationship between transcript levels of CYP82E related genes and observed levels of 
nornicotine production in fresh and cured leaves of high converter and low or nonconverter 
species was investigated by analysing relative transcript accumulation levels in fresh versus 
cured leaves. The ratio between the optical density of the CYP82E band to that from the 
GAPDH band on the agarose gel photo for each sample was used as an indicator of expression 
and calculated in fresh and cured leaves of both high converter and low or nonconverter groups 
of species. The normalised optical density of the bands resulting from transcription of the 
CYP82E related genes in fresh leaves showed no significant difference across high converter 
and low or nonconverter species. Curing was associated with a significantly higher (almost 3 
fold) optical density in the leaves of the high converter species, but only a small increase or no 
change was measured in the cured leaves for the low or nonconverter species (Figure 3-2). 
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Figure 3-2 Agarose gel electrophoretic analysis and normalised band densitometry values of the CYP82E related 
fragment produced by 35 cycles of PCR amplification of cDNA isolated from A) fresh leaves B) Cured leaves (at 
35° C for 6 hours) of 1. N. gossei 2. N. excelsior 3. N. benthamiana, 4. N. cavicola, 5. N. goodspeedii, 6. N. 
velutina. A 562 bp GAPDH fragment obtained by 35 cycles of PCR amplification of the cDNA for each sample 
is shown as an internal gene and for normalising the densitometric values that all were quantified using ImageJ 
software. The data points in graphs show mean ± std error of 3 independent experiments *: p<0.05 
3.4 Discussion 
This study has expanded the range of Australian wild Nicotiana species and subspecies 
assessed for alkaloid composition to 24 out of the 26 that are currently recognised (Table 3-3). 
The taxa missing from analysis are N. wuttkei and N. umbratica for which we were unable to 
obtain a reliable seed source. Alkaloid composition exhibited large differences between 
species, with a maximum of 8.3 and minimum of 0.3 mg/g nicotine recorded, which were for 
N. gossei and N. velutina, respectively. Alkaloid production in Nicotiana is controlled 
genetically and levels can vary dramatically throughout growth in response to environmental 
conditions (Keinanen et al., 2001) so it may be expected that different seedlots of the same 
species vary in alkaloid quantities even when grown in a single environment. However, of the 
five species for which two seed sources from different geographic locations within Australia 
were grown, very little difference in alkaloid concentrations was found for four of them (N. 
amplexicaulis, N. gossei, N. maritima, and N. velutina). The only significant difference 
between the two seedlots was for N. simulans, which showed statistically different levels of 
alkaloids for the seedlots from South Australia and New South Wales. However, even 
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considering the significant difference in absolute alkaloid concentrations for this species, 
calculations using the nicotine and nornicotine concentrations conclude that both seedlots 
exhibit the same conversion trait.  
The alkaloid composition for 19 Australian Nicotiana species were reported almost 30 years 
ago (Saitoh et al., 1985, Sisson and Severson, 1990). Differences in absolute alkaloid 
concentrations to those reported here may be associated not only with the different seedlots 
involved, but also differences in the growth environment and treatment of plants before 
harvesting leaves. The plants used in previous studies were greenhouse (Saitoh et al., 1985, 
Sisson and Severson, 1990) or field (Sisson and Severson, 1990) grown plants, whereas the 
plants in our study were lab grown and usually lab grown plants tend to contain lower alkaloid 
concentrations than those from field or greenhouse (Dewey and Xie, 2013). Despite differences 
in reported absolute concentrations for nicotine and nornicotine between this and previous 
studies, the inferred conversion trait for each species is consistent between studies. For 
example, using the nicotine and nornicotine quantification results reported by both previous 
studies (Saitoh et al., 1985, Sisson and Severson, 1990) and here (Table 3-3), the species N. 
gossei, N. excelsior and N. benthamiana are categorised as low or nonconverter, while N. 
goodspeedii, N. cavicola and N. velutina are high converter species.  
Nornicotine is an undesirable alkaloid in consumed tobacco species, because its production and 
accumulation has a positive correlation to production of the carcinogenic nitrosamine, NNN. 
Production of nornicotine via N-demethylation of nicotine in commercial tobacco is mainly 
governed by CYP82E related genes, specifically E4. Inhibition of the nicotine to nornicotine 
conversion happens as the result of silencing of the CYP82E gene subfamily. Tetcyclasis is an 
inhibitor of cytochrome P450 and arrests the nicotine demethylation (Chelvarajan et al., 1993, 
Donaldson and Luster, 1991). Carbon monoxide also is shown to inhibit nicotine demethylation 
(Chelvarajan et al., 1993, Donaldson and Luster, 1991), while light of 450 nm reverses this 
inhibition (Donaldson and Luster, 1991). 
Given the vital importance of the CYP82E related genes in nornicotine production and 
accumulation in tobacco plants and due to considerable nornicotine production in some 
Australian Nicotiana species and the unknown source of conversion in them, in this study, we 
amplified the conversion loci in the 24 Australian Nicotiana species and subspecies. This is the 
first molecular and biochemical evidence that CYP82E genes are present in Australian 
Nicotiana species. 
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Although the locus was present in all studied taxa, some of the Australian species are high 
converters of nicotine to nornicotine and accumulate high levels of nornicotine in their leaves, 
whereas some others mainly accumulate nicotine. The difference in the observed nicotine to 
nornicotine conversion phenotype could be due to the presence of the CYP82E related genes 
with different ability for encoding functional nicotine N-demethylases. It is notable that the 
main species preferred for chewing are amongst those that mainly accumulate nicotine, i.e. N. 
gossei and N. excelsior, both of which are low or nonconverters. N. benthamiana, a low 
converter, has also been mentioned to be used for chewing in Western Australia (Latz et al., 
1995, Peterson, 1979, Symon, 2005). In contrast, the high converters N. megalosiphon ssp. 
megalosiphon, N. simulans, N. occidentalis ssp. occidentalis and N. velutina have been listed 
in the literature as being rarely used or specifically avoided (Latz et al., 1995, Peterson, 1979, 
Symon, 2005). However, the high converters N. cavicola and N. goodspeedii have been 
reported to be used by Aboriginal people (Symon, 2005). N. rosulata ssp. ingulba is reportedly 
a species that is preferred for chewing due to its availability in Central Australia (Latz et al., 
1995, Peterson, 1979, Symon, 2005), but this is a medium converter. 
Due to the large number of species and the little information on the conversion locus in species 
other than N. tabacum, the varieties and number of different genes have not been identified in 
detail in this study. Instead, the functionality of the loci has been compared between a few 
selected high converters and low or nonconverter species. The functional CYP82E loci, 
especially E4, have been reported to be triggered by curing which leads to a high level of 
transcript accumulation only in high converter species, while the transcript accumulation 
happens in very low and negligible levels in low or nonconverters (Lewis et al., 2010). This 
could be an explanation for the observed significantly elevated levels of transcripts (3 to 4 fold) 
in the cured leaves of only high converter species N. goodspeedii, N. cavicola and N. velutina, 
while no significant difference was found between the level of transcript accumulation in fresh 
leaves with the fresh and cured leaves of the low or nonconverter species N. gossei and N. 
excelsior. The level of transcripts in cured leaves of N. benthamiana shows a significant 
increase compared to that observed in fresh leaves, although the increase was not as much as 
observed for the high converters. This is also consistent with the conversion phenotype of N. 
benthamiana, which tends to accumulate higher nornicotine compared to that observed for the 
other two low or nonconverter species, specifically in cured leaves, although it accumulates 
nicotine as the most abundant alkaloid. This might be due to presence of the minor functional 
NNDs in N. benthamiana. The alkaloid phenotypes of the two low or nonconverters, N. gossei 
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and N. excelsior, show a lower proportion of nornicotine to nicotine in fresh and cured leaves 
with a very small increase after curing that is also consistent with the illustrated transcript 
accumulation levels. This might be due to the loci present in these species being either non-
functional or with minor functionality and expressed only at a basic steady level. In contrast, 
the loci in high converter species, N. goodspeedii, N. cavicola and N. velutina, are functional 
and tend to be triggered to increase their transcript levels, and this in turn is responsible for 
their higher levels of nornicotine. 
The CYP82E subfamily has several genes in N. tabacum and other studied Nicotiana species 
that share a great sequence identity (in some cases more than 90%), however the majority of 
these are not functional NND genes (Lewis et al., 2010). There are also genes that are functional 
in some species, but have been mutated and become non-functional in others (Chakrabarti et 
al., 2007, Gavilano and Siminszky, 2007). This could be due to either transcriptional 
inactivation or premature translational termination of these genes, resulting in the absence of 
nornicotine in their carrying species. For example, N. tabacum is the result of hybrizidation of 
diploid Nicotiana species closely related to modern N. tomentosiformis and N. sylvestris. N. 
tomentosiformis has both active CYP82E3 and CYP82E4 which control conversion in green 
and senescing leaves, respectively. In contrast in N. tabacum a W330C amino acid substitution 
inactivates CYP82E3; moreover, in nicotine-accumulating nonconverter N. tabacum a 
CYP82E4 is also transcriptionally silenced (Gavilano et al., 2007). Another example is in the 
two closely related wild species of Alatae section, N. langsdorffii and N. alata. In N. 
langsdorffii the CYP82E genes are rendered non-functional, whereas CYP82E genes in N. 
alata act semi-dominantly and individually to increase conversion of nicotine to nornicotine 
(Pakdeechanuan et al., 2012). Furthermore, the tobacco genome contains numerous 
pseudogenes with CYP82E-like sequences that have been mutated (Pakdeechanuan et al., 
2012). CYP82E4 has been reported to be the major functional NND gene, while there are other 
genes such as CYP8210 and CYP82E5v2 within the N. tabacum genome that are also 
functional, but result in lower level of conversion and hence are considered to be minor 
functional NNDs. The functionality of the loci has not been studied in Australian Nicotiana 
before, and this study took the first step in investigating the underlying mechanism in nicotine 
to nornicotine conversion. 
In conclusion, the nicotine to nornicotine conversion rate varies between Nicotiana species 
from the Sauveolentes section. The conversion locus is present in all 24 studied taxa, but the 
functional NND enzymes seem to be active only in nornicotine accumulating species. This is 
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driven mainly by their genetic capability rather than environmental factors (Dewey and Xie, 
2013), so even in the species with two different seed sources from different environmental 
conditions the conversion trait stays the same. The observed high nicotine to nornicotine 
converter phenotype in some Australian Nicotiana species poses a potential risk of toxicity to 
chewers of these species, especially if the leaves are processed and cured before being used in 
the preparation of pituri, as nornicotine and its nitrosamine, NNN, can be detrimental to health.
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 In vitro evaluation of nicotine release 
from dry leaves of Nicotiana gossei 
used in pituri, the Australian 
Aboriginal smokeless tobacco 
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4.1 Introduction 
Tobacco consumption contributes to about 6 million deaths a year around the world (World 
Health Organization, 2011). Global efforts to promote smoking cessation are often centred on 
its harmful outcomes including premature death and diseases such as lung cancer which are 
primarily associated with the toxic chemicals inhaled in the burned tobacco smoke (Critchley 
and Unal, 2003).  
Smokeless tobacco products and oral nicotine formulations have been used as measures to aid 
smoking cessation. The nicotine present in tobacco is rapidly distributed into the brain and 
provides an instantaneous pleasure with reduced stress and anxiety in the user so it is commonly 
difficult to cease nicotine intake completely (Benowitz, 2009). Smokeless tobacco products 
have different health effects than smoking, and not all smokeless tobacco products have been 
studied for the health outcomes and diseases they may cause (Ebbert et al., 2004, Scientific 
Advisory Committee on Tobacco Products Regulation, 2010, Winstanley, 2012). Smokeless 
tobacco products contain tobacco as the main constituent and can be consumed either orally or 
nasally without combustion (International Agency for Research on Cancer, 2007). The 
differentiating factor that sets smokeless tobacco products apart from oral Nicotine 
Replacement Therapy (NRT) formulations is that they contain other plant-derived chemicals 
such as other alkaloids and the carcinogenic tobacco specific nitrosamines (TSNA) (Gartner 
and Hall, 2009). In the manufacturing process of smokeless tobacco products, tobacco plant 
leaves, stems and other parts are blended differently, thus creating products that vary 
significantly in particle size, pH, flavour, smell, taste and nicotine concentrations. Among 
these, particle size and pH can affect the release and absorption of nicotine from smokeless 
tobacco products (Davis and Curvali, 1999). The available content of nitrosamines in these 
products is influenced by the nitrite content (Burton et al., 1994, Henningfield et al., 1995b). 
Faster nicotine release from any given product can result in higher nicotine levels in the user’s 
blood, which in turn has been believed to be associated with more subjective drug effects that 
might lead to abuse (de Wit et al., 1992). 
Nicotine from smokeless tobacco products and oral NRT is absorbed by passive diffusion into 
the systemic circulation through oral mucous membranes, particularly the cheek mucosa. 
Unionized compounds diffuse rapidly through oral membranes due to their higher solubility in 
the buccal mucosa that is lipophilic in nature (Ciolino et al., 2001). Therefore, the rate and 
extent of nicotine absorption depends on the concentrations of unprotonated (unionized) 
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nicotine available (International Agency for Research on Cancer, 2007). The pH of the 
environment and the dissociation constant of the alkaloid constituents in the tobacco product 
influences the yield of unprotonated nicotine ready for absorption (Ciolino et al., 2001). 
Nicotine is a weak base with a pKa of 8.02 (International Agency for Research on Cancer, 
2007). This infers that at a pH of 8.02, half of the nicotine content would be present in the 
unionized form, and therefore free for absorption into the body, while the remaining quantity 
is ionized. The mean mucosal pH of the oral cavity is 6.8 while the pH level of saliva ranges 
from 6.0 to 7.5, which is lower than the pKa of nicotine and promotes a greater proportion of 
the nicotine as the ionized form (Aframian et al., 2006). As a result, smokeless tobacco products 
and oral NRT formulations are often buffered to an alkaline pH by adding various agents in 
order to increase unionized nicotine concentration and enhance the rate of buccal absorption 
(International Agency for Research on Cancer, 2007, Henningfield et al., 1995b). 
There are a range of commercially available smokeless tobacco products, such as loose leaf 
chewing tobacco, dry snuff, moist snuff (snus), etc. Additionally, indigenous populations of 
the Americas, Africa, the Indian subcontinent and the Asia-Pacific region have their traditional 
methods and ingredients for preparing their smokeless tobacco products (International Agency 
for Research on Cancer, 2007, Latz et al., 1995). Pituri is the most common name for a 
traditional oral tobacco product produced and used widely in Central Australia by indigenous 
Australians, using a range of wild Australian tobacco species such as N. gossei and N. excelsior. 
There are a variety of other synonyms in the literature for this smokeless tobacco product such 
as mingkulpa (Latz et al., 1995, Peterson, 1979, Ratsch et al., 2010, Young, 2005). Tobacco 
leaves are mixed with alkaline wood ash from burned twigs obtained from various plants 
including species from the Acacia, Grevillea and Eucalyptus genera, and chewed to form a 
quid. This is then kept in the mouth with some sucking and occasional chewing to further 
stimulate the release of nicotine (Ratsch et al., 2010). The preparation and consumption method 
of pituri is similar to other indigenous smokeless tobacco products such as iq’mik used by 
Indigenous people in Alaska (International Agency for Research on Cancer, 2007, Hearn et al., 
2013) and maras from Turkey (International Agency for Research on Cancer, 2007). However, 
pituri is not included in any of the IARC Monographs and there is little information available 
in the literature on its formulation, epidemiology and the health outcomes associated with its 
consumption. 
The in vitro release of nicotine from General portion (GP, pouched) and Ettan portion (EP, 
loose) Swedish snus (both Swedish Match brand) has been studied previously, whereby a 
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model mouth system consisting of modifiable factors influencing buccal conditions such as 
temperature, saliva composition and the flow rate of simulated saliva was used (Li et al., 2013), 
however this device wasn’t designed to be able to perform mastication. In another study, the 
rate of nicotine release from four different brands of moist snuff (Copenhagen, Skoal 
Wintergeen long cut, Skoal Bandit Classic and Skoal Wintergreen Fine Cut) into simulated 
saliva was compared between a direct release and release through a dialysis bag (Nasr et al., 
1998). This is the only study that also investigated the effect of chewing action on in vitro 
nicotine release from smokeless tobacco products; chewing action was simulated manually by 
pressing with a glass rod (Nasr et al., 1998). There are also reports of devices that have been 
used for testing NRT gums. They have pistons for striking the gum base (Aslani and Rafiei, 
2012, Morjaria et al., 2004, Aslani and Rostami, 2015), according to the description of an 
appropriate apparatus including stainless steel pistons, operation temperature of 37°C and a 
chewing rate of 60 strikes per minute that is described in the European Pharmacopeia 
(European Pharmacopoeia, 2010). However, there has not been sufficient data in support of the 
suitability of this apparatus (Siewert et al., 2003). These methods have limitations such as 
expensive instrumentation and the fact that it is not possible to accurately reproduce the 
mastication process. 
In this study the nicotine release rate from dry and ready for mastication leaves of N. gossei, as 
the tobacco constituent of pituri, is compared with that from similar commercially available 
smokeless tobacco and nicotine replacement therapy products that share similar consumption 
route, i.e. via putting in the mouth and sucking or chewing. These are Swedish moist snuff or 
snus, which is a popular smokeless tobacco that only contains tobacco, a similar CORESTA 
reference smokeless tobacco product containing only tobacco (CRP2, Moist Snuff) and an NRT 
chewing gum. In addition, the effects of chewing action on the in vitro release of nicotine from 
these products and effect of alkaline pH on nicotine release from pituri is evaluated. A simple 
in vitro model was developed using a dissolution apparatus and different chewing conditions 
were performed manually to simulate the buccal conditions in a controlled and reproducible 
manner. Different chewing actions were designed to better simulate the conditions in smokeless 
tobacco products consumption, since these products are not chewed as much as the NRT gum 
and are mainly sucked in the mouth with occasional chewing. To get an idea of the potential 
for exposure to other chemicals that might be present in these products, the final release media 
in the vessels with most frequent chewing was also quantified for other alkaloids (nornicotine, 
anatabine, anabasine, myosmine and cotinine) and the carcinogenic TSNAs, N-
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nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). 
4.2 Materials and methods 
4.2.1 Materials 
Acetonitrile and methanol from Merck (Darmstadt, Germany), and ammonium formate from 
Sigma-Aldrich (St. Louis, MO) were used for preparing the mobile phase for HPLC-UV and 
LC-MS/MS analysis. The deionised water was from a Milli-Q system (Millipore, Billerica, 
MA). Sodium hydroxide and hydrochloric acid from Merck (Darmstadt, Germany) were used 
for adjusting pH. The analytical standards used for LC-MS/MS analysis of carcinogenic 
nitrosamines and HPLC-UV analysis of tobacco alkaloids were N’- nitrosonornicotine (NNN), 
4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK), nornicotine, myosmine and cotinine 
from Sigma, nicotine from Fluka (Milwaukee, WI), anabasine from Sigma-Aldrich, anatabine 
from Cayman Chemical Company (AnnArbor, MI). Caffeine from Ajax Finechem (Sydney, 
Australia) was used as the internal standard for HPLC-UV analysis, and N’- nitrosonornicotine-
d4 (NNN-d4) and 4-(methylnitrosoamino)-1-(3-pyridyl-d4)-1-butanone (NNK-d4) from 
Toronto Research Chemicals (Ontario, Canada) were internal standards for LC-MS analysis. 
Simulated saliva used in the study was formulated according to a standard formula consisting 
of KH2PO4 (2.5 mmol/L), Na2HPO4 (2.4 mmol/L), KHCO3 (15 mmol/L), NaCl 10mmol/L, 
MgCl2 (1.5 mmol/L), CaCl2 (1.5 mmol/L) and citric acid (0.15 mmol/L) (Morjaria et al., 2004), 
adjusted to pH 6.7 with sodium hydroxide or hydrochloric acid accordingly. This solution also 
consisted of 0.025 mg/ml of caffeine as an internal standard to be used in the chromatography 
analysis. To mimic the effect of the ash in increasing the pH of the mouth, the experiment for 
N. gossei dry leaves was repeated with simulated saliva adjusted to pH 9.0 with 1 N NaOH. 
Four products were studied: Air dried leaves of N. gossei ready for mastication (collected and 
dried in Alice Springs by an experienced botanist who is very well informed of Australian 
Nicotiana and pituri preparation and use), moist snuff (snus) portions (General Classic Extra 
Strong, made by Swedish Match, Sweden), CORESTA reference smokeless tobacco product 
(CRP2 Moist Snuff) obtained from North Carolina State University (Tobacco Analytical 
Services Laboratory) (Wagner et al., 2014) and Nicabate gum 4 mg (GlaxoSmithKline, 
Australia). The tobacco products used in this study were stored at -20°C between receipt and 
conducting the study. The quantity of each product used was standardized to contain 4 mg of 
nicotine to allow for consistent comparison. 
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4.2.2 Simulation of a model buccal cavity 
A model buccal cavity system was constructed by using simulated saliva as media in a USP 
dissolution test apparatus II fitted with small volume (100 ml) vessels (Agilent Technologies, 
Vic, Australia). Each tobacco product was immersed completely in 50 ml of the media in the 
dissolution vessel. The dissolution system settings used were 50 rpm paddle speed at bath and 
vessel temperature of 37°C. Samples (0.4 ml) were collected at 2, 5, 10, 15, 20, 30, 60, 90 and 
120 minutes using a 1 ml syringe attached to a stainless steel cannula with full flow filter (10 
μm, Agilent Technologies) and replaced immediately with 0.4 ml of fresh media. 
Three conditions were tested: no chewing action as a control, chewing for 30 seconds following 
immersion in simulated saliva and chewing for 30 seconds at 15-minute intervals. This chewing 
action was manually performed by pressing with a glass rod at a rate specified by the European 
Pharmacopoeia of one press each second (Siewert et al., 2003). Each experiment was replicated 
three times. The samples obtained were filtered through a 0.45 μm nylon filter (Grace Davison 
Discovery Sciences) to remove any impurities that may be present. 
4.2.3 Chemical analysis 
4.2.3.1 Nicotine and other alkaloids analysis with HPLC-UV 
The tested tobacco products, snus, CRP2 and N. gossei dry leaves were analysed for nicotine 
and other pyridine alkaloids in order to standardize the amount used to contain 4 mg of nicotine. 
Nicotine concentration in the dissolution media was assessed for each sample collection time. 
The concentrations of other alkaloids were quantified in the media for the simulated chewing 
every 15 minutes at the end of the 120 minute dissolution test. Analysis of the samples was 
performed using an Agilent Technologies 1200 series High Performance Liquid 
Chromatography (HPLC) system attached to a binary pump, degasser, an auto sampler, 
thermostat column compartment and a diode array detector following our previously validated 
method as mentioned in chapter 2 (Moghbel et al., 2015). 
4.2.3.2 TSNAs analysis with LC-MS/MS 
The media in the vessels with maximum chewing action for all tested products was quantified 
for two major TSNAs, NNN and NNK following the validated LC-MS/MS method reported 
previously as mentioned in chapter 2 (Moghbel et al., 2016).  
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4.2.4 Statistical analysis 
The four products and the three chewing conditions were compared using two-way ANOVA 
followed by Tukey multiple comparisons both for amount of nicotine released at each time 
point and for cumulative dissolution of nicotine. Total alkaloids and TSNA contents in 
smokeless tobacco products, and these concentrations in the media obtained from the release 
in the vessels with maximum chewing action for all were analysed for differences using two-
way ANOVA with Tukey multiple comparisons. All analysis was performed using GraphPad 
Prism version 6 (GraphPad software, San Diego, CA, USA). 
4.3 Results 
The CRP2 was most concentrated in nicotine, containing 12 mg/g, which was more than double 
that in N. gossei dry leaves (p<0.001), which in turn was significantly higher than that in snus 
(p<0.001) (Table 4-1). All three contained small quantities of the other alkaloids. Nornicotine 
was significantly higher in N. gossei dry leaves compared to snus (p<0.05), and CRP2 (p<0.01). 
The products were not significantly different in their anatabine and anabasine content. 
Myosmine or cotinine were not detected for any of the products. 
Table 4-1 Concentration (mg/g; mean ± se for 3 independent replicates) of nicotine and related alkaloids in 
smokeless tobacco products (fresh weight basis). For each alkaloid, mean values with the same superscript letter 
are not significantly different (p<0.05). 
 Products 
Alkaloid (mg/g) Snus CRP2 
N. gossei dry 
leaves 
Nicotine 4.083 ± 0.061a 11.97 ± 0.32 b 4.89 ± 0.29 c 
Nornicotine 0.117 ± 0.005 a 0.08 ± 0.04 a 0.41 ± 0.05b 
Anatabine BLQ 0.13 ± 0.02 0.08 ± 0.01 
Anabasine 0.094 ± 0.017 N.D. 0.14 ± 0.01 
Myosmine N.D. N.D. N.D. 
Cotinine N.D. N.D. N.D. 
N.D.: Not Detected 
BLQ: Below Limit of Quantification (1.7 µg/ml) 
The quantity of material equivalent in nicotine content to a 4 mg piece of nicotine chewing 
gum was used to test for nicotine release in a dissolution test (Table 4-1). CRP2 released the 
greatest quantity of nicotine within the first 10 minutes in comparison to the other products 
(p<0.001). Nicotine release from CRP2 reached the maximum (95-97%) by 30 minutes 
irrespective of chewing condition (Figure 4-1 A). Snus, which is a commercially available 
tobacco-based product, released 59% of total nicotine during the 120 minute test when left in 
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the vessel without any chewing action and a single press at the start did not affect this. More 
frequent chewing action by pressing at 15 min intervals resulted in an increase (p<0.001) in the 
maximal cumulative nicotine release to 66% (Figure 4-1 B). Nicotine dissolution from N. 
gossei leaves was similar to that of snus, reaching 63%, but with no effect (p>0.05) of chewing 
condition (Figure 4-1 C). Additionally, changing the pH of the release media to pH 9.0 did not 
affect the rate of release or final amount released (64%) (Figure 4-1 D). 
Nicabate gum showed the greatest effect of chewing, with 42% of the nicotine released when 
pressing occurred at 15-minute intervals and only 1.8% with no chewing (p≤0.0001). Even a 
single press at the start of the test resulted in greater nicotine release (5.8%) than no pressing 
at all, and the importance of chewing for gum was displayed clearly by the cumulative amount 
of nicotine released increasing each time a press was made (Figure 4-1 E). This consistent 
increase as a result of chewing was not observed with the other tested products, but in these 
test conditions the maximum released for gum (42%; 1.7 mg) was significantly lower (p<0.001) 
than that achieved by CRP2 (97%; 3.9 mg), N. gossei leaves (64%; 2.5 mg) or snus (66%; 2.6 
mg). 
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Figure 4-1 Percent cumulative release of nicotine from (A) CRP2 (B) Snus (C) N. gossei dry leaves (D) N. 
gossei dry leaves in alkaline media adjusted to pH 9 (E) and Nicabate gum in 3 conditions of without pressing, 
initial pressing for 30 seconds and pressing for 30 seconds at every 15 minutes. The data points show mean ± std 
error of 3 independent experiments. 
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The tobacco-based products also released other alkaloids into the dissolution media (Table 4-
2), with quantities released reflecting the relative concentration within the product (Table 4-1). 
As seen with the alkaloids, the two TSNAs that were measured in the release media, NNN and 
NNK, were highest for N. gossei dry leaves. Only nicotine was measured in the dissolution 
media for the chewing gum, with no evidence for the presence of tobacco alkaloids or TSNAs 
found. 
Table 4-2 Concentration of nicotine alkaloids and TSNAs (mean ± se of 3 replicates) released into 50 ml of 
simulated saliva in vessels with chewing at 15 minute intervals from smokeless tobacco products and Nicabate 
gum at 120 min. 
  Products 
  
Gum Snus CRP2 
N. gossei dry 
leaves 
N. gossei dry 
leaves-pH9 
Alkaloid (mg)      
Nicotine  1.681 ± 0.321
 a 2.636 ± 0.057 b 3.900 ± 0.067 c 2.537 ± 0.20 b 2.575 ± 0.008 b  
Nornicotine N.D. 0.104 ± 0.005
 ab 0.067 ± 0.006 ab 0.304 ± 0.016 c 0.210 ± 0.015 abc 
Anatabine N.D. N.D. 0.003 ± 0.003 0.028 ± 0.002 0.021 ± 0.002 
Anabasine N.D. 0.014 ± 0.065 N.D. 0.019 ± 0.005 0.034 ± 0.005 
Myosmine N.D. N.D. N.D. N.D. N.D. 
Cotinine N.D. N.D. N.D. N.D. N.D. 
TSNAs (µg)      
NNN N.D. 0.032 ± 0.095
a  0.067 ± 0.010 b 0.265 ± 0.025 c 0.129 ± 0.001 a 
NNK N.D. 0.014 ± 0.016
 a 0.037 ± 0.084 bc 0.089 ± 0.032 a  0.074 ± 0.065 a  
N.D.: Not Detected 
4.4 Discussion 
N. gossei dry leaves are used in preparation of pituri, which is a smokeless tobacco product 
with a lack of information available on its prevalence of use, chemical composition, nicotine 
release and absorption pattern. In this study, nicotine release from N. gossei dry leaves is 
compared with CRP2 and Swedish snus, which are used as smokeless tobacco products, and a 
nicotine replacement therapy chewing gum, Nicabate. A quantity of each product containing 4 
mg nicotine was used in the comparisons. 
N. gossei dry leaves released nicotine at a similar rate to snus, with the maximum of 63 and 
66% released at the end of the study for N. gossei dry leaves and snus, respectively. The 
nicotine content of N. gossei dry leaves used in this study (4.9 mg/g) was slightly but 
significantly higher than snus (4.1 mg/g), though N. gossei leaves can contain even higher 
levels of nicotine, with values between 6.2 and 17.0 mg/g of nicotine reported previously 
(Saitoh et al., 1985, Sisson and Severson, 1990). This may pose a potential health risk to the 
user as the exact amount of N. gossei dry leaves used in each quid will vary and excessive 
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nicotine levels lead to high blood pressure and significant cardiac risk (Council on Scientific 
Affairs, 1986, Gupta et al., 2007). The percentage of cumulative nicotine released from snus at 
the end of the first hour was 58%, which is less than reported previously for snus in the 
literature for the same duration using different apparatus (65% (Nasr et al., 1998) and 60%-
90% (Li et al., 2013)). The snus in the present study achieved this level of release (66%) by the 
end of the 2 hour duration tested. The in vitro studies performed to evaluate nicotine release in 
smokeless tobacco products are limited to studies on moist snuff (snus) (Li et al., 2013, Nasr 
et al., 1998) performed with a maximum measurement time of 60 minutes. In the present study 
a time of 120 minutes was used because moist snuff may be kept in the mouth for more than 
60 minutes; pouched snus is commonly used for 32-115 minutes with up to 124 minutes 
reported in male users (who tend to keep snus in their mouth for longer than female users), and 
loose snus was between 36-121 minutes with the longest time of 122 minutes in males (Gupta 
et al., 2007). The smokeless tobacco standard tested in this study, CRP2, released the highest 
cumulative amount of nicotine, with almost 97% of the 4 mg being released over the 2 hours. 
Nicabate gum released the lowest cumulative amount of nicotine (42%) in this study, and in 
contrast to the smokeless tobacco products, simulated chewing was clearly the essential 
component driving nicotine release. Reported in vitro measurements for nicotine gum 
formulations are much higher; 79-83% release for 18 different formulations (Aslani and Rafiei, 
2012) and 80-90% release for 3 formulations during a 1 hour period (Morjaria et al., 2004). 
However, in addition to Nicabate gum not being included in those studies, the experimental 
designs were quite different as they used a purpose-made mastication device with a piston that 
struck the gum in various points at a chewing rate of 1 strike per second applied continuously 
for 60 minutes (Aslani and Rafiei, 2012, Morjaria et al., 2004). This procedure is aligned with 
the European Pharmacopeia method for chewing gum (European Pharmacopoeia, 2010), for 
which the Erweka DRT-3 chewing gum dissolution tester has recently become available. To 
date the only published in vitro testing of release using this device is for the medicated chewing 
gums of dextromethorphan hydrobromide (Swamy et al., 2012) and so far there has not been 
any report for nicotine gum testing with this device. Nicotine chewing gums such as Nicabate 
are specifically designed to provide sustained release of small amounts of nicotine to help 
smokers gradually wean themselves off the addiction to nicotine or smoking (Hurt et al., 1995). 
The nicotine chewing gums have a fine sugar coating consisting of powdered sugar or a sugar 
substitute surrounding the gum base. This coating is formulated to prevent the gum from losing 
its adhesive property and to enhance the taste, and chewing causes the sugar coating to 
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disintegrate and the gum base to crumble and form a softer and smoother texture, thus 
promoting a faster release rate of nicotine. Nicotine gum is generally chewed until a tingling 
sensation is felt (associated with the nicotine absorption) and then placed against the buccal 
mucosa during periods without chewing. Although continuous application of 1 chew per 
second may be somewhat faster or constant than consumers use in practice, the strike rate 
indicated in the Pharmacopoeia (European Pharmacopoeia, 2010) provides a standard for 
comparison of nicotine chewing gum formulations. 
The maximum chew rate used in the present study, with the primary aim of investigating 
nicotine release from the tobacco component of pituri, was 1 press per second for 30 seconds 
applied at fifteen minute intervals, because pituri and snus are generally held in the buccal 
cavity for extended periods of time with occasional sucking and/or chewing (International 
Agency for Research on Cancer, 2007, Ratsch et al., 2010). Simulated chewing had little or no 
effect on increasing the release from snus, N. gossei dry leaves and CRP2, and they all had 
significantly faster initial release of nicotine compared to Nicabate gum. Indeed, in vivo studies 
on comparative release and absorption of nicotine from gum and smokeless tobacco products 
such as snus have shown the maximum concentration of nicotine in the blood resulting from 
one 4 mg nicotine chewing gum is achieved slower than Swedish snus and the maximum 
concentration is also lower (Benowitz et al., 1988, Lunell and Curvall, 2011). Swedish snus is 
a commercially manufactured product that is in powdered form sealed in a permeable sachet, 
so the total concentration of nicotine in each sachet available to be absorbed into the body can 
be known. Sucking the sachet enables saliva to diffuse through the sachet and, while chewing 
may be expected to speed up the release, in the present study chewing leads to a slightly faster 
release rate (7%) compared to no chewing. Finer tobacco leaves or the ‘fine-cut’ form with a 
smaller particle size have greater surface area to be penetrated with saliva and moistened, thus 
promoting fast diffusion of nicotine from the product and absorption into the mucosal 
membranes (Lunell and Curvall, 2011, Connolly, 1995). CRP2, which is also a manufactured 
moist snuff standard in powder form with small particle size and controlled levels of nicotine, 
pH and humidity (Wagner et al., 2014), showed a very fast release of nicotine without need for 
chewing. The N. gossei dry leaves used here, which are not commercially processed, exhibited 
large variation between replicates which is likely to be associated with variable nicotine 
distribution within the leaves and inconsistent particle size. 
To simulate the effect of ash in pituri formulation, the simulated saliva was adjusted to pH 9.0. 
The rate and quantity of nicotine released was unaffected. While there is no evidence that the 
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higher pH associated with the presence of ash affects nicotine release from the leaves, it may 
result in faster absorption across mucous membranes. In commercial tobacco products, the total 
nicotine amount available for uptake into the body can be manipulated by the pH of the 
surrounding environment, so snus is commonly combined with alkalinizing agents such as 
sodium carbonate and ammonium carbonate in order to increase the absorption rate (Tomar 
and Henningfield, 1997). 
As tobacco products originate from plant material, they may contain other alkaloids and 
TSNAs other than only nicotine. The simulated salivary fluid sampled at the end of the 2 hour 
dissolution test for the maximal chewing actions performed on the tobacco products, snus, N. 
gossei dry leaves and CRP2, contained other alkaloids and TSNAs. In contrast Nicabate gum 
released only nicotine (Table 4-2). The concentration of nornicotine was greatest in the 
simulated saliva from N. gossei dry leaves, followed by snus and CRP2. Nornicotine is linked 
to health hazards such as age-related macular degeneration (Brogan et al., 2005) and 
periodontal disease (Katz et al., 2005), which again is an indication of a higher health risk for 
pituri chewers. The simulated saliva at the end of testing with N. gossei dry leaves contained 
higher concentrations for both NNN and NNK than CRP2 or snus (Table 4-2). NNN and NNK 
are identified as the most prevalent strong carcinogens in unburned tobacco products. They are 
mainly produced via nitrosation of tobacco alkaloids after harvest and during processes like 
drying, curing, ageing and especially fermentation (Brunnemann et al., 1996). 
4.5 Conclusion 
Dry leaves of N. gossei used in pituri, an indigenous smokeless tobacco product that is held in 
the mouth with occasional sucking or chewing, contain higher nicotine content than 
commercially available smokeless tobacco products such as snus and, in the absence of 
continuous chewing action, higher release rate than Nicabate chewing gum. In addition to high 
levels of nicotine, higher concentrations of other alkaloids and carcinogenic compounds are 
also released into the saliva of the users of N. gossei. Further studies are recommended in order 
to specifically investigate the pharmacokinetics of the nicotine and other alkaloids released 
from pituri in comparison to the similar products.  These all help in better understanding how 
pituri use affects both health outcomes and quality of life as it remains widely used by the 
Aboriginal population of central Australia.
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 The alkaloids chemistry and in vitro 
cytotoxicity of the Nicotiana gossei 
leaves used in Australian Aboriginal 
smokeless tobacco, ‘pituri’ compared 
to nicotine  
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5.1 Introduction 
Smokeless tobacco products are considered by many to be less hazardous than cigarette 
smoking and therefore a suitable substitute to promote harm reduction (Benowitz, 2011). 
Indeed, smokeless tobacco can deliver similar quantities of nicotine as smoking and avoids 
exposure to an extensive suite of deleterious chemicals present in smoke (International Agency 
for Research on Cancer, 2007). However, there is global concern about increasing the 
consumption of smokeless tobacco due to its adverse effects on human health. Smokeless 
tobacco products have different health effects than smoked tobacco, but few smokeless tobacco 
products have been studied for the health outcomes and diseases they may cause (Ebbert et al., 
2004, Scollo and Winstanley, 2015). A short-term increase of blood pressure and heart rate is 
attributed to smokeless tobacco use, and users are more at risk of dying from stroke and heart 
disease (International Agency for Research on Cancer, 2007). Also, significant effects on the 
soft and hard tissues of the mouth caused by smokeless tobacco can lead to oral disease such 
as bad breath, tooth decay, receding gums, leucoplakia and lesions in the mouth (Critchley and 
Unal, 2003, International Agency for Research on Cancer, 2007). In pregnant women using 
smokeless tobacco, there is a high risk of low birth weight, premature birth and preeclampsia 
(Critchley and Unal, 2003, Ebbert et al., 2004, International Agency for Research on Cancer, 
2007). In male users of smokeless tobacco, there is an increase in number of abnormal sperm, 
while sperm count and semen volume decrease (International Agency for Research on Cancer, 
2007). Based on animal and epidemiological studies, smokeless tobacco products have been 
classified as carcinogenic to humans (Hecht, 2003, International Agency for Research on 
Cancer, 2007), with mouth cancer being the most prevalent cancer type (Ebbert et al., 2004) 
though cancer of the pancreas and oesophagus have also been reported to be caused by 
smokeless tobacco products (Secretan et al., 2009). The carcinogenicity of tobacco products is 
mainly attributed to tobacco-specific N-nitrosamines (TSNAs), which are nitrosated 
derivatives of tobacco alkaloids. The main two TSNAs are N-nitrosonornicotine (NNN) and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK); both have been classified as group 1 
human carcinogens by the International Agency for Research on Cancer (IARC) (Hecht, 1998, 
International Agency for Research on Cancer, 2007). 
The two main types of smokeless tobacco products are snuff and chewing tobacco (Ebbert et 
al., 2004) and there are a wide range of products used around the world. Snuff is prepared from 
cured and ground leaves of Nicotiana spp., and can be held in the mouth and sucked or inhaled 
(in its dry form). Chewing tobacco consists of Nicotiana spp. leaves chewed in combination 
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with substances such as lime, betel leaf or areca nut (Scollo and Winstanley, 2015). Smokeless 
tobacco products vary in their composition and process of production, so each smokeless 
tobacco product will vary in terms of chemical composition and consequently pharmacological 
activity (Ebbert et al., 2004, Scollo and Winstanley, 2015). 
Tobacco plants are chewed by indigenous populations of the Americas, Africa, the Indian 
subcontinent and the Asia-Pacific region (Latz et al., 1995, International Agency for Research 
on Cancer, 2007). A range of endemic Nicotiana species, such as N. gossei and N. excelsior, 
are chewed by indigenous Australian people, primarily in the central region of Australia (Latz 
et al., 1995). Pituri is the most commonly recognised word used for this (Latz et al., 1995, 
Peterson, 1979, Young, 2005, Ratsch et al., 2010), though there are a variety of synonyms such 
as mingkulpa (Ratsch et al., 2010, Young, 2005) also in use. Currently there is no national or 
international acknowledgement of the existence of chewed tobacco use by Australian 
indigenous people. Australia was not mentioned in the IARC monographs on smokeless 
tobacco (International Agency For Research On Cancer, 2012, International Agency for 
Research on Cancer, 2007) published by the World Health Organisation, yet pituri chewing is 
a common feature in everyday life of contemporary Aboriginal populations in Central Australia 
and other areas; 41% of Aboriginal people in Central Australia were chewing pituri according 
to a survey conducted in 1987 (Fleming et al., 1991) and in a recent study over 30% of 
Aboriginal women giving birth at a large hospital regularly chew pituri throughout pregnancy 
and lactation (Ratsch, 2011). 
To prepare pituri, fresh or dry leaves of Nicotiana are broken into pieces, mixed with burnt 
wood ash and chewed to form a ‘quid’ (Latz et al., 1995, Ratsch et al., 2010) (Watson et al., 
1983). A range of wood is burned to form the ash; some species mentioned in the literature are 
Acacia spp., Grevillea spp. and Eucalyptus spp. (Peterson, 1979), with Acacia salicina being 
a particular preference because it has been reported to contain high levels (51%) of calcium 
sulphate and is considered to be a very alkaline plant ash (Higgin, 1903). Pituri is held in the 
mouth, the lower lip and buccal cavity or the cheek, for extended periods of time for absorption. 
The oral cavity has a thin epithelium and rich blood supply so absorption of the nicotine is fast 
and avoids first pass metabolism (Hukkanen et al., 2005). The quid may be passed between 
chewers and stored behind the ear, under a breast, under an arm-band or a head-band when not 
being chewed (Peterson, 1979). A quid may be retained in the buccal cavity overnight, enabling 
continuous exposure (Ratsch et al., 2010). The way in which pituri is prepared and used is 
similar to iq’mik used by indigenous people in Alaska (International Agency for Research on 
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Cancer, 2007, Hearn et al., 2013) and maras from Turkey (International Agency for Research 
on Cancer, 2007). 
In vitro studies have been used to elucidate any cell-specific effects of smokeless tobacco 
consumption that can indicate possible toxicity and carcinogenicity of smokeless tobacco 
chemicals in humans. There have been reports of cytotoxicity caused by smokeless tobacco 
products such as gutkha (Avti et al., 2010), khaini (Das et al., 2013), Sudanese toombak (Costea 
et al., 2010), American moist snuff (Misra et al., 2014), Swedish moist snuff (Coggins et al., 
2012, Costea et al., 2010), Kentucky reference moist smokeless tobacco product (Lombard et 
al., 2010) and commercial chewing tobacco (Coppe et al., 2008). The present study is the first 
assessment of cytotoxicity induced by tobacco constituents of pituri as a means of investigating 
its potential carcinogenicity. Direct comparison is made for N. gossei leaves which are the main 
ingredients of pituri and the main source of nicotine for chewers, with pure nicotine and with 
an official reference chewing tobacco (CRP2) which also contains only tobacco. 
5.2 Materials and methods 
5.2.1 Chemicals and reagents 
The solvents used for HPLC analysis were acetonitrile, from Merck (Darmstadt, Germany), 
and buffer prepared using ammonium formate from Sigma-Aldrich (St. Louis, MO). The water 
was deionised and filtered using a Milli-Q system (Millipore, Billerica, MA). Hydrochloric 
acid and sodium hydroxide used for adjusting pH were from Merck (Darmstadt, Germany). 
The analytical standards used were N’-nitrosonornicotine (NNN), 4-(methylnitrosoamino)-1-
(3-pyridyl)-1-butanone (NNK), nornicotine, myosmine and cotinine from Sigma, nicotine from 
Fluka (Milwaukee, WI), anabasine from Sigma-Aldrich, anatabine from Cayman Chemical 
Company (AnnArbor, MI), and the internal standards used were caffeine from Ajax Finechem 
(Sydney, Australia) for HPLC-UV analysis and N’-nitrosonornicotine-d4 (NNN-d4) and 4-
(methylnitrosoamino)-1-(3-pyridyl-d4)-1-butanone (NNK-d4) from Toronto Research 
Chemicals (Ontario, Canada) for LC-MS analysis. Reagents and culture medium used for cell 
culture including DMEM/F-12 (Dulbecco’s Modified Eagle Medium, nutrient mixture F-
12), FBS (Fetal Bovine Serum) and Trypsin-EDTA (0.25%) were from Gibco (Thermo Fisher 
Scientific, Vic, Australia). Triton X-100 solution used as positive control was from Sigma-
Aldrich (St. Louis, MO). MTS assay reagent, CellTiter 96 AQueous One Solution Assay was 
from Promega (Madison, WI). 
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5.2.2 Preparation of extracts 
Aqueous extracts of air dried ready for mastication leaves of N. gossei (pituri) collected in 
Alice Springs NT, Australia and Coresta reference smokeless tobacco product (CRP2 Moist 
Snuff) obtained from North Carolina State University (Tobacco Analytical Services 
Laboratory) stored at -20°C (Wagner et al., 2014) were prepared according to the method 
described by Coggins et al. (Coggins et al., 2012) with some modifications. Water (20 ml) was 
added to 1 g of material in a 50 ml tube and homogenised gently before incubating at 37°C 
with shaking for 24 hours. The mixture was centrifuged for 20 min at approximately 5000 g, 
the supernatant was decanted into an empty tube and centrifuged again at 5000 g for 20 
minutes. The supernatant was decanted again and the pH was adjusted to 7.4 ± 0.2 with 1 M 
hydrochloric acid or 1 M sodium hydroxide. The final extracts were pre-filtered through 0.45 
μm nylon filter (Grace Davison, Discovery Sciences) to remove fine particulates and finally 
filter-sterilized using a nylon filter with 0.2 μm pore size (Grace Davison, Discovery Sciences). 
The sterile filtrate was then lyophilized and stored at -80°C to be used for chemical analysis 
and preparing stock concentrations in sterile media as required for experiments (Das et al., 
2013). All containers and solutions used in the extraction steps were sterilised prior to use in 
order to prevent contamination. 
5.2.3 Quantification of nicotine and other alkaloids 
The freeze-dried extracts from pituri leaves and CRP2 were quantified for nicotine and other 
alkaloids in order to determine the concentrations for treatments. Chemical analysis of the 
extracts was carried out on an Agilent 1100 series high performance liquid chromatography 
(HPLC) system equipped with a UV detector and Zorbax Extend C18 column (Agilent 
Technologies, Mulgrave, Vic, Australia) with a mobile phase consisting of 15 mM ammonium 
formate buffer and acetonitrile according to our previously validated method as mentioned in 
chapter 2 (Moghbel et al., 2015). The powdered extracts were dissolved in 10% aqueous 
acetonitrile containing 25 mg/ml caffeine as internal standard and quantification was performed 
using a constructed calibration curve of nicotine, nornicotine, anatabine, anabasine, myosmine 
and cotinine over a range of concentrations in 10% aqueous acetonitrile. 
5.2.4 Quantification of NNN and NNK 
SLT products, pituri leaves, CRP2, and their freeze-dried extracts, were quantified for two 
major TSNAs, NNN and NNK using LC-MS/MS. The analysis was performed on a 2.1 × 150 
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mm Poroshell 120 HILIC column with 2.7 µm particle size (Agilent Technologies). The MS-
MS detection and quantification was performed following the validated LC-MS/MS method 
described in chapter 2. 
5.2.5 Cell culture, treatment and viability assay 
Human Lung Carcinoma Epithelial Cells (A549), provided by Professor Tom Gonda (School 
of Pharmacy, The University of Queensland), were seeded onto T25 plastic tissue culture flasks 
in DMEM-F12 medium containing 10% FBS, and incubated at 37°C in a 5% CO2-air 
humidified incubator. Passaging of the cells was carried out at 3-day intervals when cell growth 
in culture flasks reached about 80% confluency. For experimental cultures, cells were detached 
by trypsinisation using trypsin-EDTA solution (0.25% trypsin, 0.53 mM MEDTA-4Na). The 
detached cells were suspended in culture medium and then centrifuged at 1500 rpm for 2 min. 
The resulting cell pellet was resuspended in media, the number of cells determined using a 
hemocytometer, cells plated at a density of 1×104 cells per well in 96-well culture plates and 
incubated overnight to allow adequate attachment of cells. Triplicate sets of cells were treated 
with 2, 10, 20, 50 mg/ml of the aqueous extracts from pituri leaves or CRP2 dissolved in 
DMEM-F12, or nicotine standard in DMEM-F12 at a concentration range covering the 
corresponding concentrations present in the extracts (0.1, 0.2, 0.5, 1 and 1.5 mg/ml), and 
incubated for 1, 3, 6 and 24 hours at 37°C. Triplicate sets of cells were treated with DMEM-
F12 medium as a negative control, or 1% Triton X-100 in DMEM-F12 medium as a positive 
control. 
Cytotoxicity testing was carried out using the Promega CellTiter 96 AQueous One Solution 
Assay (MTS) to estimate the viability of cells in culture according to the manufacturer’s 
instructions and Malich et al. (Malich et al., 1997). The AQueous One Solution reagent (20 
µL) was added to each well and the culture plates were incubated for 3 h before measuring the 
absorbance at 490 nm with iMark microplate reader (Bio-Rad, NSW, Australia). The 
absorbance at 490 nm, which corresponds to the quantity of formazan product, is proportional 
to the number of living cells in the culture. To correct for the potential for the extracts to 
contribute to the absorbance, triplicate sets of blank wells without cells were treated and tested 
in exactly the same way and their absorbance at 490 nm measured. The cell viability (%) was 
calculated as (abs-t – abs-b)/abs-c × 100, where abs-t is the average absorbance of treated wells, 
abs-b is the average absorbance of blank wells, and abs-c is the average absorbance of control 
wells containing only cell culture medium. Each experiment was performed in triplicate. 
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5.2.6 Data analysis 
The cell viability values obtained after 24 hours treatment of the cells with 2, 10, 20 and 50 
mg/ml of the aqueous extracts of both pituri leaves and CRP2 were used for calculating IC50. 
For nicotine, in addition to 0.1, 0.2, 0.5, 1 and 1.5 mg/ml, which were used as comparable 
concentrations of the nicotine present in the extracts, treatments with 5 and 10 mg/ml were 
included for calculating the IC50.  
Prism (GraphPad, San Diego, CA) was used to conduct statistical analysis. One-way analysis 
of variance (ANOVA) with Bonferroni multiple comparisons test were applied. Values of p < 
0.05 were considered to be significant. 
5.3 Results 
5.3.1 Chemical analysis of the extracts 
Concentrations of nicotine and other alkaloids and two major carcinogenic TSNAs, NNN and 
NNK, were assessed in the aqueous extracts from pituri leaf and CRP2 snuff and the results 
were used to calculate the concentrations present in the original dry leaves and snuff product, 
respectively. Nicotine was the main alkaloid constituent in pituri leaf (4.8 mg/g) and CRP2 
(11.97 mg/g) (Table 5-1). A much smaller quantity of nornicotine was extracted from both 
products, but at a greater concentration from the pituri leaves (0.4 mg/g) than CRP2 (0.08 
mg/g). Low levels of anatabine and anabasine were also quantified in both extracts (Table 5-
1). 
Table 5-1 Alkaloid and TSNA composition (mean ± se for 3 independent replicates) of the Coresta reference 
smokeless tobacco product (CRP2 Moist Snuff) and dry leaves of Nicotiana gossei, along with freeze-dried 
aqueous extracts of CRP2 and dry leaves of N. gossei. ND: not detected. 
 
Concentration in original product (fresh 
weight) 
Concentration in freeze-dried aqueous extract 
(dry weight) 
 N. gossei dry leaves CRP2 N. gossei dry leaves CRP2 
Alkaloid (mg/g) 
Nicotine 4.89 ± 0.29 11.97 ± 0.32 25.54 ± 2.10 26.37 ± 0.70 
Nornicotine 0.41 ± 0.05 0.077 ± 0.04 2.15 ± 0.20 0.17 ± 0.09 
Anatabine 0.08 ± 0.01 0.13 ± 0.02 0.41 ± 0.04 0.30 ± 0.01 
Anabasine 0.14 ± 0.01 ND 0.14 ± 0.02 ND 
Myosmine ND ND ND ND 
Cotinine ND ND ND ND 
TSNAs (µg/g) 
NNN 8.37 ± 2.22 2.39 ± 1.42 43.70 ± 14.49 10.52 ± 6.24 
NNK 6.91 ± 0.07 0.36 ± 0.01 36.07 ± 0.35 3.21 ± 0.02 
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Neither of the extracts contained myosmine and cotinine, both of which would have been 
detected and quantified by the HPLC-UV method if they were present at levels above 1.2 and 
1.8 µg/ml, respectively. The concentration of nicotine in CRP2 moist snuff measured here was 
the same as that reported during official annual testing (12 mg/g) (Wagner et al., 2014). The 
alkaloid composition of N. gossei was lower than that reported previously for this species (6.2 
– 16.8 mg/g dw) (Saitoh et al., 1985, Sisson and Severson, 1990), which is a reflection of the 
very different seed source, growth environment and chemical extraction method used between 
studies. 
This study is the first to report the concentration of NNN and NNK in pituri leaves; NNN was 
present at 8.37 µg/g and NNK was 6.91 µg/g. The concentration of NNN and NNK have been 
analysed in CRP2 in different years (2010, 2011) and different laboratories, and ranged from 
1.439 to 2.157 µg/g for NNN and 0.370 to 0.537 µg/g for NNK (Wagner et al., 2014). The 
concentration quantified in this study was 2.39 ± 1.42 and 0.36 ± 0.01 µg/g of original CRP2 
product for NNN and NNK, respectively (Table 5-1). 
5.3.2 Effect of nicotine and smokeless tobacco extracts on cell viability 
Four concentrations of the aqueous extract from N. gossei leaves and CRP2 were tested for 
cytotoxicity: 2, 10, 20 and 50 mg/ml dissolved in DMEM-F12 medium. Based on the values in 
Table 5-1, the concentration of nicotine in these four quantities of aqueous extract from pituri 
leaves was calculated to be 0.051, 0.255, 0.511 and 1.270 mg/ml respectively, and for the 
aqueous extract from CRP2 the values were 0.053, 0.264, 0528 and 1.320, respectively. A 
corresponding concentration range of the nicotine standard was selected for testing, i.e. 0.05, 
0.2, 0.5, 1 and 1.5 mg/ml. The growth of the cells was negatively affected by increasing 
concentrations and duration of treatment for both extracts (Fig. 5-1 A, B). For the 10 mg/ml 
concentration of extract from pituri leaves only 20% of the cells survived at 24 hours of 
cultivation while the inhibition was almost three-fold lower for CRP2 with about 60% of 
survival for the same duration of exposure to 10 mg/ml of the extract (p< 0.05). Both extracts 
resulted in significant reduction of viability after 24 hours of treatment at concentration of 20 
mg/ml with viability reaching 5 and 24% for the extracts from pituri leaves and CRP2, 
respectively (P< 0.01). The maximum inhibition for both products was caused by treating the 
cells with 50 mg/ml of extracts for 24 hours, resulting in only 1.5 and 6% viability for extracts 
from pituri leaves and CRP2, respectively (p< 0.001) (Fig. 5-1 A, B). 
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Figure 5-1 MTS assay results showing the effects of A) aqueous extract of N. gossei leaves used in pituri and B) 
aqueous extract of CRP2 on cell viability of human lung epithelial cells (A549). Applied concentrations of both 
extracts were 2, 10, 20, 50 mg/ml that were equivalent to approximately 0.05, 0.2, 0.5, 1-1.5 mg/ml of nicotine 
respectively. The data show the mean ± SEM of the 3 replicate experiments.  
Exposing cells to nicotine alone also resulted in a decrease in cell viability. This was 
remarkably lower than observed for pituri leaf and CRP2 extracts. The nicotine concentrations 
of 1 and 1.5 mg/ml, between which lies the concentration of nicotine found in 50 mg/ml of 
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extracts from pituri leaves and CRP2, resulted in cell viability of 86.4 and 76.8%, respectively, 
for 24 hour treatments of the cells (Fig. 5-2). 
Figure 5-2 MTS assay results showing the effects of a concentration range of nicotine standard on cell viability 
of human lung epithelial cells (A549). Concentrations of 0.05 to 1.5 mg/ml covers the concentration range found 
in the 2-50 mg/ml of the pituri leaf and CRP2 extracts. Higher concentrations of 5 and 10 mg/ml were applied for 
calculation of IC50. The data show the mean ± SEM of the 3 replicate experiments. . 
Figure 5-3 Nicotine equivalent concentrations of extracts from pituri leaves and CRP2, and concentration of 
nicotine standard that resulted in 50% inhibition of growth in human lung epithelial cells (A549). The data show 
the mean ± SEM of the 3 replicate experiments. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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The concentrations causing 50% inhibition of cell growth (IC50) after 24 hours incubation were 
9.1 mg/ml of the aqueous extract from pituri and 32.5 mg/ml of the aqueous extract from CRP2. 
Calculated in terms of their nicotine equivalent concentrations (Fig. 5-3), the IC50 was 0.23 
mg/ml for pituri leaves and 0.85 mg/ml for CRP2. The IC50 for nicotine was 5.6 mg/ml for the 
same treatment duration, which is substantially higher than both pituri and CRP2 (P<0.01) (Fig. 
5-3). 
5.4 Discussion 
Nicotine is the most abundant alkaloid (~95%) in tobacco plants and products such as snuff, 
chewing tobacco and pituri and some of them can deliver higher doses of nicotine than 
cigarettes. Nicotine from smokeless tobacco products is readily absorbed through the lining of 
the mouth or the nose (Scollo and Winstanley, 2015) and although absorption is slower than 
that from cigarettes, blood levels of nicotine in users can be similar to that in smokers 
(International Agency for Research on Cancer, 2007). Nicotine has been shown to cause cell 
cycle arrest and growth inhibition (Lee et al., 2005). It also causes selective mutagenesis that 
relates to an increased risk of squamous cell carcinoma (Waggoner and Wang, 1994) and 
induces differentiation in immortalized oral keratinocytes (Lee et al., 2005) 
According to our results, a large amount of nicotine is required to cause toxicity in the human 
lung epithelial cells (A549) used here. Toxic effects of nicotine usually require higher 
concentrations than is physiologically attainable and can vary with cell type (Lee et al., 2005). 
It has been reported that the concentration of nicotine in the blood of smokers (~100 nM or 
16.2 ng/ml) does not affect the growth of several lines of lung cancer cells (Maneckjee and 
Minna, 1990). In contrast, some studies reported the positive effects of nicotine on cell growth 
in other cell types, such as primary human endothelial cells at 50 ng/ ml (Boutherin-Falson and 
Blaes, 1990) and lung cancer line neuroendocrine carcinoma at concentration of 1 M (162 
ng/ml) (Schuller, 1989). In our study the growth of lung epithelial cells remained unaffected 
until 6 and 24 hours treatment with 1.5 mg/ml of nicotine, and all the treatments with 5 and 10 
mg/ml nicotine significantly decreased cell viability (p < 0.05). 
The cytotoxic effect on mitochondrial function of aqueous extracts from dry leaves of N. 
gossei, as the main ingredient of pituri, and reference smokeless tobacco products (CRP2) was 
measured. The IC50 calculated for 24 hours of treatment were 0.23 and 0.86 mg/ml for pituri 
leaves and CRP2, respectively, which is substantially lower than the IC50 for nicotine (5.6 
mg/ml). In fact, the quantity of extract giving rise to this concentration of nicotine would be 
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220 and 212 mg/ml for pituri leaves and CRP2, respectively, indicating that the smokeless 
tobacco extracts exhibited greater toxicity than nicotine is responsible for. Nicotine can inhibit 
cell growth and proliferation (Chang et al., 2002)and can cause chromosome aberrations, but 
only in higher dose (Trivedi et al., 1990). Nicotine has been reported to increase the 
intracellular thiol level (Chang et al., 2002), but the levels of glutathione (GSH) and 
malondialdehyde (MDA) is higher in cells exposed to smokeless tobacco extracts than those 
exposed to only nicotine. This suggests that nicotine is less effective in induction of oxidative 
stress than the extracts of smokeless tobacco which contain other active compounds (Yildiz et 
al., 1999). These compounds trigger the formation of harmful free radicals. Pituri is prepared 
from a range of wild Australian species of Nicotiana, the major species being N. gossei. Other 
biologically active compounds are present in smokeless tobacco, such as the other alkaloids 
measured here (Table 5-1). More importantly, during curing and fermentation, tobacco 
alkaloids can give rise to tobacco specific N-nitrosamines via nitrosation which are by far the 
most prevalent strong carcinogens in unburned tobacco products (Hecht, 2003). Their levels 
per unit dose are reported to be even higher in SLTs compared with the levels in the mainstream 
cigarette smoke. TSNAs have been detected and measured in fresh leaves of tobacco plants, 
but drying is the main driver to increase levels by about 6 fold. Levels of TNSAs vary 
considerably between different smokeless tobacco products due to differences in type of 
product (manufactured, indigenous), type of tobacco plants used, climatic conditions, post-
harvest processing and curing methods, storage conditions and the applied analytical methods 
(International Agency for Research on Cancer, 2007). Two specific TSNAs, NNK and NNN, 
are believed to be involved in the induction of oral cancer in SLT users (Hecht, 2003), while 
N-nitrosoanabasine (NAB) is reported to be a weak carcinogen and N-nitrosoanatabine (NAT) 
apparently lacks activity (Hecht et al., 1983). Levels range from 3 mg of NNN and 8 mg of 
NNK in each gram of Toombak, which is an SLT used in Sudan, to 0.5 and 0.1 µg/g of NNN 
and NNK, respectively in Naswar from Uzbekistan (International Agency for Research on 
Cancer, 2007). Smokeless tobacco from Australia was not included in this international 
comparison of TSNA levels. The present study has measured dry Nicotiana leaf used in the 
preparation of pituri rather than the prepared smokeless tobacco product, but the levels of NNN 
(8.37 µg/g) and NNK (6.91 µg/g) are consistent with smokeless tobacco products in use around 
the world. NNN and NNK have been extensively studied for their mechanism of action in 
different model tissues (Hecht et al., 1983). Their metabolic transformation through -
hydroxylation is believed to be important in making them electrophilic and leading to their 
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binding to nucleophilic centres in DNA. This binding results in point mutations that can 
eventually activate oncogenes (Barbacid, 1986). Other than nitrosamines, PAHs such as 
benzo(a)pyrene that are present in smokeless tobacco products, have been reported to form 
covalent bonds with DNA, triggering carcinogenesis (Hoffmann and Hecht, 1990). 
5.5 Conclusion 
In conclusion, this study has taken the first steps in considering the potential for negative 
consequences of pituri use. We have demonstrated that the induced cell death of human lung 
epithelial cells by aqueous extracts from pituri leaves and CRP2 is much higher than that by 
nicotine alone and that carcinogenic TSNAs are present in pituri.
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6.1 Summary and conclusions 
Smokeless tobacco products, commercially manufactured or traditional, are relatively similar 
to smoked tobacco in terms of health outcomes and causing addiction, although they are 
considered to cause milder harms and in some cases recommended as possible substitute in 
quit smoking schemes (Arabi, 2008). The urgent need for further evaluation of their chemical 
composition for risk assessment purposes has resulted in studies mainly on manufactured and 
commercially available products such as American and Swedish snus (International Agency 
for Research on Cancer, 2007). Nicotiana tabacum is the main species in tobacco products and 
therefore has been studied extensively for its alkaloid chemistry and biosynthetic pathways 
(Dewey and Xie, 2013). In addition to nicotine, the production of certain other alkaloids, 
particularly nornicotine, is more important from a health perspective because of its higher risk 
to users, and consequently the tobacco industry has been focused on breeding low nornicotine 
producing varieties (Roberts, 1988). 
Australian Nicotiana species have received very little attention, largely because so little is 
known about the extent of their use. Some of these species have a traditional use as pituri, a 
smokeless tobacco used by Aboriginal Australians in Central Australia (Ratsch et al., 2010). 
Hence, the overall objective of this thesis was to investigate the Nicotiana component of pituri 
in terms of pyridine alkaloids and tobacco-specific nitrosamines, their production, release and 
toxicity. This was dealt with by addressing four aims, and each of these will be discussed below 
before subsequently consider wider implications of the findings. As the focus of the study was 
on the chemistry of species due to their use in pituri, the nicotine release from the most common 
species chewed in pituri was investigated in the presence and absence of mastication and 
compared to the similar smokeless tobacco products and a commercial nicotine chewing gum. 
Finally the potential of the most common species used in pituri to be cytotoxic was investigated 
and compared to a standard smokeless tobacco and pure nicotine in the same concentrations as 
found in pituri. 
AIM 1: to establish suitable analytical methods to ensure reliable and efficient chemical 
analysis that was planned for the alkaloid characterisation of the studied species, and alkaloids 
and TSNAs analysis of the products used in different phases of the study.  
A new method was developed, optimised and validated for quantitation of alkaloids. This is a 
faster and more efficient HPLC-UV method than any previously available in the literature, and 
allows quantitative analysis of six alkaloids, nicotine, nornicotine, anatabine, anabasine, 
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myosmine and cotinine, in tobacco plants and products (Moghbel et al., 2015). Also an efficient 
LC-MS/MS method was adopted from published methods and validated in our lab for 
quantifying the two important carcinogenic TSNAs, NNN and NNK that stem from tobacco 
alkaloids during post-harvest processing of tobacco products. The validation results proved the 
efficiency of both developed methods to meet the aim to quantify the target alkaloids and 
TSNAs in studied plants and products (Chapter 2). 
AIM 2: To determine the abundance of psychoactive alkaloids in Australian Nicotiana species, 
and to consider the nicotine to nornicotine conversion characteristics in some nicotine 
dominant versus nornicotine dominant species. 
There are 26 Nicotiana species and subspecies currently recognised as Australian, all within 
the section Suaveolentes. A range of these species have been reported to be used by Aboriginal 
Australians for the preparation of smokeless tobacco known as pituri or mingkulpa (Latz et al., 
1995, Peterson, 1979, Symon, 2005). The leaves are used either fresh or fire/sun dried and are 
mixed with ash that is prepared by burning wood such as Acacia. The mixture is then chewed 
to make a ‘quid’ (Latz et al., 1995, Ratsch et al., 2010, Watson et al., 1983). The particular 
species used in pituri can be quite variable and depends on availability in any given geographic 
location (Latz et al., 1995). Therefore the aim was to investigate all 26 Australian taxa of 
Nicotiana to ensure all of those potentially used for chewing were included. One approach for 
studying the chemistry of all these species was collecting their leaves from the plants grown in 
their natural habitat for analysis, but the wide distribution of the species and the need for proper 
identification before collection of their leaves made this option too difficult to achieve within 
a reasonable timeframe. More importantly, since the chemical composition of the leaves could 
be affected by their different geographical localization, it was decided to grow them all from 
seed under the same condition to obtain the needed leaf samples for chemical analysis. 
Therefore, a total of 73 seedlots (Apendix 1) were obtained from seed banks, botanic gardens 
and herbaria across Australia to grow all the taxa. However, some of the seedlots were from 
very old collections, also not all of the obtained seedlots were stored and maintained properly 
before receipt; hence the majority of them didn’t have sufficient viability and failed 
germination. Out of the 73, only 29 seedlots covering 24 taxa achieved satisfactory germination 
and resulted in healthy plants that were then used for different analysis in the course of this 
study. These covered the main species that have been reported or are likely to be chewed due 
to their distribution across the areas where pituri chewing is reported to be practiced. The 
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remaining 2 taxa for which no reliable seed source or germination was obtained have very 
restricted distribution (Ladiges et al., 2011) and most probably aren’t used for chewing. 
Chemical analysis of the 24 species confirmed the hypothesis that Australian Nicotiana spp. 
have different levels of alkaloids and nicotine to nornicotine conversion phenotypes, although 
the conversion locus is present in all. The main species preferred to be chewed by Aboriginal 
pituri users are amongst rather safer, nicotine dominant species. These include N. gossei and 
N. excelsior, both of which are low or nonconverters. N. benthamiana, also a low converter, 
has been reported to be chewed mainly by Western Australian Aboriginals (Latz et al., 1995, 
Symon, 2005). However, there are reports in the literature of more hazardous high converter 
species consumption in some areas. These include N. cavicola in Western Australia (Symon, 
2005) and N. goodspeedii by Aboriginal people at the western end of the Nullarbor Plain in 
Western Australia (Symon, 2005). N. rosulata ssp. ingulba, a medium converter has been also 
a preferred species for chewing due to its availability in Central Australia (Latz et al., 1995, 
Peterson, 1979, Symon, 2005). There are also reports mentioning some high converters as 
rarely used or specifically avoided which include N. megalosiphon ssp. megalosiphon, N. 
simulans, N. occidentalis ssp. occidentalis and N. velutina (Latz et al., 1995, Peterson, 1979, 
Symon, 2005). Therefore, the nicotine to nornicotine conversion, which is regulated by a group 
of cytochrome P450 genes that encode active demethylase enzymes (Siminszky et al., 2005), 
was further studied in six selected species with different conversion and nicotine or nornicotine 
accumulation capability by investigating the functionality of the locus before and after curing 
the leaves with heat. The studied species included N. gossei, N. excelsior and N. benthamiana 
as none or low converters and N. cavicola, N. goodspeedii and N. velutina as high converters 
of nicotine to nornicotine. The active genes have been reported to be triggered to express more 
by drying or curing and also during senescence (Lewis et al., 2010). The result obtained in this 
study also confirmed the hypothesis on the importance of the curing process in increasing the 
transcription of the functional locus that are active only in high converter species. Leaves from 
Nicotiana plants used in pituri preparation might undergo a sun or fire drying process that can 
lead to higher accumulation of nornicotine in high converter chewed species which can in turn, 
result in higher toxicity with nornicotine and its derivative carcinogenic TSNA, NNN (Chapter 
3). 
AIM 3: to investigate the nicotine release pattern of the tobacco constituent of pituri in 
comparison with available similar smokeless tobacco and NRT products.  
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Oral consumption of smokeless tobacco products implies the release and absorption of the 
addictive component, nicotine, through the lining of the mouth, which is slower than through 
the lungs and via smoking (Benowitz et al., 1988). Nicotine replacement therapy gums are also 
designed to provide nicotine through the same path, however, the release from the gum 
formulation depends highly on the chewing and mastication process performed by parallel 
function of the teeth and tongue (Hurt et al., 1995). The result from the in vitro release studies 
conducted here using a model buccal cavity system showed that this is not the case in oral 
consumption of the smokeless tobacco products, such as the CORESTA reference smokeless 
tobacco (CRP2), the tobacco component of pituri and Swedish snus, as these showed minimal 
or insignificant dependence on chewing actions. Similar to snus, the dry and ready for 
mastication leaves of N. gossei used here, which is one of the most common ingredients for 
pituri users, are generally held in the mouth and sucked rather than being chewed. Both these 
products tend to release higher concentrations of nicotine faster than the formulated chewing 
gums under non-chewed conditions, which proved the hypothesis for this section. It is also 
important to note that extensive nicotine uptake from N. gossei leaves can result in 
cardiovascular implications (Savitz et al., 2006). The hypothesis on the positive effect of ash 
for increasing the release of nicotine was rejected as the induced alkaline pH for mimicking 
the ash component in pituri in terms of pH was shown to be insignificant in increasing the 
release rate; it is likely that the pH is of more relevance to the absorption of nicotine through 
the mucosa rather than release from the plant tissues. The chemical analysis of the released 
media indicated that the consumption of N. gossei leaves in pituri exposes the users to other 
toxic chemicals such as nornicotine and carcinogenic TSNAs, NNN and NNK (Chapter 4). 
AIM 4: To consider the cytotoxic potential of tobacco constituent of pituri compared to that 
from nicotine alone.  
Nicotine is believed to be the main psychoactive chemical in tobacco plants and products which 
result in the addiction in users. However, nicotine is not the only chemical received through 
consumption of smokeless tobacco products. So it was hypothesised that tobacco constituents 
of N. gossei are more toxic than nicotine alone. The cytotoxic effect of the extracts from 
smokeless tobacco products such as N. gossei dry leaves used in pituri and a reference moist 
snuff, CRP2, on human lung epithelium cells (A549) was compared with that from only 
nicotine in similar concentrations. The observed viability of the cells treated with nicotine only, 
in the similar concentration as what has been determined for the extract from N. gossei dry 
leaves and CRP2, was much higher than the viability obtained after the treatment with the two 
 111 
 
aforementioned extracts, which proved the hypothesis made for this section. Biologically active 
compounds such as alkaloids (other than nicotine) and carcinogenic TSNAs, NNN and NNK, 
are present in both extracts. Levels of NNN and NNK in different smokeless tobacco products 
reported so far range from 3 mg to 0.5 µg/g for NNN and 8 mg to 0.1 µg/g for NNK 
(International Agency for Research on Cancer, 2007). The levels measured for NNN (8.37 
µg/g) and NNK (6.91 µg/g) for N. gossei leaves, which reflects the levels in the final product, 
pituri, are consistent with smokeless tobacco products in use around the world. The presence 
of other alkaloids and carcinogenic NNN and NNK is in line with the observed higher 
cytotoxicity of these products rather that attributed to  nicotine alone (Moghbel et al., 2016) 
(Chapter 5). 
In conclusion, pituri as a smokeless tobacco product is considered to be less harmful than 
cigarette smoke, however possible harm might arise from the lack of knowledge on the 
different chemistry of the wide variety of species that might be used in its preparation and due 
to general misconception of its being “safe” rather than “less hazardous”. While the main 
concerns about cigarette smoke are the chemicals such as polycyclic aromatic hydrocarbons 
that are produced during combustion, there are compounds such as TSNAs which come in the 
tobacco constituent such as the wild Australian Nicotiana species used in pituri. 
The Nicotiana species studied here vary in their alkaloid composition, with genetics driving 
some to have higher nornicotine contents than others, which can lead to production of higher 
levels of carcinogenic TSNAs such as NNN. Although the most preferred species N. gossei, is 
a nicotine dominant and a safer species, there are sporadic mentions in the literature of the use 
of some high converter species as pituri, due largely to accessibility within specific geographic 
locations. N. cavicola, N. goodspeedii, N. megalosiphon ssp. megalosiphon, N. simulans, N. 
occidentalis ssp. occidentalis and N. velutina as high-nornicotine species have a more 
hazardous nature especially due to the chemical changes that occur during the storage and 
processing practices such as curing (drying). The reports in the literature on which species are 
chewed is limited and it is possible that some other species such as N. monoschizocarpa, N. 
megalosiphon ssp. sessilifolia (high converters) and N. occidentalis ssp. obliqua (medium 
converter) are also chewed since their distribution range includes the central desert area where 
pituri chewing is believed to be most common. Therefore, the information on nicotine to 
nornicotine conversion status of these species indicates that chewers should avoid these 
species. 
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The N. gossei dry leaves tested in this study contain more nicotine than the commercial 
Swedish snus, but the nicotine release rate is similar for these two products and is not 
apparently increased by chewing. However, the release of other toxic chemicals such asNNN 
and NNK makes N. gossei dry leaves a more toxic smokeless tobacco than Swedish snus. The 
nicotine chewing gum is a better alternative for nicotine supply because no other alkaloids or 
nitrosamines were released from it, however it might not be favoured by Aboriginal chewers 
since they have to pay for it, whereas pituri is a free source of nicotine. Testing the extract from 
dry leaves of N. gossei against human lung epithelium cells resulted in higher toxicity 
compared to nicotine at similar concentrations, indicating its higher toxic potential that could 
be due to other alkaloids and carcinogenic NNN and NNK present in the extract from N. gossei 
leaves. It is likely that nornicotine dominant species have even higher levels of these TSNAs 
and therefore higher toxic potential if used in preparation of pituri, especially if their leaves 
undergo drying before consumption. Therefore, avoiding consumption of high converters, and 
preferably medium converters, will help in harm reduction to pituri chewers.  
The work undertaken in this thesis has been conducted with respect for the Convention on 
Biological Diversity and the Nagoya Protocol. The biological resources necessary to conduct 
this project were provided by a range of contributors across Australia. The vast majority of 
these are members of the Australian Seedbank Partnership, which has the Convention on 
Biological Diversity and the preservation of traditional knowledge, resources and rights as a 
major focus. Agreements regarding the use of the material for this project and information 
sharing were signed where available, and the seedbanks, herbaria, botanic gardens and 
individual collectors have been acknowledged at each stage. The research outcomes from this 
project are shared with those contributors, and, through publication of the results, with the 
wider public.   
6.2 Future direction 
The knowledge of processing and preparing pituri has a sacred ritual significance in Aboriginal 
life, yet there is a paucity of information on the species and processes used in preparation of 
pituri (Low, 1987, Watson et al., 1983). To date there are limited and sporadic studies in the 
literature on pituri, the majority of which are very old and not thoroughly focused on it as a 
stand-alone product. Furthermore, apart from Nicotiana species, Duboisia hopwoodii has also 
been mentioned and known as the plant constituent in pituri. Although the plant material 
currently used for pituri preparation in central Australia is the wild Nicotiana spp. and not D. 
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hopwoodii, there is a great deal of confusion in the scientific and lay media and no clear 
distinction between the species used in any given geographic locations where pituri chewing is 
practiced (Ratsch et al., 2010). Apart from pyridine alkaloids like nicotine, D. hopwoodii 
contains tropane alkaloids such as scopolamine (de Rios and Stachalek, 1999). Chemical 
analysis of D. hopwoodii and the possible metabolites of its tropane alkaloids in the users, if 
any, will be of value for elucidation of possible harms. Therefore, ethnobotanical research in 
the area where pituri remains very popular with Aboriginal chewers, could help in getting a 
better picture on the species as well as details on the production process to further expand the 
investigation on the possible health effects and the scale of chemical exposure to the users. 
This thesis took the first step in amplifying the putative loci encoding N-demethylases in 24 
out of 26 Australian Nicotiana. The loci was found to be triggered by heat and expressed more 
in the cured leaves of only high converter species. The difference in the observed expression 
levels between the cured leaves of high converter and low or nonconverter species could be 
due to the presence of the different members of the CYP82E subfamily and also silencing of 
the active conversion loci in the low or nonconverter species (Chakrabarti et al., 2007). It would 
be interesting to study this further by identification of the present members of the CYP82E in 
studied high converter and low or nonconverter species and investigating if any such 
transcriptional silencing of the active conversion loci is involved in the observed conversion 
phenotypes in Australian Nicotiana spp. 
In terms of nicotine release, the next step would be to consider release from quids. These would 
have to be prepared in the manner practiced by Aboriginal chewers, which involves mastication 
to create a unified piece of pituri quid. A closer determination of the size and amount of each 
ingredient in the quids as well as the extent to which each quid is chewed or sucked can help 
in better investigating the release rate. A proper chewing device may be more appropriate for 
in vitro testing, such as the Erweka DRT-3 mastication device that has been used for testing the 
medicated chewing gums of dextromethorphan hydrobromide (Swamy et al., 2012), or a device 
may need to be designed that simulates sucking to better represent the case in pituri 
consumption. The need for release testing with proper methods is even more urgent recently 
with the growing number of tobacco companies which have started producing products such 
as tobacco gums and lozenges that are similar in design to the nicotine replacement therapy 
products produced by pharmaceutical companies (Kostygina et al., 2016). The rate of 
absorption of tobacco chemicals such as nicotine and nornicotine present in pituri through 
mucosal membranes could also be investigated in in vitro setting using an appropriate 
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membrane such as a dialysis membrane (Nasr et al., 1998), bovine (Ìkinci et al., 2004) or 
porcine (Nair et al., 1997) buccal mucosa that have been implemented for nicotine absorption 
and diffusion studies, to get an idea of the rate of nicotine absorption in the presence and 
absence of different concentrations of the ash. 
Ultimately, in vivo testing would be the most valuable approach for determining differences in 
nicotine absorption between pituri quids, commercial tobacco or nicotine products and other 
traditional smokeless tobacco products. Bioanalytical studies of the nicotine and hazardous 
TSNAs metabolites in biological matrices of the pituri users with consideration of different 
methods and duration of chewing/sucking, different ingredients such as high/low nornicotine 
species or fresh/dry leaves, proportion of tobacco to ash and the quantity of total product can 
be a starting point. Then comparison of these metabolites and their pharmacokinetics in pituri 
chewers with the metabolites in the users of other similar smokeless tobacco products, nicotine 
replacement therapy products, and even smokers as well as a control groups of non-
chewer/non-smokers could really broaden the knowledge surrounding pituri risk assessment.  
Investigation into the cytotoxicity of pituri could be expanded by checking the cytotoxic 
potential of the different species that might be used as the tobacco constituent of pituri, the ash 
and the final quids for effects. Determining the chemistry of the different types of the ash used 
in pituri especially in regard to the toxic chemicals such as the polycyclic aromatic 
hydrocarbons (PAHs) or heavy metals that might affect cell survival will help to get a better 
understanding of the extent of toxicity as well as the pathways involved in cytotoxicity. Also 
parallel to this would be applying a range of other cell assays such as mutagenicity assays (Wan 
et al., 2009) to detect genetic damage that leads to gene mutations, genotoxicity (Misra et al., 
2014) to investigate DNA damage as an indication of potential carcinogenicity, apoptosis 
assays (Bagchi et al., 1999) to look for higher than normal apoptosis that can be attributed to 
pituri chemicals, and assays that evaluate the inflammatory response (Nordskog et al., 2003) 
to exposure with pituri chemicals. 
The information available on the prevalence and frequency of pituri consumption is minimal, 
except for a mention of pituri as a form of tobacco in major drug use pattern and tobacco 
epidemiologic studies. The main study reporting on prevalence of pituri dates back to 1987, in 
which 38% of Aboriginal women and 11% of men in the NT were reported to be chewing 
pituri. According to this survey chewing has been particularly common among women in the 
central desert region, with nearly two thirds of them (61%) chewing tobacco (Fleming et al., 
1991). The epidemic seems to be unabated and might even be accelerating. According to a 
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more recent study from 2011, over 30% of Aboriginal women giving birth at a large hospital 
in Alice Springs regularly chew pituri throughout pregnancy and lactation (Ratsch, 2011). With 
this notion of the considerable affected population, more systematic epidemiologic studies 
conducted in the area where it remains popular will make the interpretation of pituri and its 
pathology more precise. Currently, there is ongoing research to investigate the maternal and 
neonatal outcomes of pituri consumption among the pregnant Aboriginal women chewing 
pituri compared to smokers and non-users. Associated with this, it would be valuable to 
investigate the prevalence of tobacco related disease such as oral disease, heart disease, 
cancers, etc. not only in pregnant women and neonates, but also in the wider population of 
chewers. 
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Appendix 1. Australian Nicotiana spp. seedlots received, with their corresponding internal seedlot number, source seedlot code, herbarium voucher number, collection date, 
the Australian state from which they were collected, and seed viability (V) according to tetrazolium staining. Seed germination and plant growth was attempted for all seedlots; 
those that resulted in successful germination of sufficient replicate plants to have been used in this study are highlighted. For successful seedlots without a herbarium voucher 
number, vouchers were identified by Dr Neville Walsh (NW), senior conservation botanist at Royal Botanic Gardens Victoria, and Dr. Daniel Duval (DD) at South Australian 
Seed Conservation Centre, Botanic Gardens of South Australia. Missing data occurred for some seedlots not tested for viability due to small numbers of seeds being provided, 
and seedlots for which insufficient germination was achieved were not pursued to complete their collection information and confirm identification. 
Seed sources in the table are: ATGGC: Australian Tropical Grains Germplasm Centre, Biloela, Qld; Herbalistics: purchased from herbalistics.com.au; NSW: Australian 
Botanic Garden, Mount Annan; NT: Alice Springs Desert Park; Qld: Brisbane Botanic Gardens; SA: Botanic Gardens of South Australia; UniMel: University of Melbourne; 
Vic: Royal Botanic Gardens Victoria; WA: Botanic Garden and Parks Authority, Perth; WASABC: WA State Agricultural Biotechnology Centre  
 
Species Seedlot Source seedlot code Voucher Source collection date Collection state % V 
N. amplexicaulis N.T.Burb 19 NSW4157044 NSW 234670 NSW 21/10/1990 QLD 60 
65 TS 298 (AusTRCF317546) MEL 2396301 ATGGC -  - 50 
49 TS 286 (AusTRCF303897)  ATGGC   50 
N. benthamiana Domin 3 A109412 DNA A0109412 NT 18/07/2001 WA 90 
4 D0182096 DNA D0182096 NT 12/07/2007 SA 80 
28 -   Herbalistics - NT 90 
N. burbidgae Symon 73 DJD3167 Voucher confirmed (DD) SA Sep-15 SA 20 
40 SL54  UniMel 11/10/2005 SA 0 
N. cavicola N.Burb. 18 NSW877057 NSW951497 NSW 3/08/1995 SA 100 
30 -   Herbalistics -  0 
33 SL9 (AusTRCF303902) -  UniMel 4/09/2013 WA 0 
50 TS 205 (AusTRCF303692) - ATGGC 1956  100 
N. excelsior (J.Black) J.Black 5 D194512 AD 246203 NT 21/09/2009 SA 50 
10 D0221380 DNA D0221380 NT 8/09/2012 NT 50 
27 MJT438 AD 264269 SA 4/09/2013 SA 90 
N. forsteri Roem. & Schult. 1 BGQLD.0727 BRI AQ0840316 QLD 27/05/2010 QLD 50 
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Species Seedlot Source seedlot code Voucher Source collection date Collection state % V 
2 RJ 3238 NSW 906082 NSW 1/02/2013 NSW 90 
N. goodspeedii H.Wheeler 12 DJD213 AD 192908 SA 22/11/2005 SA 100 
N. gossei Domin 6 D204093 DNA D0204093 NT 25/04/2011 NSW 100 
21 NSW4022326 Voucher confirmed (NW) NSW Sep-97 NT 90 
31 -   Herbalistics -  80 
N. heterantha Symon & 
Kenneally 
64 AusTRCF313551 MEL 2396300 ATGGC -  - 60 
38 SL33 MELU D106511, 
D106512, D106513 
UniMel 20/03/2005  50 
N. maritima H. Wheeler 16 DJD3341 Voucher confirmed (DD) SA 7/01/2013 SA 50 
69 MKJ140 AD 187318 SA 15/11/2005 SA 80 
51 TS 107 (AusTRCF303768) -  ATGGC 1954  80 
N. megalosiphon Van Heurck & 
Mull. Arg. ssp. megalosiphon 
26 NSW870550 NSW2010147 NSW 8/11/2010 NSW 100 
41 -   Herbalistics 3/07/1905 NSW 100 
N. megalosiphon Van Heurck & 
Mull. Arg. ssp. sessifolia 
P.Horton 
52 AusTRCF303829 MEL 2396303 ATGGC - -  30 
N. monoschizocarpa (P.Horton) 
Symon & Lepschi 
72 AusTRCF303666 Voucher confirmed (NW) WASABC 1/09/1986 NT 50 
N. occidentalis H.Wheeler 
ssp.hesperis (N.Burb.) P.Horton 
56 TS 341 (AusTRCF303767) MEL 2396304 ATGGC 1960  - 82 
55 TS 331 (AusTRCF303764) -  ATGGC 1970 - 70 
N. occidentalis H.Wheeler ssp. 
obliqua N. Burb. 
34 SL17 (AusTRCF303779) MELU D106540 UniMel 1/08/1956 WA 70 
29 -   Herbalistics - NT 20 
22 NSW4150998 NSW4150998 NSW 25/11/1980 SA - 
67 - - WA 1992 - 100 
42 DJD3051 voucher submitted SA 25/09/2014 - 100 
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Species Seedlot Source seedlot code Voucher Source collection date Collection state % V 
45 19921000 - WA - - 10 
N. occidentalis H.Wheeler ssp. 
occidentalis 
54 L 3569 (AusTRCF303738) MELU D106542, 
D106543 
ATGGC 1959  - 30 
53 TS 182 (AusTRCF303732) - ATGGC 1956 - 4 
N. rosulata (S.Moore) Domin ssp. 
ingulba (J.Black) P. Horton 
58 TS 75 (AusTRCF303907) MEL 2396302 ATGGC   - 84 
7 98A97266 98A97266 NT 2/09/1998 NT 0 
43 - - WA - - 30 
57 TS 63 (AusTRCF303906)  ATGGC - - 70 
68 - - WA 1/01/2015 - 100 
N. rosulata (S.Moore) Domin ssp. 
rosulata 
44 20070392 PERTH 7821336 WA 20/07/2006 SA 100 
48 AD112312 AD112312 SA 24/12/2000 SA 100 
N. rotundifolia Lindley 71 - MEL 2396305 WASABC Aug-15 WA 100 
23 NSW4080337 NSW4080337 NSW 17/10/1980 WA - 
59 73/229 (AusTRCF303745) -  ATGGC 1953 - 10 
60 TS 192 (AusTRCF317526) -  ATGGC - - 32 
35 SL20 (AusTRCF303626) MELU D106465, 
D106466, D106467, 
D106468 
UniMel - - 0 
N. simulans N.Burb. 13 RJB70944 AD 206232 SA 12/03/2007 SA 80 
25 NSW872310 ASBP 20101508 NSW 15/11/2010 NSW 40 
N. sp. ‘Corunna’ Symon17088 36 SL23 (MELU D106460, 
D106461, D106462, 
D106463, D106464) 
 
AD 239243 
UniMel 14/09/2005 SA 50 
70 DES17088 AD 169953  SA 17/09/2004 - 80 
N. suaveolens H. Wheeler 11 DJD1980 AD 239956 SA 6/10/2010 SA 100 
61 TS 261 (AusTRCF303886) - ATGGC - - 90 
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Species Seedlot Source seedlot code Voucher Source collection date Collection state % V 
47 NSW 4084762 NSW 4084762 NSW 20/01/1989 NSW 0 
46 NSW 874839 ASBP 20110237 NSW 30/03/2011 NSW 100 
17 NSW4088842 NSW 197546 NSW 22/10/1986 NSW 0 
37 SL24 MELU D106487 (field); 
D106488, D106489, 
D106490, D106491 
UniMel - VIC 0 
N. truncata Symon 14 TST1056 AD 250303 SA 7/10/2010 SA 50 
39 SL44 MELU D106487 (field); 
D106488, D106489, 
D106490, D106491 
UniMel 10/10/2005 SA 0 
N. umbratica N.Burb. 66 TS 303 (AusTRCF317549) -  ATGGC - - - 
74 - - WASABC 2013 SA - 
N. velutina H.Wheeler 15 DJD233 AD 192706 SA 24/11/2005 SA 70 
24 NSW4139564 NSW 213331 NSW 24/01/1989 VIC 60 
8 98A97216 - WASABC 2/09/1998 NT 0 
9 MEL2338142 MEL2338142 Vic 24/11/2010 VIC 60 
N. wuttkei J.Clarkson & Symon 62 ZZ 305 (AusTRCF323099) -  ATGGC - - - 
63 73/276 (AusTRCF323100) -  ATGGC - - 20 
75 73/280 (AusTRCF323101) plants identified as N. 
tabacum 
ATGGC - -  
 
